

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 February 2002 (21.02.2002)

PCT

(10) International Publication Number
WO 02/14366 A2

- (51) International Patent Classification⁷: **C07K 14/47**
- (21) International Application Number: **PCT/NL01/00610**
- (22) International Filing Date: **16 August 2001 (16.08.2001)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
00202867.8 **16 August 2000 (16.08.2000)** **EP**
- (71) Applicant (*for all designated States except US*): **UNIVERSITEIT UTRECHT [NL/NL]; Heidelberglaan 100, NL-3584 CX Utrecht (NL).**
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **GROOT, Pieter, Cornelis [NL/NL]; Roelofsstraat 43, NL-2596 VK The Hague (NL). VAN BERGENHENEGOUWEN, Bram, Jeroen [NL/NL]; Mgr. V.d. Weteringstraat 34, NL-3581 EJ Utrecht (NL). VAN OOSTERHOUT, Antoon, J., M. [NL/NL]; T. Masrijkstraat 35, NL-3573 PJ Utrecht (NL).**
- (74) Agent: **PRINS, A., W.; Vereenigde, Nieuwe Parklaan 97, NL-2587 BN The Hague (NL).**
- (81) Designated States (*national*): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.**
- (84) Designated States (*regional*): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).**
- Published:
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **GENES INVOLVED IN IMMUNE RELATED RESPONSES OBSERVED WITH ASTHMA**

(57) Abstract: Asthma is one of the most common chronic diseases (155 million people worldwide) and is rapidly increasing (20-50 % per decade), particularly in children (currently 10 % in The Netherlands). Asthma impairs the quality of life and is a major cause of absence from school and work. Asthma, if not treated properly, can be life threatening. The invention provides a nucleic acid library comprising genes or functional fragments thereof said genes are essentially capable of initiation and/or progression and/or suppression and/or repression of an immune response.

WO 02/14366 A2

Genes involved in immune related responses observed with asthma

10 The invention relates to the field of immunology, gene therapy and
medicine. Asthma is one of the most common chronic diseases (155 million
people worldwide) and is rapidly increasing (20-50% per decade), particularly in
children (currently 10% in The Netherlands). Asthma impairs the quality of life
and is a major cause of absence from school and work. Asthma, if not treated
15 properly, can be life threatening.

 Allergic asthma can be characterized by reversible airway obstruction,
elevated levels of IgE, chronic airway inflammation and airway
hyperresponsiveness to bronchoconstrictive stimuli, airway tissue remodeling
and mucus hypersecretion. The allergic inflammatory infiltrate in the airway
20 tissue predominantly consists of eosinophils and CD4⁺ T-lymphocytes. It is now
widely accepted that type 2 T-helper (Th2) lymphocytes which produce a limited
set of cytokines including interleukin-3 (IL3), IL4, IL5, IL9, IL10 and IL13 play
an important role in the initiation and progression of allergic asthma [Corrigan
and Kay (1992). *Immunology Today*. 13, 501-507; Romagnani, S. (2000) *J Allergy*
25 *Clin Immunol* 105, 399-408]. Chronic asthma appears to be driven and
maintained by persistence of a subset of chronically activated memory T-cells
(lymphocytes). Besides T-lymphocytes many other inflammatory cell-types are
involved in the pathophysiology of allergic asthma such as eosinophils, mast-
cells, B-lymphocytes, dendritic cells, macrophages and monocytes as well as
30 resident airway cells such as epithelial cells and smooth muscle cells. Moreover,
sensory neurons of which the cell bodies are located in the dorsal root ganglia
play an important role in airway inflammation, hyperresponsiveness and cough.

 Currently used pharmacological therapies in allergic asthma only provide
temporal symptomatic relief. A more fundamental treatment aimed at antigen-
35 specific T-lymphocytes and antigen-presenting cells is desirable since these cell-
types play a crucial role in the initiation and progression of allergic asthma.
Furthermore, T-lymphocytes may be the only cells that have the potential to
induce long-term relieve of symptoms. Current therapy for moderate to severe
asthma essentially involves multiple classes of molecules: anti-inflammatory

5 glucocorticoids, bronchodilator drugs, and mast-cell inhibitors. The current preferred method is to treat the chronic phase of asthmatic symptoms, as manifested by airway hyperresponsiveness and eosinophilic inflammation, with glucocorticoids to reduce the inflammatory component and hyperresponsiveness (Barnes , 1990; Schleimer, 1990). These drugs are not very selective, targeting
10 non-inflammatory cells as well as inflammatory cells and often have moderate to serious side effects after chronic treatment, especially in children. Furthermore, a subgroup (10%) of asthma patients become relatively resistant to glucocorticoid therapy and increasingly become dependent upon non-glucocorticoid treatment. In addition, there is a strong need for so-called "add-on" therapies to limit the
15 use of high doses of glucocorticoids and the associated side-effects. Hence, there is a strong need for a safer, more selective and more efficacious therapeutic which displays a long-term clinical benefit to asthma patients.

20 The invention provides a nucleic acid library comprising genes or functional fragments, derivatives or analogues thereof essentially capable of modulating an immune response observed with airway hyper-responsiveness and/or bronchoalveolar manifestations of asthma. Modulation herein can refer to up-regulation or down-regulation of an immune response, for example by
25 activation and/or suppression of gene(s) which are essentially capable of initiation and/or progression and/or suppression and/or repression of an immune response and/or symptoms of said immune response. Modulation herein can also refer, for example to positive (i.e up-regulation) or negative (i.e down-regulation) regulation of gene transcription, and to the modulation of the gene and gene
30 product. Methods for modulating the expression of genes and gene products are known. The definition 'functional fragment thereof' means that a particular subject sequence may vary from the reference sequence by one or more substitutions, deletions, or additions, the net effect of which does not result in an adverse functional dissimilarity between the reference and the subject sequence. An
35 analogue is a compound having functional equivalence or being related to a molecule in question.

The invention provides a nucleic acid library comprising nucleic acid or functional fragments, derivatives or analogues thereof comprising at least one gene as listed in table 1, 2 or 3, genes which play an important role in all

5 immune system related disorders such as all allergic diseases (asthma, rhinitis, atopic dermatitis, urticaria) and auto-immune diseases (i.e multiple sclerosis). The invention provides a nucleic acid library comprising such genes or fragments thereof said genes essentially capable of modulating an immune response observed with airway hyperresponsiveness and/or bronchoalveolar

10 manifestations of asthma wherein said immune response is up-regulated and/or down-regulated. An immune response herein refers to the physiological response(s) stemming from activation of the immune system by antigens, including immunity to pathogenic organisms and auto-immunity to self-antigens, allergies, inflammatory response and graft rejection. An immune response herein

15 further applies to all immune system related disorders. Usually the antigenic invader comprises a protein or protein attached moiety. The invention further provides a library comprising genes or functional fragments derivatives or analogue thereof said genes essentially capable of initiation and/or progression (i.e. up-regulation) and/or suppression and/or repression (down-regulation) of an

20 immune response wherein said immune response are airway hyperresponsiveness and/or bronchoalveolar manifestations of asthma. The invention provides a nucleic acid or functional fragments thereof selected from those listed in table 1, 2 or 3, capable of initiation and/or progression and/or suppression and/or repression of an immune response wherein said immune

25 response is asthma. Methods of detecting nucleic acids capable of initiation and/or progression and/or suppression and/or repression of an immune response are known. In one embodiment such a nucleic acid is derived from a DC-SIGN gene is described herein. DC-SIGN (signature sequence OtS1-B7) in the primary cultures of bone-marrow derived dendritic cells demonstrates an important role

30 of this gene and the encoding protein in the cellular function of dendritic cells. Bone-marrow derived dendritic cells or cell-lines representing dendritic cells such as XS52 cell-line or other primary cell cultures of this cell-type can be used to determine the gene/protein function and screening of a compound (agonist or antagonist) that modulates at least one of the functions of the gene/protein.

35 Dendritic cells are so-called professional antigen-presenting cells (APC) and thus play a crucial role in the initiation and progression of immune- and inflammatory responses mediated by T-lymphocytes. Blockade of mDC-SIGN is beneficial in the treatment of T-lymphocyte mediated diseases such as allergy,

5 asthma, COPD, auto-immune diseases, inflammatory bowel diseases, allograft rejection and infectious diseases.

In another embodiment, such a gene is derived from a calcium-activated chloride channel gene as also described below. Calcium-activated chloride channels (CLCA1-4) can be blocked by mono- and polyclonal antibodies or
10 fragments thereof directed against the ion channel (protein or peptide fragments); known non-specific chloride channel antagonists such as 4,4'-diisothiocyanatostilbene-2,2'-disulphonic acid (DIDS), 4-acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic acid (SITS), 5-nitro-2-(3-phenylpropylamino)benzoic acid (NPPD), niflumic acid, and the anti-allergic
15 drug cromolyn

Changes in gene expression underlie most, if not all, pathophysiological processes. A variety of methods for detecting changes in gene expression in a healthy versus a diseased animal to detect nucleic acid for the formation of a library the subject of the invention are known. These procedures include, but are
20 not limited to DNA-DNA or DNA-RNA hybridisation. The form of such quantitative methods may include, Southern or Northern analysis, dot/slot blot or other membrane based technologies; PCR technologies such as DNA Chip, Taqman®, NASBA, SDA, TMA, *in-situ*-hybridisation, protein bioassay or immunoassay techniques ELISA, IFA, proteomic and metabolomic technologies.
25 These technologies are often found at the basis of my commercially available diagnostic kits often used for screening purposes.

The invention provides a nucleic acid library comprising genes or fragments thereof said genes essentially capable of modulating an immune response observed with airway hyperresponsiveness and/or bronchoalveolar
30 manifestations of asthma wherein said genes comprises a nucleic acid essentially equivalent to a signature sequence as shown in table 1, 2 or 3. A signature sequence herein refers to a marker sequence and/or sequence or any other mode of identification of a sequence (i.e name). Nucleic acid sequence as used herein refers to an oligonucleotide, nucleotide or polynucleotide, and fragments or
35 portions thereof, and to DNA or RNA of genomic or synthetic origin which may be single- or double-stranded, and represents the sense or antisense strand. The definition 'antisense' RNA is an RNA sequence which is complementary to a sequence of bases in the corresponding mRNA: complementary in the sense that each base (or majority of bases) in the antisense strand (read in the 5' to 3' sense)

5 is capable of pairing with the corresponding base (G with C, A with U), in the mRNA sequence read in the 5' to 3' sense. The definition 'sense' RNA is an RNA sequence which is substantially homologous to at least part of the corresponding mRNA sequence. Preferably the nucleic acid is an 'immune response gene'. An immune response gene is any gene that determines the ability of lymphocytes to
10 mount an immune response to specific antigens. The definition 'essentially equivalent' means that the subject signature sequence can vary from the reference sequence by one or more substitutions, deletions, or additions, the net effect of which will not result in a functional dissimilarity between the two sequences. It may be advantageous to produce nucleotide sequences, the subject
15 of the invention or derivatives thereof possessing a substantially different codon usage. It is known by those skilled in the art that as a result of degeneracy of the genetic code, a multitude of gene sequences, some bearing minimal homology to the nucleotide sequences of any known and any naturally occurring genes may be produced. The invention includes each and every possible variation of the
20 nucleotide sequences that could be made by selecting combinations based on possible codon choices.

The invention provides a library wherein said genes encode a regulatory molecule and/or co-stimulatory molecule and/or adhesion molecule and/or receptor molecule involved in modulating an immune response. The definition
25 'regulatory molecule' is an entity which assists the cell in 'sensing' its environment. For example 'a regulatory molecule' can effect a immune response by modulating either positively or negatively gene transcription. The definition 'stimulatory molecule' is an entity which can activate an immune response. The definition 'adhesion molecules' is any pair of complementary molecules that bind
30 specifically to one another to effect a positive or negative immune response. The molecule can be any entity which can bind to for example nucleic acid, proteinaceous substance or receptor etc., to effect a positive or negative immune response. The definition 'receptor' is an entity to which a ligand binds which triggers an immune response. The definition 'receptor molecule' could be for
35 example a ligand (i.e any macromolecule) which binds to a receptor to effect an immune response. A ligand is a molecule that binds to a complementary site on a given structure. For example oxygen is a ligand for haemoglobin and a substrate of an enzyme molecule is a specific ligand of that molecule. The invention further provides a method for modulating an immune response of an individual

5 comprising modulating a gene comprising a nucleic acid at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in table 1, 2 or 3.

The invention provides a substance such as a proteinaceous substance capable of modulating a gene comprising a nucleic acid at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in
10 table 1, 2 or 3 and use of said substance for the production of an antagonist against said substance for example Gob-5 (signature sequence R1-SO-R1-C11). Gob 5 is a cell-membrane protein belonging to the family of calcium-activated chloride channels and discovered in intestinal goblet cells in mice. Human
15 CaCC1 and the identical CLCA1 are most likely the human homologs of murine gob-5. Gob-5 can have another function as a cell adhesion molecule. Northern blot analysis revealed that gob-5 is abundantly expressed in the stomach, small intestine, uterus and slightly expressed in the trachea of mice. *In-situ* hybridization demonstrated that gob-5 expression is located in the mucus-
20 secreting cells of these three tissues. In humans, CaCC1/CLCA1 are also primarily expressed in the digestive tract. Gob-5 is expressed in lymph-nodes, lung tissue, bronchoalveolar lavage cells and bone-marrow from mice and is up-regulated in these tissues in the mouse asthma model. Mucus secreting goblet cells have never been described in lymph nodes or bone-marrow. In addition, Gob
25 5 is expressed in murine bone-marrow derived mast-cells and murine mast-cell lines. Gob-5 plays a role in secretory processes based on its function as a chloride channel. Chloride channels have been shown to be involved in mast-cell activation and degranulation since inhibition of these channels by non-selective broad spectrum chloride channel inhibitors inhibit IgE-mediated rat mast-cell
30 degranulation *in-vitro*. Additionally a strong up-regulation of gob-5 in the dorsal root ganglia (DRG) in the mouse asthma model was observed. The expression of other members of the calcium-activated chloride channel gene family by PCR (table 2) was investigated. Murine homolog of human CaCC3 (EST AA726662) was identified and their expression was shown to be strongly upregulated in
35 DRG of the mouse asthma model.

The invention provides a substance such as a proteinaceous substance capable of modulating a gene comprising a nucleic acid at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in table 1, 2 or 3 and use of said substance for the production of an antagonist

5 against said substance for example LR8 (R1-OS-B1-D3). LR8 belongs to the family of the tetraspanin (4TM) superfamily. LR8 mRNA was not detectable by PCR in human smooth muscle cells, endothelial cells or epithelial cells. Murine LR8 mRNA expression in lymph nodes from mice was confirmed along with a down-regulation in a mouse asthma model. Bio-informatics analysis of the LR8
10 protein confirmed the presumed 4TM structure of the protein and revealed a striking homology with the beta chain of the high affinity IgE receptor (FceRI). The tetraspanin superfamily has grown to nearly 20 known genes since its discovery in 1990. All encode cell-surface proteins that span the membrane four times, forming two extracellular loops. Many of these proteins have a flair for
15 promiscuous associations with other molecules, including lineage-specific proteins, integrins, and other tetraspanins. In terms of function, they are involved in diverse processes such as cell activation and proliferation, adhesion and motility, differentiation, and cancer. These functions relate to their ability to act as "molecular facilitators," grouping specific cell-surface proteins and thus
20 increasing the formation and stability of functional signaling complexes. LR8 is similar to CLAST1, a murine gene that is activated upon ligation of CD40 (Genbank: BAA83596). CD40 is predominantly expressed on so-called "antigen-presenting cells" and ligation of CD40 induces the expression of several molecules involved in the activation and regulation of T-lymphocytes (CD80;
25 CD86; IL12). CD40 is an important maturation signal for dendritic cells. Immature dendritic cells take up antigen in peripheral tissues and migrate to secondary lymphoid tissues (draining lymph node) where they mature and present antigen to lymphocytes. Several proteins are induced or down-regulated upon dendritic cell maturation. Many of the differentially activated genes appear
30 to be involved in the modulation (regulation/activation) of T-lymphocytes (table 1, 2 or 3).

The invention provides a substance such as a proteinaceous substance capable of modulating a gene comprising a nucleic acid at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in
35 table 1, 2 or 3 and use of said substance for the production of an antagonist against said substance for example β -Amyloid-precursor like protein 2 (APLP2) (SvO2-1-B7). APLP2 is a highly conserved protein and is located on mouse chromosome 9. Moreover, in an experimental asthma model, airway hyper-responsiveness has been linked to a locus on chromosome 9, syntenic with

5 human 11q24. APLP2 is a member of the Alzheimer precursor protein family including the Alzheimer peptide precursor (APP). These proteins all share three domains of similarity, interdispersed with completely divergent regions. APLP2 is a type-I integral membrane protein that contains a single membrane spanning domain with a large extracellular N-terminal domain and a short C-terminal
10 cytoplasmic domain. APPL2 is ubiquitously expressed. Alternative splicing of APPL2 pre-mRNA generates at least four transcripts. Several functional domains have been identified in APLP2, including a DNA binding motif, an N-terminal cysteine rich domain exhibiting zinc, copper, and heparin binding activity, followed by a very acidic region and, depending on the isoform, the
15 Kunitz protease inhibitor (KPI) domain. Interestingly, the KPI domain inhibits serine proteases like trypsin, plasmin, tryptase and chymase of which the latter two are released by activated mast-cells. Tryptase has been implicated in the development of airway hyperresponsiveness. Mast-cell mediator serotonin stimulates the release of APLP2 ectodomain (containing the KPI domain). Other
20 functions that have been described for APLP2 are (i) an interaction with MHC class I, (ii) a role as adhesion molecule through interactions with extracellular matrix components, (iii) a role in epithelial wound healing and (iv) a potential role in the inhibition of platelet activation by the N-terminal cysteine-rich domain.

25 The invention provides a substance such as a proteinaceous substance capable of modulating a gene comprising a nucleic acid at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in table 1, 2 or 3 and use of said substance for the production of an antagonist against said substance. For example the invention provides a method for the
30 treatment of an immune response more particularly asthma and COPD comprising providing APLP2 or its KPI domain or by induction of APLP2 expression. APLP2 through the inhibition of the detrimental effects of mast-cell proteases, by repair of epithelial damage and by inhibition of platelet activation is capable of treating an immune related response. Furthermore, many allergens
35 have been shown to have protease activities that appear to be crucial for allergic sensitization. By its KPI domain, APLP2 can inhibit the proteolytic activities of allergens and thereby prevent the initiation and progression of allergic responses. Another effect of the KPI domain of APLP2 is inhibition of the activation of protease-activated receptors (PARs) by serine proteases. PAR2 is

5 involved in bronchorelaxation and protection against bronchoconstriction by
stimulating the generation of prostaglandin E2 by airway epithelial cells.
However, it was demonstrated that trypsin and a PAR2 ligand induced
bronchoconstriction in guinea pigs *in vivo*, despite the induction of relaxation by
these mediators in isolated trachea and bronchi. The bronchoconstriction
10 appeared to be mediated by a neural mechanism since the bronchoconstriction
was inhibited by the combination of NK1 and NK2 receptor antagonists. These
data suggest that the PAR2 ligand activates sensory nerves. In agreement
herewith, trypsin and mast-cell tryptase induced a wide-spread neurogenic
inflammation initiated by activation of neuronal PAR2 receptors. Inhibition of
15 tryptase and other serine proteases by APLP2 or its KPI domain can antagonize
neurogenic inflammation and bronchoconstriction. Moreover, other PARs appear
to be involved in inflammation. Activation of these receptors (PAR2) by serine
proteases is sensitive to inhibition by APLP2 or its KPI domain. Analogous to
intra-membrane cleavage of APP and Notch by aspartyl proteases (γ -secretase,
20 presenilins). APLP2 can be cleaved by these aspartyl proteases since it is
homologous to APP in the region (IATVIVI) where γ -secretase cleaves APP. This
cleavage will lead to the generation of the extracellular part of APLP2 and an
intracellular part of 57 amino acids, which may directly or indirectly modify the
transcription of target genes. The APLP2 C57 peptide contains the "NPTY"
25 sequence, which is present in many growth factor receptors and appears to be
involved in cellular signaling. Interestingly, T-lymphocytes have been shown to
express presenilin-1 and 2 at the cell-surface. Cleavage of APLP2 is involved in
T-lymphocyte activation. Another, at present unidentified protease may cleave
APLP2 in its transmembrane region and generate the release of an intracellular
30 peptide containing the "NPTY" sequence.

The invention provides a substance such as a proteinaceous substance
capable of modulating a gene comprising a nucleic acid at least functionally
equivalent to a nucleic acid identifiable by a signature sequence as shown in
table 1, 2 or 3 and use of said substance for the production of an antagonist
35 against said substance. For example phosphotyrosine binding (PTB) domains
have been identified in a large number of proteins. PTB domains play an
important role in signal transduction by growth factor receptors. Several PTB
proteins have been shown to bind to amyloid proteins through the "NPTY" motif

5 like Fe65, Fe65-like, X11 and X11-like proteins, Shc and IRS-1. The interactions of APLP2 with Shc and IRS-1 is dependent on tyrosine phosphorylation whereas the interactions with Fe65 and X11 are not. The Fe65 adaptor protein interacts with the transcription factor CP2/LSF/LBP1. The "NPTY" motif, has been shown to be involved in binding to Shc, a Src homology 2 (SH2)-containing proto
10 oncogene product implicated in activating Ras via association with Grb2 protein. Activation of the Ras pathway involves the MAPK signal transduction pathway which has been shown to be involved in the induction of many inflammatory genes. The Shc/Grb2/Sos complex is also involved in the activation of the Ras pathway in T-lymphocytes. It is unknown whether APLP2 or other proteins of
15 this family with an "NPTY" domain are involved in T-cell activation and differentiation. Caspases can also cleave APP at the caspase consensus site "VEVD", leading to the generation of a C-terminal 31 amino acid peptide which contains the internalization sequence "NPTY". Since APLP2 contains both the caspase consensus site "VEVD" as well as the internalization sequence "NPTY",
20 it is clear that APLP2 can also be cleaved by caspases leading to the generation of a C-terminal 31 amino acid peptide which is homologous to the peptide generated by APP cleavage. The APP C31 peptide has been demonstrated to initiate cell death. Apoptosis or cell-death is an important mechanism to limit immune and inflammatory reactions. On the other hand, cell-death may be
25 unwanted i.e. death of airway epithelial cells may increase airway responsiveness. The invention provides a method for the treatment and/or prevention of an immune related response more particularly allergic asthma and related inflammatory diseases and COPD comprising modulating APLP2 or its KPI domain and/or by induction of APLP2 expression. Treatment by providing
30 APLP2 or its KPI domain or induction of APLP2 expression is effective in the treatment of (1) the neurogenic component of inflammatory responses, (2) hyperalgesia during inflammatory responses, (3) cough due to airway inflammation and (4) bronchoconstriction induced by activation of sensory nerves. Cleavage of APLP2 by presenilins (γ -secretase) or other proteases or by
35 caspase is involved in activation-induced cell-death in T-lymphocytes and is involved in the induction of peripheral tolerance.

The invention provides a substance such as a proteinaceous substance capable of modulating a gene comprising a nucleic acid at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in

5 table 1, 2 or 3 and use of said substance for the production of an antagonist
against said substance. The invention further provides the use of said antagonist
such as an antibody directed against a proteinaceous substance derived from at
least a nucleic acid as shown table 1, 2 or 3 for the production of a medicament
for the treatment of an immune response observed with airway
10 hyperresponsiveness and/or bronchoalveolar manifestations of asthma for
example the invention provides a method for the treatment of immune responses
comprising stimulating the cleavage of the intracellular domain of APLP2 by
allosteric activation of proteases or by binding of APLP2 to its ligand together
with an antigen-specific stimulation which will induce peripheral tolerance to
15 the antigen. This treatment is effective for allergic asthma and other diseases
mediated by T-lymphocytes such as auto-immunity and graft-rejection.

The invention provides a substance such as a proteinaceous substance
capable of modulating a gene comprising a nucleic acid at least functionally
equivalent to a nucleic acid identifiable by a signature sequence as shown in
20 table 1, 2 or 3 and use of said substance for the production of an antagonist
against said substance for example mouse GDP-dissociation inhibitor (Ly-GDI:
signature sequence Sv-O2-1-D8). Ly-GDI was originally identified in
lymphocytes and likewise called "lymphoid-specific GDI" (Ly-GDI).
Independently, Ly-GDI gene was cloned from human and from mouse and it
25 GDP-dissociation inhibitor D4 was designated. Mouse and human D4-GDI (Ly-
GDI) share 89% amino acid sequence identity. Murine Ly-GDI is located on
chromosome 6, the human homolog (Ly-GDI or D4-GDI) is located on
chromosome 12p12.3. Northern blot analysis demonstrated that Ly-GDI was
expressed abundantly in lung, and at lower levels in several other tissues.
30 Another study using Northern blot analysis revealed that Ly-GDI is expressed as
a 1.4-kb transcript only in hematopoietic tissues. Antibodies against Ly-GDI
recognized a 27-kD protein on Western blots of B- and T-cell line lysates. It is
now generally accepted that Ly-GDI is preferentially expressed in
hematopoietic cells and can function as a GDP-dissociation inhibitor of Rho GTP
35 binding proteins (Rac and Cdc42) but with less potency than the ubiquitously
expressed RhoGDI. There are three subfamilies of small GTP-binding proteins,
Ras, Rho and Rab. The present thinking is that Ras proteins are principally
involved in signal transduction and cell proliferation, Rho proteins (Rac1, Rac2,
TC10 and Cdc42) regulate cytoskeletal organization and Rab proteins are

5 involved in the control of intracellular membrane traffic. The GTP-binding proteins are active only in the GTP-bound state. At least 2 classes of proteins tightly regulate cycling between the GTP-bound (active) and GDP-bound (inactive) states: GTPase-activating proteins (GAPs) and GDP/GTP exchange factors (GEF). GAPs inactivate small GTP-binding proteins by stimulating their
10 low intrinsic GTPase activity to cause hydrolysis of GTP to GDP. GEFs are of two types including GDP dissociation stimulators (GDS, alternatively called guanine nucleotide releasing factors (GRF) and GDP-dissociation inhibitors (GDIs). The GDIs decrease the rate of GDP dissociation from Ras-like GTPases. It was found that Ly-GDI bound RhoA, and *in-vitro* inhibited GDP dissociation from RhoA.

15 Stimulation of T lymphocytes with phorbol ester led to phosphorylation (activation) of Ly-GDI. It has been suggested that Ly-GDI may be involved in the regulation of hematopoietic-specific Rho-family GTPases because it is less potent than the ubiquitously expressed Rho-GDI. In T-lymphocytes, Rac and Cdc42 are important Rho-family GTPases involved in T-cell activation. Both Rac and Cdc42
20 are activated by Vav that has GDS activity (see figure 1). Rac and Cdc42 are involved in downstream signaling to the nucleus via the JNK pathway leading to the transcription factors AP1 (fos/jun) and NFAT (nuclear factor of activated T-cells). These transcription factors are involved in transcription of cytokines such as IL1, IL4, GM-CSF etc. Recently, it was demonstrated that Ly-GDI also
25 interacts with the proto-oncogene Vav. Vav functions as a specific GDS for Rho, Rac and Cdc42 and is regulated by tyrosine phosphorylation in hematopoietic cells. Vav integrates signals from lymphocyte antigen receptors and co-stimulatory molecules to control development, differentiation and cell cycle. Interestingly, Vav knock-out mice have a defective IgE antibody production that
30 can be attributed to compromised T cell help due to impaired IL-4 transcription. Ly-GDI knock-out mice have been generated and did not show striking abnormalities of lymphoid development or thymocyte selection. The mice also exhibited normal immune responses including lymphocyte proliferation, IL-2 production, cytotoxic T lymphocyte activity, antibody production, antigen
35 processing and presentation, immune cell aggregation and migration, and protection against an intracellular protozoan. However, Ly-GDI-deficient mice exhibited deregulated T and B cell interactions after *in vitro* cultivation of mixed lymphocyte populations in concanavalin A (Con A) leading to overexpansion of B lymphocytes. Further studies revealed that Ly-GDI deficiency decreased IL-2

5 withdrawal-induced apoptosis of lymph node cells while dexamethasone- and T
cell receptor-induced apoptosis remained intact. These data implicate the
regulation of the Rho GTPase by Ly-GDI in lymphocyte survival and
responsiveness, but suggest that these functions may be partially complemented
by other Rho regulatory proteins when the Ly-GDI protein is deficient. Increased
10 expression of GDP-dissociation inhibitor in the mouse asthma model in the lung-
draining lymph nodes of "asthmatic" (OVA-challenged) compared to "healthy"
(saline-challenged) mice was observed. A role for the GDP-dissociation inhibitor
in the generation of Th2 immune responses is provided.

The invention provides a substance such as a proteinaceous substance
15 capable of modulating a gene comprising a nucleic acid at least functionally
equivalent to a nucleic acid identifiable by a signature sequence as shown in
table 1, 2 or 3 and use of said substance for the production of an antagonist
against said substance for example a mouse fragment (signature sequence R1-
SO-R1-A12) homologous to several mouse EST's and human (Cdc42-GAP) was
20 identified. Human Cdc42 GTPase-activating (Cdc42-GAP) functions as a GAP for
the Rho-family GTPase Cdc42 (See figure 1). Cdc42 can regulate the actin
cytoskeleton through activation of Wiskott-Aldrich syndrome protein (WASP).
Mutations in WASP lead to the Wiskott-Aldrich syndrome, a paediatric disorder
characterized by actin cytoskeletal defects in hematopoietic cells, leading
25 clinically to thrombocytopenia, eczema and immunodeficiency. Recently, WASP-
interacting protein (WIP) was shown to enhance the Vav-mediated activation of
NF-AT/AP-1 gene transcription. Moreover, the interaction of WIP with WASP is
necessary, but not sufficient for the ability of WIP to regulate NF-AT/AP-1
activity. Both Ly-GDI and Cdc42-GAP function in concert as inactivators of
30 Cdc42. The invention provides a method for the treatment of immune responses
more in particular allergic asthma and related allergic and Th2-mediated
inflammatory diseases comprising providing blockade of Ly-GDI and/or Cdc42-
GAP by selective antagonist(s) which inhibit T-helper lymphocyte type-2 (Th2)
responses. The invention provides a method for the treatment of immune
35 responses more in particular Th1-lymphocyte mediated diseases like auto-
immune diseases comprising modulating Ly-GDI and/or Cdc42-GAP, more
preferably inducing the expression of these proteins. Induction of the expression
of these proteins induces T-helper lymphocyte type-2 responses and is therefore

5 effective in the treatment of Th1-lymphocyte mediated diseases like auto-immune diseases.

The invention provides a substance such as a proteinaceous substance capable of modulating a gene comprising a nucleic acid at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in
10 table 1, 2 or 3 and use of said substance for the production of an antagonist against said substance for example TIS11d/tristetraprolin homolog (signature sequence OtS2-A7). The human TIS11d protein is part of the TIS11 family of proteins also called tristetraprolin protein. These are basic proline-rich proteins and contain an unusual CCCH type of zinc finger structure. Tumor necrosis
15 factor- α is a major mediator of both acute and chronic inflammatory responses in many diseases. In addition to its well-known role in acute septic shock, it has been implicated in the pathogenesis of chronic processes such as autoimmunity, graft-versus-host disease, rheumatoid arthritis, Crohn disease, and the cachexia accompanying cancer and AIDS. TIS11 interferes with TNF- α production by
20 destabilizing its mRNA. This pathway represents a potential target for anti-TNF- α therapies. TIS11 deficiency also results in increased cellular production of granulocyte-macrophage colony-stimulating factor and increased stability of its mRNA, apparently secondary to decreased deadenylation. TIS11 is a physiologic regulator of GM-CSF mRNA deadenylation and stability. The
25 invention provides a method for the treatment of an immune related response, comprising modulating expression, more preferably increased expression of TIS11d protein which inhibits the development of allergic asthma and related allergic and inflammatory diseases.

The invention provides a substance such as a proteinaceous substance
30 capable of modulating a gene comprising a nucleic acid at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in table 1, 2 or 3 and use of said substance for the production of an antagonist against said substance. The invention further provides the use of said antagonist such as an antibody directed against a proteinaceous substance derived from at
35 least a nucleic acid as shown table 1, 2 or 3 for the production of a medicament for the treatment of an immune response observed with airway hyperresponsiveness and/or bronchoalveolar manifestations of asthma. For example many of the differentially activated genes as listed in table 1, 2 or 3 are

5 involved in the regulation/activation of T-lymphocytes (T-lymphocyte activation molecules). Those up-regulated genes/proteins included terminal deoxynucleotidyl transferase (signature sequence: R1-SO-R1-E7), CsA-19 (signature sequence: ST-O1-B3), Pendulin (signature sequence: R1-SO-R1-E11), RA70 (signature sequence: STO1-D3), Ly-GDI (signature sequence SVO2-1-D8),
 10 Plastin-2 EST (signature sequence: SV02-1-C4), RNA Polymerase-II subunit EST (signature sequence: SV02-1-G3), Clathrin EST (signature sequence: SV02-1-D4), Cdc42-GAP (signature sequence: R1-SO-R1-A12). Those down-regulated genes/proteins were Stat-1 (signature sequence: R1-OS-B1-G3) IL2-R-gamma (signature sequence: OTS2-D9) IFN- γ -R (signature sequence: OTS2-A10).

15 The invention provides a method for modulating an immune response of an individual comprising modulating a gene comprising a nucleic acid at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in table 1, 2 or 3, wherein said gene modulates a signal transduction cascade pertaining to an immune response. Method for modulating the
 20 expression of a nucleic acid are well known. In a preferred embodiment are nucleic acids as shown in table 1, 2 or 3 and functional equivalents whose products are capable of modulating genes of pathways central to immune response. 'Modulating' herein can also mean activation or suppression. More preferable is that the nucleic acid is involved in signal transduction cascades
 25 leading to suppression or activation of an immune responses. More preferable is that the nucleic acid encodes a proteinous substance (e.g a transcription factor) which may be involved in the activation or suppression of the Ras pathway in T-lymphocytes. Activation of the RAS pathway involves the MAP kinase (MAPK) signal transduction pathway which is involved in the induction of many immune
 30 related genes.

The invention provides a substance such as a proteinaceous substance capable of modulating a gene comprising a nucleic acid at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in
 table 1, 2 or 3 and use of said substance for the production of an antagonist
 35 against said substance for example LR8. LR8 is part of a multi-chain Fc receptor and is involved in the signal transduction by this Fc receptor upon ligand (immunoglobulin) binding. The invention provides a method for the treatment of an immune response comprising providing blockade of LR8. Blockade of LR8 prevents the activation of inflammatory cells through this Fc receptor. The

5 invention provides a method for the treatment and/or prevention of an immune
related response comprising modulating inhibition of aspartyl proteases such as
presenilins (γ -secretase) involved in the cleavage of the intracellular 57 amino-
acid part of APLP2 and blockade of the "NPTY" motif, which prevents activation
of downstream signal transduction pathways including the Ras and MAPK
10 pathway and associated changes in gene expression.

The invention provides a substance such as a proteinaceous substance
capable of modulating a gene comprising a nucleic acid at least functionally
equivalent to a nucleic acid identifiable by a signature sequence as shown in
table 1, 2 or 3 and use of said substance for the production of an antagonist
15 against said substance for example Heat-shock protein 84 (Hsp84)(signature
sequence: OTS2-C6). Hsp84 is a member of the Hsp90 family of heat-shock
proteins. Hsp90 proteins are ubiquitous molecular chaperones with key roles in
the folding, activation and assembly of a range of client proteins typically
involved in signal transduction, cell cycle control or transcriptional regulation.
20 Hsp90 has been shown to possess an inherent ATPase activity that is essential
for the activation of authentic client proteins. Recently, Hsp90 and hsc70
(signature sequence: OTS2-H2) are both necessary and sufficient to activate
hormone binding by the glucocorticoid receptor. A deficiency of Hsp90 or Hsp70
proteins may thus decrease the sensitivity of cells to the effects of
25 glucocorticoids. In asthma, a gradual decrease in glucocorticoid sensitivity
occurs. This decrease in glucocorticoid sensitivity can be mimicked by several
cytokines e.g. IL-4. The invention provides a method for the treatment and/or
prevention of an immune related response comprising modulating expression,
more preferably increased expression of Hsp90 and/or Hsp70 proteins. This
30 increases the sensitivity to the anti-inflammatory effects of glucocorticoids and is
valuable in the treatment of asthma and other chronic inflammatory diseases.

Transcription factors are directed to the nucleus by their nuclear
localization sequence (NLS) in a multistep process. The first step is to dock the
NLS-containing protein to the nuclear pore and this is carried out by pendulin
35 and Srp1. Pendulin (signature sequence R1-SO-R1-E11) contains an armadillo
repeat region that is involved in NLS binding. Pendulin has been shown to be
involved in the nuclear localization of lymphoid enhancer factor 1 (LEF-1) but
not of the highly related T-cell factor 1 (TCF-1). Pendulin is the mouse homolog
of human Rch1/Srp1 α /importin- α . In contrast to a low-level of expression of

5 mSrp1 and pendulin in all tissues examined, mouse pendulin is highly expressed in spleen, thymus and heart. Pendulin may perform additional or unique functions in tissues that express high levels of this protein. Increased expression of pendulin in lymph nodes of the mouse asthma model was observed. The invention provides a method for treatment and/or prevention of an immune
10 related response, more preferably asthma and related auto-immune and inflammatory diseases, comprising modulating expression of pendulin, more preferably increasing expression of pendulin.

The invention provides a method for modulating an immune response comprising modulating a gene(s) involved in signal transduction cascades
15 leading to the production of cytokines and/or chemokines and/or growth factors pertaining to an immune response. Cytokines are primarily involved in signaling between cells of the immune system (e.g IL-4, IL-6, IL-8, IL-17 and IL-18). Chemokines are defined primarily as those compounds that draw cells and other factors to sites of injury in the body (e.g human GRO- β , Human IP-10). Growth
20 factors promote cell division and proliferation of certain cell types (e.g human transforming growth factor β -1 etc).

The invention provides a method for modulating an immune response comprising modulating a gene, wherein said gene is involved in sensory nerve activation involved in an immune response. More preferably the immune
25 response is an inflammatory response. Chloride channels appear to be involved in neuronal excitability. Dorsal root ganglia contain sensory nerve bodies that are involved in neurogenic inflammation which contributes to allergic inflammation and pain (inflammatory hyperalgesia). Interference with these chloride channels blockade of hCaCC1 (or gob-5) and/or hCaCC3 (or the murine
30 homolog) by selective antagonists can limit neurogenic inflammation in asthma and other diseases with a neurogenic inflammatory component. Furthermore, cough, which is a prominent symptom of asthma, is believed to be a result of sensory nerve activation. The invention provides a method for the treatment of immune related responses comprising providing blockade of hCaCC1 (or gob-5)
35 and/or hCaCC3 (or the murine homolog) by selective antagonists.

The invention provides a substance such as a proteinaceous substance capable of modulating a gene comprising a nucleic acid at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in table 1, 2 or 3 and use of said substance for the production of an antagonist

5 against said substance for example blockade of hCaCC1 (or gob-5) by a selective antagonist inhibits mast-cell activation and can be used in diseases in which mast-cells play an important role such as all allergic diseases (rhinitis, atopic dermatitis, asthma, urticaria) and auto-immune diseases (i.e. multiple sclerosis). Blockade of hCaCC1 (or gob-5) and/or hCaCC3 inhibits the excitability of sensory
10 neurons and thereby prevents or decreases (1) the neurogenic component of inflammatory responses, (2) hyperalgesia during inflammatory responses and (3) cough due to airway inflammation. Activation of receptors (PAR2) by serine proteases is sensitive to inhibition by APLP2 or its KPI domain and treatment with APLP2 or its KPI domain or induction of APLP2 expression is effective in
15 the treatment of bronchoconstriction induced by activation of sensory nerves.

The invention provides a method for modulating an immune response comprising modulating a gene wherein said gene modulates a Th1 (by way of example but not limitation auto-immune diseases) and/or Th2 (by way of example but not limitation inflammatory diseases) mediated immune response.

20 The invention provides a substance such as a proteinaceous substance capable of modulating a gene comprising a nucleic acid at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in table 1, 2 or 3 and use of said substance for the production of an antagonist against said substance for example membrane C-type lectin like homolog (EST AA914211: signature
25 sequence OtS1-B7). C-type (Ca^{2+} -dependent) lectins represent an important recognition mechanism for oligosaccharides at cell surfaces, attached to circulating proteins and in the extra-cellular matrix. Binding of specific sugar structures by these lectins mediates biological events such as cell-cell adhesion, serum glycoprotein turnover and innate immune responses to potential
30 pathogens. These proteins contain carbohydrate-recognition domains (CRDs) that mediate sugar binding. C-type lectins also contain a Ca^{2+} binding site. C-type lectins have been demonstrated to be present in antigen-presenting cells such as macrophages and dendritic cells. Interestingly, alveolar macrophages have been demonstrated to phagocytose allergens via an undefined C-type lectin
35 leading to the induction of iNOS and subsequent generation of NO by alveolar macrophages. The NO generated by these macrophages may drive T-cell differentiation into the Th2 pathway by inhibition of Th1 responses. The invention provides a method for the treatment and/or prevention of an immune related response comprising providing the targeting of an antigen to this C-type

5 lectin. This induces a Th2 dominated immune response and is effective in the treatment of Th1 mediated diseases such as auto-immune diseases.

The invention provides a substance such as a proteinaceous substance capable of modulating a gene comprising a nucleic acid at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in
10 table 1, 2 or 3 and use of said substance for the production of an antagonist against said substance. The invention further provides the use of said antagonist such as an antibody directed against a proteinaceous substance derived from at least a nucleic acid as shown table 1, 2 or 3 for the production of a medicament for the treatment of an immune response observed with airway
15 hyperresponsiveness and/or bronchoalveolar manifestations of asthma. For example a protein inhibitor of neuronal nitric oxide synthase (mPIN) (signature sequence R1-OS-B1-B1). Nitric oxide (NO) can be produced by several nitric oxide synthase enzymes (nNOS, iNOS and eNOS). Murine PIN is a cytoplasmic protein and is a selective inhibitor of neuronal nitric oxide synthase (nNOS). The
20 human homolog appears to be dynein light chain 1 (hdlc1). NO has been implicated in several diseases including asthma and other inflammatory diseases. Interestingly, nNOS is located on chromosome 12q that has been linked to asthma. The invention shows a down-regulation of mPIN mRNA in lymph nodes of a mouse asthma model. NO negatively regulates type-1 T-helper
25 lymphocyte (Th1) development. Likewise, NO may tip the balance between Th1 and Th2 cells in favor of Th2 responses. The invention provides a method for the treatment and/or prevention of an immune related response, more particular Th2-mediated immune responses such as allergy and asthma comprising modulating PIN expression, more preferably decreasing expression which leads
30 to increased NO release and facilitation of Th2-mediated immune responses such as allergy and asthma. The invention provides a method for the treatment and/or prevention of an immune related response, comprising blockade of PIN activity which is beneficial in Th1 mediated diseases such as auto-immunity by increasing regulatory Th2 cells. Treatment with PIN is beneficial in Th2
35 mediated responses such as asthma and allergy by increasing regulatory Th1 cells. Besides a role of PIN in the regulation T-cells, it plays a role in airway hyper-responsiveness. Neuronal NOS but not iNOS nor eNOS has been demonstrated to be crucial for baseline- and antigen-induced airway hyperresponsiveness in mice. Expression of nNOS but not eNOS nor iNOS in

5 airway epithelial cells of our mouse model of allergic asthma is demonstrated. The invention provides a method for the treatment and/or prevention of an immune related response, comprising modulating nNOS and PIN, more preferably up-regulating nNOS in airway epithelial cells and down-regulating PIN. Up-regulation of nNOS in airway epithelial cells and a down-regulation of
10 PIN can strongly potentiate the production of NO or its metabolites. The invention provides a method for the treatment and/or prevention of an immune related response, comprising modulating expression of PIN, more preferably increasing expression of PIN which inhibits NO production by nNOS and inhibits airway hyperresponsiveness in asthma and related respiratory diseases
15 associated with hyperresponsiveness such as COPD.

The invention provides a substance such as a proteinaceous substance capable of modulating a gene comprising a nucleic acid at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in table 1, 2 or 3 and use of said substance for the production of an
20 antagonist against said substance. The invention further provides the use of said antagonist such as an antibody directed against a proteinaceous substance derived from at least a nucleic acid as shown table 1, 2 or 3 for the production of a medicament for the treatment of an immune response observed with airway hyperresponsiveness and/or bronchoalveolar manifestations of asthma for
25 example cathepsin B (signature sequence: OtS2-F2). Exogenous antigens are processed by lysosomal proteases within antigen-presenting cells to create antigenic peptides which are loaded into MHC class II molecules and expressed on the cell-surface to CD4⁺ T-lymphocytes. Enzymes such as aspartate proteases (e.g. cathepsin D and E) and cysteine proteases (e.g. cathepsin B, L and S) are
30 proposed to be involved in this process. Interestingly, cathepsin B appears to be involved in the generation of Th2 dominated immune responses to ovalbumin and to a Leishmania infection in BALB/c mice. The invention provides a method for the treatment and/or prevention of an immune related response, comprising providing inhibition of the activity of cathepsin B by inhibitors. This inhibits
35 allergic asthma and related allergic and Th2-mediated inflammatory responses.

Furthermore the invention provides a method for the treatment and/or prevention of an immune related response, comprising providing targeting of antigen to LR8 which will induce a Th2 dominated immune response and is effective in the treatment of Th1 mediated diseases such as auto-immune

5 diseases. The invention provides a method for the treatment and/or prevention of
an immune related response, comprising modulating Ly-GDI and/or Cdc42-GAP,
more preferably inducing the expression of these proteins. Modulating Ly-GDI
and/or Cdc42-GAP, or inducing the expression of these proteins induces T-helper
10 lymphocyte type-2 responses and is effective in the treatment of Th1-lymphocyte
mediated diseases like auto-immune diseases.

The invention provides a nucleic acid library comprising nucleic
acid or functional fragments, derivatives or analogues thereof comprising genes
as listed in table 1, 2 or 3 which are implicated in oxidative stress responses
and/or programmed cell death (PCD) (i.e cellular apoptosis). The invention
15 provides a method for treatment of an immune response wherein said nucleic
acid is involved in the generation of anti-oxidants or free radicals. An
'antioxidant' or free radical scavenger is an enzyme that prevents build up of
reactive oxygen species (ROS) in cells. In general anti-oxidants prevent tissue
damage by oxidative stress. Free 'radical generator' is a enzyme that is involved
20 in the generation of ROS.

The invention provides a substance such as a proteinaceous substance
capable of modulating a gene comprising a nucleic acid at least functionally
equivalent to a nucleic acid identifiable by a signature sequence as shown in
table 1, 2 or 3 and use of said substance for the production of an antagonist
25 against said substance. The invention further provides the use of said antagonist
such as an antibody directed against a proteinaceous substance derived from at
least a nucleic acid as shown table 1, 2 or 3 for the production of a medicament
for the treatment of an immune response observed with airway
hyperresponsiveness and/or bronchoalveolar manifestations of asthma for
30 example clusterin/Apolipoproteine J/sulphated glycoprotein 2 (signature
sequence OtS2-B12). Clusterin is a 75-80 kDa disulphide-linked heterodimeric
secreted glycoprotein. It is encoded by a single gene and the translated product is
internally cleaved to produce its α and β subunits prior to secretion from the cell.
It is ubiquitously expressed. There is extensive evidence of a correlation between
35 clusterin expression and diseases e.g. Alzheimer, glioma's or pathological stress.
Many functions have been ascribed to clusterin such as controlling cell-cell and
cell-substratum interactions; regulating apoptosis; transporting lipids;
regulating complement and a general chaperone/heat-shock protein function.

5 The invention provides a method for the treatment and/or prevention of an immune related response, comprising modulating clusterin, more preferably increasing the expression of clusterin, which will inhibit allergic asthma and related allergic and inflammatory diseases.

 Moreover, anti-oxidants may inhibit the expression of genes regulated by
10 the "redox status" within inflammatory cells, such as the ras pathway. Oxidative stress also appears to be involved in the activation of the CD4-associated protein tyrosine kinase p56^{lck}. P56^{lck} is an important protein in the activation of CD4⁺ T-lymphocytes. Oxidative stress is increased in patients with asthma and chronic obstructive pulmonary disease (COPD) and it is possible that reactive oxygen
15 species contribute to its pathophysiology. Likewise, antioxidants might be of use in the therapy of these respiratory diseases. Oxidative stress has also been shown to regulate the cellular glucocorticoid responsiveness. A decreased sensitivity to glucocorticoids has been observed in patients with allergic asthma leading to treatment with either high-doses of glucocorticoids or inappropriate
20 treatment. The invention provides a substance such as a proteinaceous substance capable of modulating a gene comprising a nucleic acid at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in table 1, 2 or 3 and use of said substance for the production of an antagonist against said substance. The invention provides various anti-oxidant
25 proteins down-regulated upon OVA-challenge in the mouse asthma model e.g Selenoprotein P (signature sequence: R1-OS-B1-H1), Gluthation-S-transferase mu2 (signature sequence: OtS2-E6), Ferritine (signature sequence: R1-OS-B1-O5), Anti-oxidant protein 2 (signature sequence: OtS2-A6).

 The invention provides a substance such as a proteinaceous substance
30 capable of modulating a gene comprising a nucleic acid at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in table 1, 2 or 3 and use of said substance for the production of an antagonist against said substance. The invention further provides the use of said antagonist such as an antibody directed against a proteinaceous substance derived from at
35 least a nucleic acid as shown table 1, 2 or 3 for the production of a medicament for the treatment of an immune response observed with airway hyperresponsiveness and/or bronchoalveolar manifestations of asthma for example selenium. Selenium is an essential trace element that is incorporated as selenocysteine into the primary structure of selenoproteins. There are at least 10

5 animal selenoproteins. Animal studies have demonstrated a role for selenium in
oxidant defense, thyroid hormone metabolism, and defense against viral
infections. Selenoproteins presumably mediate these biologic effects. Most of the
human selenoproteins are members of the glutathione peroxidase or
iodothyronine deiodinase families. Selenoprotein P (SEPP1) is not a member of
10 these families. It is an extracellular glycoprotein that is present in several
isoforms and is the only selenoprotein known to contain multiple selenocysteine
residues. It is a heparin-binding protein that appears to be associated with
endothelial cells and has been implicated as an oxidant defense in the
extracellular space. There is evidence that several isoforms of the protein exist,
15 likely products of the same gene. Human selenoprotein has been mapped to
chromosome 5q31. Interestingly, many studies have demonstrated a linkage
between chromosome 5q and allergy, asthma and airway hyperreactivity. There
is considerable evidence that oxidative stress is increased in patients with
chronic obstructive pulmonary disease (COPD) and that reactive oxygen species
20 contribute to its pathophysiology. Likewise, it has been postulated that
antioxidants might be of use in the therapy of COPD. Selenoprotein P may be
useful as a therapeutic protein in diseases that are associated with increased
oxidative stress such as COPD, asthma and other inflammatory diseases. It was
observed that mRNA levels of selenoprotein P are decreased in lymph node
25 tissue of a mouse asthma model. Selenium and selenoproteins have been shown
to play a role in the function of granulocytes and lymphocytes. The invention
provides a method for the treatment and/or prevention of an immune related
response, comprising modulating selenoprotein P.

The invention provides a method for modulating an immune related
30 response, comprising modulating the generation of anti-oxidants or free radicals.
Treatment with anti-oxidant proteins (e.g by inhalation) or induction of the
expression of these proteins and/or suppression of free radical generators in
airway tissue can be used to treat allergic inflammation or related inflammatory
diseases or diseases associated with increased oxidative stress such as asthma
35 and COPD. Treatment with anti-oxidant proteins or induction of the expression
of these proteins in airway tissue together with glucocorticoid treatment can
limit the dose of glucocorticoids required for a therapeutic effect in patients with
allergic asthma and other chronic inflammatory diseases associated with
glucocorticoid insensitivity.

5 The invention provides a substance such as a proteinaceous substance capable of modulating a gene comprising a nucleic acid at least functionally table 1, 2 or 3 and use of said substance for the production of an antagonist against said substance. The invention further provides the use of said antagonist such as an antibody directed against a proteinaceous substance derived from at least a

10 nucleic acid as shown table 1, 2 or 3 for the production of a medicament for the treatment of an immune response observed with airway hyperresponsiveness and/or bronchoalveolar manifestations of asthma for example cytochrome P-450 naphthalene hydroxylase (CYP2F2) enzymes (signature sequence R1-OS-B1-A1). CYP2F2 are a superfamily of more than 160 known members that play a major

15 role in the metabolism of numerous physiological substrates and a wide array of xenobiotics including drugs, chemical carcinogens, insecticides, petroleum products, and other environmental pollutants. Oxidative metabolism catalyzed by cytochrome P450s can result in detoxification. In some instances it results in metabolic activation of a chemical to cytotoxic and/or carcinogenic forms.

20 Although the liver is the primary organ for drug metabolism, extrahepatic tissues such as lung, kidney and intestine, also play an important role in detoxification or biotransformation of xenobiotics. Each tissue has a unique P450 isozyme distribution and regulatory mechanism for cytochrome P450 gene expression. Currently, the members of the CYP2F gene subfamily that are

25 selectively expressed in lung tissues consist of human CYP2F1 and mouse CYP2F2 and CYP2F3. Human CYP2F1 bioactivates 3-methylindole, while mouse CYP2F2 bioactivates naphthalene. Mouse CYP2F3 catalyzes the dehydrogenation of 3-methylindole but not its hydroxylation. Murine CYP2F2 is expressed in lung tissue as well as in liver. In the lung, it plays an important role in the metabolic

30 activation of substrates that cause lung injury. CYP2F2 is involved in the hydroxylation of naphthalene and it specifically catalyses the production of a very reactive and potentially toxic intermediate, the 2R, 2S arene oxide, that is associated with necrosis of unciliated bronchiolar epithelial cells or CLARA cells in lung. Several P450 enzymes with epoxygenase activity have also been shown

35 to be involved in the metabolism of arachidonic acid into biologically active eicosanoids. Based on the bioactivation of naphthalene, we anticipate that CYP2F enzymes also displays epoxygenase activity. The epoxygenase pathway leads to the formation of four regio-isomeric epoxy-eicosatrienoic acids (EETs): 14,15-EET, 11,12-EET, 8,9-EET and 5,6-EET. From these epoxides, other lipid

5 mediators can be generated such as 14,15-DHET, 11,12-DHET, 8,9-DHET, 5,6-DHET and 5,6-epoxy prostaglandin E1. Some of these epoxides have been shown to induce vasorelaxation. 5,6-EET and 11,12-EET have also been shown to modulate tracheal chloride-channel activity and induce airway smooth muscle relaxation. Epoxides generated through CYP2F may therefore protect against
10 excessive bronchoconstriction and may be involved in airway hyperreactivity in asthma and other respiratory diseases. Epoxygenase metabolites have also been shown to have anti-inflammatory activities such as inhibition of leukocyte adhesion to the vascular wall and inhibition of I κ B kinase thereby preventing the activation of NF- κ B. Cytochrome P-450 naphthalene hydroxylase (CYP2F2). A
15 strong (>10-fold) down-regulation of cytochrome P450 (CYP2F2) mRNA in a mouse asthma model in the lymph nodes of "asthmatic" (OVA-challenged) compared to "healthy" (saline-challenged) mice was observed. The invention provides a method for the treatment and/or prevention of an immune related response, comprising modulating the expression of CYP2F, more preferably
20 increasing expression of CYP2F in airway tissue and/or by preventing its down-regulation. This inhibits airway hyperresponsiveness and excessive bronchoconstriction and can be used to treat allergic asthma and other respiratory diseases associated with hyperresponsiveness such as COPD. The invention provides a method for the treatment and/or prevention of an immune
25 related response, comprising providing local treatment (inhalation) with CYP2F metabolites of arachidonic acid, in particular 11,12-EET, which inhibits airway inflammation for treatment of allergic asthma and other respiratory inflammatory diseases such as COPD. The invention provides for a method of treatment and/or prevention of an immune related response, comprising
30 modulating the enzymatic activity of CYF2F, more preferably stimulating the enzymatic activity of CYF2F by an allosteric stimulator which increases the generation of epoxides and likewise inhibits airway hyperresponsiveness and airway inflammation. Stimulation of the enzymatic activity of CYF2F by an allosteric stimulator is effective in the treatment of allergic asthma and other
35 respiratory diseases such as COPD.

The invention provides a substance such as a proteinaceous substance capable of modulating a gene comprising a nucleic acid at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in

5 table 1, 2 or 3 and use of said substance for the production of an antagonist
against said substance. The invention further provides the use of said antagonist
such as an antibody directed against a proteinaceous substance derived from at
least a nucleic acid as shown table 1, 2 or 3 for the production of a medicament
for the treatment of an immune response observed with airway
10 hyperresponsiveness and/or bronchoalveolar manifestations of asthma. For
example four families of structurally related heat-shock proteins are
distinguished based on their molecular weights: Hsp90, Hsp70, Hsp60 and small
Hsp's. By definition, Hsp expression is elevated in cells undergoing stress, such
as those in damaged or inflamed tissue. Conditions as diverse as a rise in
15 temperature, hypoxia, irradiation, infection and exposure to toxic chemicals can
all result in increased Hsp expression. Heat-shock cognate protein (Hsc)73 is a
constitutively expressed member of the Hsp70 family. Hsc73 is expressed in the
cytosol but is also present in lysosomes. Hsc73 plays a role in binding and
protecting peptides from extensive degradation and facilitating the kinetics of
20 peptide transfer to MHC class II molecules. Hsc73 is also present in dendritic
cell-derived exosomes which have been shown to elicit potent T-cell dependent
immune responses in mice. Moreover, a receptor for Hsp70 proteins is present on
the surface of macrophages and dendritic cells and Hsp70 can induce
macrophages to activate T-cells independently of antigen. Thus, Hsc73 appears
25 to be involved in antigen-presentation and T-cell activation. Administration of
antigen or antigenic peptides together with Hsp70 proteins has been shown to
generate CD8⁺ T-lymphocyte responses when administered to laboratory
animals. Moreover, Hsp70 is involved in cross-priming of CD8⁺ cells by APC
upon antigen processing. Recently, Hsp70 has also been shown to be involved in
30 the induction of regulatory T-cells. Hsc73 (signature sequence: OtS2-H2) may
also be involved in the induction of inducible nitric oxide synthase (iNOS) by LPS
or cytokines via an effect on p38 mitogen-activated protein (MAP) kinase. In
agreement herewith, the selective hsc73 inhibitor deoxyspergualin inhibits the
induction of iNOS by cytokine- or endotoxin-activated macrophages. NO has
35 been shown to inhibit the generation of Th1 lymphocytes thereby tipping the
balance towards Th2 immune responses. In airway epithelial cells, Hsp70 has
been shown to have potent anti-inflammatory effects by stabilization of I κ B α
through preventing the activation of I κ B kinase leading to inhibition of NF- κ B

5 activation and down-stream gene transcription. In airway epithelial cells, increased Hsp70 expression suppressed cytokine-induced expression of pro-inflammatory cytokines IL8 and TNF α .

The invention provides a substance such as a proteinaceous substance capable of modulating a gene comprising a nucleic acid at least functionally
10 equivalent to a nucleic acid identifiable by a signature sequence as shown in table 1, 2 or 3 and use of said substance for the production of an antagonist against said substance. The invention further provides the use of said antagonist such as an antibody directed against a proteinaceous substance derived from at least a nucleic acid as shown table 1, 2 or 3 for the production of a medicament
15 for the treatment of an immune response observed with airway hyperresponsiveness and/or bronchoalveolar manifestations of asthma. For example the invention provides for a method of treatment and/or prevention of an immune related response, comprising providing an antagonist(s) directed against Hsc73. This inhibits the generation of NO by APC's and thereby limits a
20 Th2 dominated immune response by increasing Th1 immunity. This treatment is effective in the treatment of allergic asthma and related allergic and inflammatory responses.

The invention provides a substance such as a proteinaceous substance capable of modulating a gene comprising a nucleic acid at least functionally
25 equivalent to a nucleic acid identifiable by a signature sequence as shown in table 1, 2 or 3 and use of said substance for the production of an antagonist against said substance. The invention further provides the use of said antagonist such as an antibody directed against a proteinaceous substance derived from at least a nucleic acid as shown table 1, 2 or 3 for the production of a medicament
30 for the treatment of an immune response observed with airway hyperresponsiveness and/or bronchoalveolar manifestations of asthma. For example, the invention provides for a method of treatment and/or prevention of an immune related response, more particularly allergic inflammation or related inflammatory diseases (e.g. COPD) comprising modulating, more preferably up-
35 regulating the expression of Hsc73 leading to induction and/or elevation of the expression of Hsc73 protein in airway epithelial cells.

The invention provides a method for treatment of an immune response comprising providing an antagonist of antigen processing and presentation. 'Antagonist' herein refers to a molecule that bears sufficient structural

5 similarity to a second molecule to compete with that molecule for binding sites
on a third molecule, such as for example an antibody. An 'antibody' herein refers
to a protein produced by lymphoid cells in response to foreign substances
(antigens) and capable of coupling specifically with it's homologous antigen (the
one that stimulated the immune response) or with substances that are
10 chemically very similar to that antigen. Antibody herein refers to both polyclonal
and monoclonal antibodies.

The invention provides a substance such as a proteinaceous substance
capable of modulating a gene comprising a nucleic acid at least functionally
equivalent to a nucleic acid identifiable by a signature sequence as shown in
15 table 1, 2 or 3 and use of said substance for the production of an antagonist
against said substance by way of example the invention provides nucleic acids as
listed in table 1, 2 or 3 which are involved in antigen processing and
presentation MHC-II (signature sequence: StO1-B5), H2-Oa (MHC-II: signature
sequence: SvO2-1-A4), EST: Clathrin (signature sequence: SvO2-1-D4), Aspartyl
20 aminopeptidase (signature sequence: StO1-c1), Cathepsin B (signature sequence:
OtS2-F2), Breast heat shock 73 protein (signature sequence: OtS2-H2), EST: C-
type lectin (signature sequence: OtS1-B7), Ubiquitin-specific protease (signature
sequence: R1-OSB1-A2), Ubiquitin/60s (signature sequence: SVO2-1-C12) and
Lysozyme M (OtS2-B1). Antigen-presenting cells play an important role in the
25 differentiation of CD4⁺ and CD8⁺ T-lymphocytes into particular subsets (Type-1,
Type-2, Type-3 or regulatory types) and are important for the generation of
either a detrimental or a beneficial immune response to antigens.

The invention provides for a method of treatment and/or prevention of an
immune related response, comprising providing an antagonist(s) directed against
30 a proteinaceous substance derived from a nucleic acid sequence at least
functionally equivalent to a nucleic acid identifiable by a signature sequence as
shown in table 1, 2 or 3. The invention provides a substance such as a
proteinaceous substance capable of modulating a gene comprising a nucleic acid
at least functionally equivalent to a nucleic acid identifiable by a signature
35 sequence as shown in table 1, 2 or 3 and use of said substance for the production
of an antagonist against said substance. The invention further provides the use
of said antagonist such as an antibody directed against a proteinaceous
substance derived from at least a nucleic acid as shown table 1, 2 or 3 for the
production of a medicament for the treatment of an immune response observed

5 with airway hyperresponsiveness and/or bronchoalveolar manifestations of
asthma. For example Phospholipase Cy2 (PLCy2). (signature sequence: SvO2-1-
A8). PLCy2 unlike PLCy1 which is expressed in many cell-types, PLCy2 is only
expressed in hematopoietic cells (e.g. B-lymphocytes, NK-cells, platelets,
granulocytes, monocytes/macrophages and mast cells). PLCy2 is a cell signaling
10 molecule with many regulatory domains e.g. SH2, SH3, pH domains. It catalyzes
the hydrolysis of phosphatidyl-inositol 4,5-biphosphate to yield the second
messengers, IP3 and DAG. PLCy2 has been shown to be involved in production of
reactive oxygen intermediates by neutrophils. In addition to PLCy1, PLCy2 is
activated upon triggering of mast-cells via Fcε RI. The promotor region of PLCy2
15 has Sp1, NF1, AP2, SRE, EBF and CACCC box consensus sites. In B-cells,
mRNA expression of PLCy2 is enhanced by serum, TPA, retinoic acid and 5-
azacytidine. The invention provides for a method of treatment and/or prevention
of an immune related response, comprising providing an antagonist(s) directed
against a proteinaceous substance derived from a nucleic acid sequence at least
20 functionally equivalent to a nucleic acid identifiable by a signature sequence as
shown in table 1, 2 or 3. The invention provides a substance such as a
proteinaceous substance capable of modulating a gene comprising a nucleic acid
at least functionally equivalent to a nucleic acid identifiable by a signature
sequence as shown in table 1, 2 or 3 and use of said substance for the production
25 of an antagonist against said substance. The invention further provides the use
of said antagonist such as an antibody directed against a proteinaceous
substance derived from at least a nucleic acid as shown table 1, 2 or 3 for the
production of a medicament for the treatment of an immune response observed
with airway hyperresponsiveness and/or bronchoalveolar manifestations of
30 asthma. For example the invention provides for a method of treatment and/or
prevention of an immune related response, comprising providing an
antagonist(s) directed against PLCy2 or a proteinaceous substance comprising
PLCy2 is effective in the treatment of allergic asthma and related allergic and
inflammatory diseases.

35 The invention provides for a method of treatment and/or prevention of an
immune related response, comprising providing an antagonist(s) directed against
a proteinaceous substance derived from a nucleic acid sequence at least
functionally equivalent to a nucleic acid identifiable by a signature sequence as

5 shown in table 1, 2 or 3. The invention provides a substance such as a
proteinaceous substance capable of modulating a gene comprising a nucleic acid
at least functionally equivalent to a nucleic acid identifiable by a signature
sequence as shown in table 1, 2 or 3 and use of said substance for the production
of an antagonist against said substance. The invention further provides the use
10 of said antagonist such as an antibody directed against a proteinaceous
substance derived from at least a nucleic acid as shown table 1, 2 or 3 for the
production of a medicament for the treatment of an immune response observed
with airway hyperresponsiveness and/or bronchoalveolar manifestations of
asthma. For example APLP2 C31 (signature sequence: SvO2-1-B7) peptide is
15 involved in cell death (apoptosis). Apoptosis or cell-death is an important
mechanism to limit immune reactions. The cytoplasmic domain of APLP2
containing the "NPTY" motif is involved in T-lymphocyte activation upon
phosphorylation of the tyrosine (Y) residue leading to Shc binding. The invention
provides for a method of treatment and/or prevention of an immune related
20 response, comprising providing an antagonist(s) directed against a proteinaceous
substance derived from a nucleic acid sequence at least functionally equivalent
to a nucleic acid identifiable by a signature sequence as shown in table 1, 2 or 3.
The invention provides a substance such as a proteinaceous substance capable of
modulating a gene comprising a nucleic acid at least functionally equivalent to a
25 nucleic acid identifiable by a signature sequence as shown in table 1, 2 or 3 and
use of said substance for the production of an antagonist against said substance.
The invention further provides the use of said antagonist such as an antibody
directed against a proteinaceous substance derived from at least a nucleic acid as
shown table 1, 2 or 3 for the production of a medicament for the treatment of an
30 immune response observed with airway hyperresponsiveness and/or
bronchoalveolar manifestations of asthma. For example the invention provides
for a method of treatment and/or prevention of an immune related response,
comprising providing an antagonist(s) directed against APLP2, more specifically
the cytoplasmic domain of APLP2 containing the "NPTY" motif. This prevents
35 the Ras-pathway of T-lymphocyte activation and inhibits an immune response
and is effective in the treatment of allergic asthma and related allergic and
inflammatory diseases. The invention provides for a method of treatment and/or
prevention of an immune related response, comprising providing an
antagonist(s) directed against "VEVD" and "NPTY" motif inhibits unwanted cell

5 death mediated by this pathway and is effective in the treatment of allergic
asthma and related allergic and inflammatory diseases. The invention provides
for a method of treatment and/or prevention of an immune related response,
comprising providing an antagonist(s) directed against a proteinaceous
substance derived from a nucleic acid sequence at least functionally equivalent
10 to a nucleic acid identifiable by a signature sequence as shown in table 1, 2 or 3.
The invention provides a substance such as a proteinaceous substance capable of
modulating a gene comprising a nucleic acid at least functionally equivalent to a
nucleic acid identifiable by a signature sequence as shown in table 1, 2 or 3 and
use of said substance for the production of an antagonist against said substance.
15 The invention further provides the use of said antagonist such as an antibody
directed against a proteinaceous substance derived from at least a nucleic acid as
shown table 1, 2 or 3 for the production of a medicament for the treatment of an
immune response observed with airway hyperresponsiveness and/or
bronchoalveolar manifestations of asthma. For example the invention provides
20 for a method of treatment and/or prevention of an immune related response,
comprising providing inhibition of the generation of the C-terminal 31 amino
acid APLP2 peptide by caspases and/or proteases encoded by the nucleic acid of
table 1, 2 or 3 which inhibits unwanted cell death mediated by this pathway.

The invention provides for a method of treatment and/or prevention of an
25 immune related response, comprising providing an antagonist(s) directed against
a proteinaceous substance derived from a nucleic acid sequence at least
functionally equivalent to a nucleic acid identifiable by a signature sequence as
shown in table 1, 2 or 3. The invention provides a substance such as a
proteinaceous substance capable of modulating a gene comprising a nucleic acid
30 at least functionally equivalent to a nucleic acid identifiable by a signature
sequence as shown in table 1, 2 or 3 and use of said substance for the production
of an antagonist against said substance. The invention further provides the use
of said antagonist such as an antibody directed against a proteinaceous
substance derived from at least a nucleic acid as shown table 1, 2 or 3 for the
35 production of a medicament for the treatment of an immune response observed
with airway hyperresponsiveness and/or bronchoalveolar manifestations of
asthma. For example the invention provides for a method of treatment and/or
prevention of an immune related response, comprising providing an
antagonist(s) directed against hCaCC1 (or gob-5) (signature sequence: R1-SO-

5 R1-C11) which inhibits mast-cell activation and can be used in the treatment of immune diseases in which mast-cells play an important role such as all allergic diseases (rhinitis, atopic dermatitis, asthma, urticaria) and auto-immune diseases (i.e. multiple sclerosis).

10 The invention provides for a method of treatment and/or prevention of an immune related response, comprising providing an antagonist(s) directed against a proteinaceous substance derived from a nucleic acid sequence at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in table 1, 2 or 3. The invention provides a substance such as a proteinaceous substance capable of modulating a gene comprising a nucleic acid
15 at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in table 1, 2 or 3 and use of said substance for the production of an antagonist against said substance. The invention further provides the use of said antagonist such as an antibody directed against a proteinaceous substance derived from at least a nucleic acid as shown table 1, 2 or 3 for the
20 production of a medicament for the treatment of an immune response observed with airway hyperresponsiveness and/or bronchoalveolar manifestations of asthma. For example the invention provides for a method of treatment and/or prevention of an immune related response, comprising providing an antagonist(s) directed against Hsc73. This inhibits the generation of NO by
25 APC's and thereby limits a Th2 dominated immune response by increasing Th1 immunity. This treatment is effective in the treatment of allergic asthma and related allergic and inflammatory responses.

The invention provides for a method of treatment and/or prevention of an immune related response, comprising providing an antagonist(s) directed against
30 a proteinaceous substance derived from a nucleic acid sequence at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in table 1, 2 or 3. The invention provides a substance such as a proteinaceous substance capable of modulating a gene comprising a nucleic acid at least functionally equivalent to a nucleic acid identifiable by a signature
35 sequence as shown in table 1, 2 or 3 and use of said substance for the production of an antagonist against said substance. The invention further provides the use of said antagonist such as an antibody directed against a proteinaceous substance derived from at least a nucleic acid as shown table 1-3 for the production of a medicament for the treatment of an immune response observed

5 with airway hyperresponsiveness and/or bronchoalveolar manifestations of asthma. For example the invention provides for a method of treatment and/or prevention of an immune related response, comprising providing an antagonist(s) directed against LR8 which inhibits allergic asthma and related allergic and inflammatory diseases.

10 The invention provides for a method of treatment and/or prevention of an immune related response, comprising providing an antagonist(s) directed against a proteinaceous substance derived from a nucleic acid sequence at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in table 1, 2 or 3. The invention provides a substance such as a
15 proteinaceous substance capable of modulating a gene comprising a nucleic acid at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in table 1-3 and use of said substance for the production of an antagonist against said substance. The invention further provides the use of said antagonist such as an antibody directed against a proteinaceous substance
20 derived from at least a nucleic acid as shown table 1-3 for the production of a medicament for the treatment of an immune response observed with airway hyperresponsiveness and/or bronchoalveolar manifestations of asthma. More preferably a method of treatment and/or prevention of an immune related response, more preferably allergic asthma and related allergic and inflammatory
25 diseases, comprising providing an antagonist(s) directed against one or more up-regulated genes as listed in table 1, 2 or 3 or the corresponding proteinaceous substances.

The invention provides for a method of treatment and/or prevention of an immune related response, comprising providing an antagonist(s) directed against
30 a proteinaceous substance derived from a nucleic acid sequence at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in table 1, 2 or 3. The invention provides a substance such as a proteinaceous substance capable of modulating a gene comprising a nucleic acid at least functionally equivalent to a nucleic acid identifiable by a signature
35 sequence as shown in table 1-3 and use of said substance for the production of an antagonist against said substance. The invention further provides the use of said antagonist such as an antibody directed against a proteinaceous substance derived from at least a nucleic acid as shown table 1-3 for the production of a medicament for the treatment of an immune response observed with airway

5 hyperresponsiveness and/or bronchoalveolar manifestations of asthma. For
example the invention provides for a method of treatment and/or prevention of
an immune related response, comprising providing an antagonist(s) directed
against Ly-GDI (signature sequence: SVO2-1-D8) and/or Cdc42-GAP (signature
sequence: R1-SO-R1-A12) which inhibits T-helper lymphocyte type-2 (Th2)
10 responses and is effective in the treatment of allergic asthma and related allergic
and Th2-mediated inflammatory diseases.

The invention provides for a method of treatment and/or prevention of an
immune related response, comprising providing an antagonist(s) directed against
a proteinaceous substance derived from a nucleic acid sequence at least
15 functionally equivalent to a nucleic acid identifiable by a signature sequence as
shown in table 1, 2 or 3. The invention provides a substance such as a
proteinaceous substance capable of modulating a gene comprising a nucleic acid
at least functionally equivalent to a nucleic acid identifiable by a signature
sequence as shown in table 1-3 and use of said substance for the production of an
20 antagonist against said substance. The invention further provides the use of said
antagonist such as an antibody directed against a proteinaceous substance
derived from at least a nucleic acid as shown table 1-3 for the production of a
medicament for the treatment of an immune response observed with airway
hyperresponsiveness and/or bronchoalveolar manifestations of asthma. For
25 example the invention provides for a method of treatment and/or prevention of
an immune related response, comprising providing an antagonist(s) directed
against C-type lectin (signature sequence: Ot-S2-B7) which inhibits antigen
presentation and skewing towards a Th2 dominated immune response. This
blockade is effective in the treatment of allergic asthma and related allergic and
30 inflammatory diseases.

The invention provides a method for modulating an immune response
wherein said gene modulates CD8⁺ T-lymphocyte responses. Also provided is a
gene or gene product capable of inducing a specific regulatory CD4⁺ and/or CD8⁺
T-lymphocyte response that inhibits Th2 dominated allergic responses. The
35 invention provides a method for modulating an immune response wherein said
gene modulates CD4⁺ T-lymphocyte responses. The invention provides for a
method of treatment and/or prevention of an immune related response,
comprising providing an antagonist(s) directed against a proteinaceous
substance derived from a nucleic acid sequence at least functionally equivalent

5 to a nucleic acid identifiable by a signature sequence as shown in table 1, 2 or 3. The invention provides a substance such as a proteinaceous substance capable of modulating a gene comprising a nucleic acid at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in table 1-3 and use of said substance for the production of an antagonist against said substance. The

10 invention further provides the use of said antagonist such as an antibody directed against a proteinaceous substance derived from at least a nucleic acid as shown table 1-3 for the production of a medicament for the treatment of an immune response observed with airway hyperresponsiveness and/or bronchoalveolar manifestations of asthma for example Ubiquitin-specific

15 protease (UBP43)(signature sequence R1-OS-B1-A2). UBP43 belongs to a family of ubiquitin-specific proteases (UBP) and has a molecular mass of 43 kDa. Protein ubiquitination has been implicated in many important cellular events. The human homolog of this protein is ISG43. In wild-type adult mice, UBP43 is highly expressed in thymus and peritoneal macrophages. Furthermore, it is

20 expressed in cell-lines of the monocytic lineage and its expression is regulated during cytokine-induced monocytic cell differentiation. Over expression of UBP43 has been shown to block cytokine-induced terminal differentiation of the monocytic cell-line M1. Down-regulation of UBP43 mRNA in lymph nodes of a mouse asthma model was observed. The invention provides for a method of

25 treatment and/or prevention of an immune related response, comprising modulating the expression of UBP43, more preferably increasing the expression of UBP43 in APC's which prevents allergic asthma and related respiratory disease by increasing the generation of regulatory CD8⁺ T-lymphocytes. The proteasome is involved in the generation of MHC class-I peptides by proteases.

30 The invention provides for a method of treatment and/or prevention of an immune related response, comprising providing an antagonist(s) directed against a proteinaceous substance derived from a nucleic acid sequence at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in table 1, 2 or 3. The invention provides a substance such as a

35 proteinaceous substance capable of modulating a gene comprising a nucleic acid at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in table 1-3 and use of said substance for the production of an antagonist against said substance. The invention further provides the use of said antagonist such as an antibody directed against a proteinaceous substance

5 derived from at least a nucleic acid as shown table 1-3 for the production of a
medicament for the treatment of an immune response observed with airway
hyperresponsiveness and/or bronchoalveolar manifestations of asthma. For
example the invention provides for a method of treatment and/or prevention of
an immune related response, comprising providing inhibition of peptide loading
10 into MHC class-I molecules by proteases encoded by the nucleic acid as outlined
in table 1, 2 or 3, which inhibits the generation of CD8⁺ T-lymphocyte responses
(i.e T-lymphocyte costimulation). Airway wall remodeling is an established
pathological feature of asthma but its causes are not well understood. One
cytokine of potential relevance is transforming growth factor-beta1 (TGF-beta 1).
15 In patients with asthma, matrix-associated TGF-beta 1 is likely to be bound at
least in part to decorin (signature sequence: R1-OS-B1-C5). This interaction may
provide a reservoir of TGF-beta 1 that can be released in an active form in
response to appropriate stimuli. Decorin is also a natural inhibitor of TGF-beta
and has been shown to restore T-lymphocyte responses to mycobacteria. The
20 invention provides for a method of treatment and/or prevention of an immune
related response, comprising modulating the expression of decorin, preferably
increasing the expression of decorin. Increased expression of decorin in airway
tissue and/or treatment (inhalation) with decorin inhibits the effects on TGF-
beta on airway tissue remodeling and is effective in the treatment of immune
25 related responses.

The invention provides for a method of treatment and/or prevention of an
immune related response, comprising providing an antagonist(s) directed against
a proteinaceous substance derived from a nucleic acid sequence at least
functionally equivalent to a nucleic acid identifiable by a signature sequence as
30 shown in table 1, 2 or 3. The invention provides a substance such as a
proteinaceous substance capable of modulating a gene comprising a nucleic acid
at least functionally equivalent to a nucleic acid identifiable by a signature
sequence as shown in table 1-3 and use of said substance for the production of an
antagonist against said substance for example the invention provides for a
35 method of treatment and/or prevention of an immune related response,
comprising providing immunotherapy using Hsc73, alone or together with
antigen/allergen. An allergen herein is defined as a substance inducing
hypersensitivity. Immunotherapy using Hsc73, alone or together with

5 antigen/allergen induces a specific regulatory CD4⁺ or CD8⁺ T-lymphocyte response that inhibits Th2 dominated allergic responses.

The invention provides for a method of treatment and/or prevention of an immune related response, comprising providing an antagonist(s) directed against a proteinaceous substance derived from a nucleic acid sequence at least
10 functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in table 1, 2 or 3. The invention provides a substance such as a proteinaceous substance capable of modulating a gene comprising a nucleic acid at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in table 1-3 and use of said substance for the production of an
15 antagonist against said substance for example the invention provides a method for modulating an immune response of an individual wherein said gene encodes a gene product capable of modulating an immune response. A gene product herein refers the mRNA and the polypeptide chain translated from an mRNA molecule, which in turn is transcribed from a gene; if the RNA transcript is not
20 translated (e.g rRNA, tRNA) the RNA molecule represents the gene product. The gene product herein can refer to any proteinaceous substance. A proteinaceous substance can refer to any molecule comprising amino acid and/or peptide or protein.

The invention provides alleles of the polypeptide(s) encoded by nucleic
25 acid sequences of this invention. As used herein, an 'allele' or 'allelic sequence' is an alternative form of the polypeptides described above. Alleles result from a mutation [eg. a change in the nucleic acid sequence, and generally produce altered mRNA or polypeptide whose structure or function may or may not be altered]. Any given polypeptide may have none, or more allelic forms. Common
30 allelic changes that give rise to alleles are generally ascribed to natural deletions, additions or substitutions of amino acids. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence. Deliberate amino acid substitution may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, and/or the
35 amphipathetic nature of the residues as long as the biological activity of the polypeptide is retained. Altered nucleic acid sequences of this invention include deletions, insertions, substitutions of different nucleotides resulting in the polynucleotides that encode the same or are functionally equivalent. A 'deletion' is defined as a change in either nucleotide or amino acid sequence in which one

5 or more nucleotides or amino acid residues, respectively, are absent. An
'insertion' or 'addition' is that change in nucleotide or amino acid sequence which
has resulted in the addition of one or more nucleotides or amino acid residues,
respectively, as compared to the naturally occurring polypeptide(s). A
'substitution' results from the replacement of one or more nucleotides or amino
10 acids by different nucleotides or amino acids, respectively. The invention
includes variants of the polypeptide. A 'variant' of a polypeptide is defined as an
amino acid sequence that is different by one or more amino acid 'substitutions'. A
variant may have 'conservative' changes, wherein a substituted amino acid has
similar structural or chemical properties eg replacement of leucine with
15 isoleucine. More rarely a variant may have 'non-conservative' changes (eg
replacement of a glycine with a tryptophan). Similar minor variations may also
include amino acid deletions or insertions, or both. Guidance in determining
which and how many amino acid residues may be substituted, inserted or
deleted, without abolishing biological or immunological activity may be found
20 using computer programs well known in the art, for example, DNASTar software.

The invention provides a method modulating an immune response
wherein said immune response comprise airway hyperresponsiveness and/or
bronchoalveolar manifestations of asthma.

The invention provides a method modulating an immune response
25 wherein said gene is modulated by transducing a cell of said individual.
Methods to transduce cells are known in the art. Target cells can be transduced
with a nucleic acid delivery vehicle comprising at least one nucleic acid the
subject of the invention. A 'gene delivery vehicle' herein is used as a term for a
recombinant virus particle or the nucleic acid within such a particle, or the
30 vector itself, wherein the vector comprises the nucleic acid to be delivered to the
target cell(s) and is further provided with a means to enter said cell(s). This
cell(s) can be used for drug screening and drug discovery.

The invention provides for a method of treatment and/or prevention of an
immune related response, comprising providing an antagonist(s) directed against
35 a proteinaceous substance derived from a nucleic acid sequence at least
functionally equivalent to a nucleic acid identifiable by a signature sequence as
shown in table 1, 2 or 3. The invention provides a substance such as a
proteinaceous substance capable of modulating a gene comprising a nucleic acid
at least functionally equivalent to a nucleic acid identifiable by a signature

5 sequence as shown in table 1-3 and use of said substance for the production of an antagonist against said substance, for example the invention provides a substance capable of modulating a gene comprising a nucleic acid at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in table 1, 2 or 3.

10 A substance herein refers to any material entity capable of modulating a gene the subject of the invention, for example an 'entity' can be a molecule wherein said molecule is a chemical compound. The substance can also be an 'antigen' a foreign invader comprising a protein or protein attached moiety. The substance can also be of proteinaceous origin comprising amino acid and/or
15 peptide or protein.

The invention provides a medicament comprising a substance capable of modulating a gene(s) the subject of the invention. A preferred embodiment is a medicament which is a pharmaceutical. Suitable pharmaceutical compositions are known.

20 The invention provides the use of a substance for the production of a medicament for the treatment of an immune response observed with airway hyperresponsiveness and/or bronchoalveolar manifestations of asthma.

The invention provides for a method of treatment and/or prevention of an immune related response, comprising providing an antagonist(s) directed against
25 a proteinaceous substance derived from a nucleic acid sequence at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in table 1, 2 or 3. The invention provides a substance such as a proteinaceous substance capable of modulating a gene comprising a nucleic acid at least functionally equivalent to a nucleic acid identifiable by a signature
30 sequence as shown in table 1-3 and use of said substance for the production of an antagonist against said substance, for example the invention provides the use of a proteinaceous substance derived from a nucleic acid at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in table 1, 2 or 3 for the production of an antagonist against said substance.
35 'Antagonist' herein refers to a molecule that bears sufficient structural similarity to a second molecule to compete with that molecule for binding sites on a third molecule, for example an antibody.

The invention provides the use of a proteinaceous substance derived from a nucleic acid at least functionally equivalent to a nucleic acid identifiable by a

5 signature sequence as shown in table 1, 2 or 3 for the production of an antagonist against said substance, wherein said antagonist is an antibody or functional equivalent thereof. An 'antibody' herein refers to a protein produced by cells in response to foreign substances (antigens) and capable of coupling specifically with its homologous antigen (the one that stimulated the immune response) or
10 with substances that are chemically very similar to that antigen. Antibody herein refers to both polyclonal and monoclonal antibodies.

The invention provides for a method of treatment and/or prevention of an immune related response, comprising providing an antagonist(s) directed against a proteinaceous substance derived from a nucleic acid sequence at least
15 functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in table 1, 2 or 3. The invention provides a substance such as a proteinaceous substance capable of modulating a gene comprising a nucleic acid at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in table 1-3 and use of said substance for the production of an
20 antagonist against said substance for example the invention provides an antagonist directed against a proteinaceous substance derived from a nucleic acid at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in table 1, 2 or 3. 'Functionally equivalent' herein means that the subject signature sequence can vary from the reference sequence by one or
25 more substitutions, deletions, or additions, the net effect of which will not result in a functional dissimilarity between the two sequences.

The invention provides an antagonist comprising an antibody or functional equivalent thereof. An antibody or functional equivalent thereof can refer to synthetic molecules (i.e antibodies derived by chemical synthesis) and
30 encompasses all molecules capable of coupling with proteinaceous substance(s) derived from nucleic acid of the invention. Proteinaceous substance herein can refer to an entity derived from said nucleic acids the subject of the invention capable of modulating an immune response.

The invention provides a medicament comprising an antagonist. The
35 invention provides the use of an antagonist for the production of a medicament for the treatment of an immune response observed with airway hyperresponsiveness and/or bronchoalveolar manifestations of asthma.

5 The invention provides for use of an antagonist for the production of a medicament for the treatment of an immune response observed with airway hyperresponsiveness and/or bronchoalveolar manifestations of asthma.

 The invention further provides a diagnostic kit for screening for an immune response comprising providing a nucleic acid the subject of the
10 invention. Methods of screening are known in the art. These procedures include, but are not limited to DNA-DNA, DNA-RNA hybridisation. The form of such quantitative methods may include, Southern or Northern analysis, dot/slot blot or other membrane based technologies; PCR technologies such as DNA Chip, Taqman®, NASBA, SDA, TMA, *in-situ*-hybridisation, protein bioassay or
15 immunoassay techniques ELISA, IFA, proteomic and metabolomic technologies.

5

Exempl s**Exempl 1: Development of murine model of allergic asthma**

10 Due to the limitations of experimental studies in patients with allergic asthma a murine model with immunologic and pathophysiologic features reminiscent of allergic asthma was developed [Oosterhout AJ (1998): *Am J Respir Cell Mol Biol*; 19:826-35]. There are several advantages to using a murine model compared to using tissues obtained from asthma patients such as (i) availability of isolated
15 tissues or cells (ii) genetic homogeneity, (iii) identical age, (iv) well-controlled environment (food, specified pathogens, climate), and (v) ability to do time-series experiments (i.e induction vs effector phase). In this model, Balb/c mice are sensitized with ovalbumin (OVA) and repeatedly challenged by inhalation of OVA aerosol. This model is characterized by the presence of OVA-specific IgE
20 antibodies in serum, airway eosinophilia and non-specific hyperresponsiveness concomitant with the appearance of Th2-like cells in lung tissue and lung draining (thoracic) lymph nodes.

Example 2: Representational Difference Analysis (RDA)

25

Representational Difference Analysis of cDNA's (RDA) was employed to identify novel key regulatory molecules involved in the initiation and/or progression and/or suppression and/or repression of asthma symptoms. RDA analysis was performed according to previously defined methods [Groot and van Oost (1998).
30 *Nucleic Acids Res*: 26:4476-81][Welford *et al.*, (1998): *Nucleic Acids Res* 1998; 26:3059-65] [Geng *et al.*, (1998): *Biotechniques* 25:434-8]. Gene expression between lung-draining lymph nodes (containing amongst others dendritic cells, macrophages, B- and T-lymphocytes, mast-cells) obtained from "healthy" control animals and those obtained from "asthmatic" mice that display airway
35 manifestations of asthma such as airway hyperresponsiveness and bronchoalveolar eosinophilia were compared. Balb/c mice were intraperitoneally sensitized with ovalbumin and later on repeated challenged by inhalation of saline aerosol (control or "healthy" animals) or ovalbumin aerosol ("asthmatic"). Lymph nodes were isolated at 6 hours after the last challenge. Using RDA

5 differentially expressed gene fragments were identified. Up-regulated genes are those that are expressed at higher levels in asthmatic tissue compared to healthy tissue. Vice versa, down-regulated genes are those that are expressed at lower levels in asthmatic tissue compared to healthy tissue. NCBI (National center of biotechnology information) BLAST searches with the differentially expressed
10 gene fragments against publicly available databases revealed significant alignment with either known genes (human or mouse), with expressed sequence tags (ESTs) or in some cases did not reveal a significant alignment or an incomplete alignment (unknown genes). The identified differentially expressed genes are listed in Table 1.

15

Example 3: Microarray experiment

Detection of differentially expressed genes in "asthmatic" mice compared with "healthy" control animals was performed using representational differences
20 analysis coupled to microarray hybridization methods as described previously [Welford *et al.*, (1998). *Nucleic Acids Res.* 26:3059-65]. Unique differentially expressed genes (tethered nucleic acid: target) obtained from the RDA experiment (example 2) were amplified by PCR using M13 primers, precipitated and spotted (arrayed in duplicate) onto chemically-modified glass slides
25 (Corning) using a robotic printing device. Messenger RNA obtained from both lymph nodes of "healthy" and from "asthmatic" mice was transcribed into double-stranded cDNA and amplicons were generated. Amplicons were subsequently fluorescently labeled with either cyanine 3 (Cy3-ULS) or cyanine 5 (Cy5-ULS) dyes (i.e one mRNA population (probe: free nucleic acid) was labeled with
30 cyanine 3 (Cy3-ULS) and the other with cyanine 5 (Cy5-ULS)). The labeled probes (free nucleic acids) were then mixed and hybridized simultaneously to a microarray. The microarray was hybridized with both the Cy3 and Cy5 labeled probes in order to determine the expression ratio between both samples. After hybridization, the fluorescence pattern of each microarray was recorded for the
35 Cy3 and Cy5 fluorescent dyes. Detailed statistical analyses were applied in order to determine the minimal significant ratio in each experiment. Clones that exhibited differential fluorescence were identified. In table 1, the expression ratio ("asthma" : "healthy") is given.

5

Example 4: Virtual Northern Blot

Messenger RNA obtained from lymph nodes of "healthy" and "asthmatic" mice was transcribed into double-stranded cDNA and amplicons were generated.

- 10 Using agarose gel electrophoresis, different amounts of amplicons were run and subsequently blotted onto Hybond filter membrane. Specific and individual gene fragments obtained by RDA from the lymph nodes of "healthy" and "asthmatic" mice were subcloned and subsequently amplified using M13 primers and fluorescently labeled (by random primer labeling). Labeled gene fragments were
- 15 hybridized on the filter membrane containing the blotted amplicons and analyzed by a fluor-imager. After hybridization, based on the fluorescence intensity between amplicons obtained from "healthy" and "asthmatic" mice, an expression ratio ("asthma":"healthy") was determined (table 1).

- 20 **Example 5:** By way of example one novel therapeutic target protein for the treatment of immune and/or inflammatory responses.

- The mRNA expression of gob 5 has been examined by PCR using gene-specific primer pairs (sense primer: GCCTTCGGACAGCATTTACA; anti-sense primer
- 25 TGCGTTGTCCAGGTGATAAG; product length 435 base-pairs). Gob 5 mRNA is present in lymph nodes, lung tissue, bronchoalveolar lavage cells and bone-marrow obtained from healthy BALB/c mice. In tissues obtained from "asthmatic" mice compared to tissues obtained from "healthy" mice, the expression of gob 5 mRNA is increased in lymph nodes (approximately 4 fold),
- 30 bronchoalveolar lavage cells (>10 fold), and bone marrow cells (approximately 2 fold). Mucus secreting goblet cells have never been described in lymph nodes or bone-marrow. The expression of gob 5 in murine bone-marrow derived mast-cells and murine mast-cell lines is demonstrated (P815 and CFTL-12). Additionally, a strong up-regulation of gob 5 in the dorsal root ganglia (DRG) obtained from the
- 35 mouse asthma model was observed (figure 2). The expression of other members of the calcium activated chloride channel family was determined by PCR (table 1, Table 2 and figure 2). We have identified a murine homolog of CaCC3 (EST AA726662) and we show that the expression is strongly upregulated (>16 fold) in DRG of the mouse asthma model compared to healthy mice (figure 2). In

5 contrast, the expression of the murine homolog (m_CaCC or m_CLCA1) of human CLCA3 was strongly down-regulated in DRG from the mouse asthma model (figure 2).

10 **Example 6:** By way of example one novel therapeutic target protein for the treatment of immune and/or inflammatory responses

LR8/CLAST1 belongs to the family of the tetraspanin (4TM) superfamily and has been discovered in a subpopulation of human lung fibroblasts. LR8 mRNA was not detectable by PCR in human smooth muscle cells, endothelial cells or
15 epithelial cells. A murine homolog of LR8 (Signature sequence R1-OS-B1-D3) showed gene (i.e mRNA) expression in lymph nodes from mice and a down-regulation in the mouse asthma model. Bio-informatics analysis of the LR8 protein confirmed the presumed 4TM structure of the protein and revealed a striking homology with the beta chain of the high affinity IgE receptor (FceRI)
20 (Figure 3).

Example 7: Expression of genes in a second mouse model of allergic asthma:

25 In order to validate the differentially expressed genes, a second, independent mouse model of allergic asthma was used. In this model, Balb/c mice are sensitized by two intraperitoneal injections of ovalbumin (OVA, 10 µg in 2.25 mg Alum adjuvant on day 0 and 7. Subsequently, the mice are exposed to three challenges (day 21, 24, 27) by inhalation of OVA (10 mg/ml) aerosol during 20
30 minutes. This model is characterized by high serum levels of OVA-specific IgE, strong airway eosinophilia, airway hyperresponsiveness to methacholine and goblet cell hyperplasia, concomitant with the appearance of Th2-like cells in lung tissue. Control sensitized mice are challenged by inhalation of saline and do not develop airway manifestations of asthma as described above. OVA sensitized
35 Balb/c mice were challenged by inhalation of either saline or OVA aerosol and at 24 hours after the last challenge, we have isolated the lung, trachea, lung draining (thoracic) lymph nodes (TLN) and dorsal root ganglia (DRG) from these mice. Tissues were immediately stored in RNAlater (Ambion) and within one month transferred to Trizol (GibcoBRL) and total RNA was isolated according to

5 the manufacturer's instructions. ds-cDNA was generated using the SMART-PCR
cDNA synthesis kit (Clontech). DNA concentrations were determined
spectrophotometrically. Subsequently, these cDNAs were serially two-fold
diluted in the wells of 96-well microtiter plates, concentrations ranging from 1.5
ng/ μ l in sample 1, 0.75 ng/ μ l in sample 2, down to 0.73 pg/ μ l in sample 12 (2048x
10 dilution of sample 1).

Five μ l of each sample of each dilution series was used as input in a 20 μ l PCR in
the following buffer: 66.0 mM Tris-HCl (pH 8.8 at 25°C); 4.0 mM MgCl₂; 16.0
mM (NH₄)₂SO₄; 33.2 μ g/ml BSA; 340 μ M of dGTP, dATP, dTTP and dCTP; and
0.02 Units/ μ l Taq polymerase (Gibco-BRL).

15 In table 7, a list of specific primer pairs for the indicated genes is given. Two or
three sets of primers were combined in each PCR-reaction: one of the two HPRT-
primer-pairs and one or two gene-specific primer pairs. Each combination was
chosen in such a way that fragments of clearly different lengths were obtained
for each gene/EST or for the HPRT-control. Also, primers were cross-checked in
20 such a way that formation of primer-dimers was prevented (i.e., primerpairs
with more than 4 bp of complementary sequences -especially when they were
present at the end of a primer - were not used together in a PCR-reaction).
Primer concentrations in the PCR-reactions were 0.5 μ M for the gene/EST-
specific primers. For the HPRT-primers, the concentrations used ranged from 0.3
25 μ M down to 0.16 μ M.

PCR was performed on a PCT100 (MJ research) or a PE9700 thermal cycler
(Perkin Elmer), both with a heated lid (no oil used). A denaturation step of 3' at
95 degrees Celsius was followed by 33-35 cycles of 30 sec 95 degrees Celsius, 40
seconds at 55 or 68 degrees Celsius (depending on primersets used) and 2
30 minutes 72 degrees Celsius and then by a final 3 minutes at 72 degrees Celsius.
After PCR, 5 μ l loading dye was added to each sample and the whole samples
were loaded onto 200 ml 2.5% Seakem LE-agarose-gels in 0.5x TBE in 50-well
OwL electrophoresis trays and run at 80-100 Volt until the DNA's had migrated
long enough to see each gene/EST-specific band (usually 1-2 hrs).

35 Each gel was photographed with a CCD-camera. At least three photographs were
taken from each gel at different diaphragm-settings. All pictures were stored
electronically.

cDNA dilutions from similar tissues obtained from differently treated mice
(saline-vs. OVA-challenge) were loaded in such a way in the microtiterplates

5 used to setup the PCR reactions that they would end up next to each other on the gel.

During the whole procedure described above, multichannelpipets were used to setup the PCR-reactions and to load the gels. Furthermore, mastermixes containing everything but the cDNAs (i.e., including the PCR-buffer, nucleotides, 10 primers and Taq-polymerase) were prepared for each set of primerpairs used. In this way experimental variation is kept to a minimum. Also, one can be sure that the total absence of one specific band in one dilution-series is not an artifact if this band is present in another series setup with the same mastermix.

To determine the level of differential expression, the patterns obtained on gel 15 were scored by eye.

For the gene/EST specific bands and for the HPRT-control-band the highest dilution in which the band was still present was scored.

Using the HPRT-band as a reference the difference in gene-expression was scored as a "+1", "+2", "+3" etc., indicating that the gene/EST tested was 20 overexpressed at a respectively 2-fold, 4-fold, 8-fold etc. higher level in the OVA than in the saline-sample, or as "-1", "-2", "-3" etc., indicating that the gene/EST tested was overexpressed at a respectively 2-fold, 4-fold, 8-fold etc. lower level in the OVA than in the saline-samples.

As an example in Figure 1A, the results are shown for the genes with signature 25 sequences OS-B1-C3 and OtS2-C5. The interpretation, based on careful visual inspection (if necessary using photo's taken at different diaphragm-settings) is given by the bars below the photograph: For both saline and OVA the HPRT-band is visible down to dilution number 12.

For OS-B1-C3 no band is visible in the saline-dilution-series, whereas the band 30 can be seen down to dilution number 10 in the OVA-dilution series, indicating that the gene from which this EST is derived is expressed in the Dorsal Root Ganglia of OVA-challenged animals at least 1024-fold (2^{10} , in table 8, this is scored as a 10) more strongly than in saline-challenged mice.

For OtS2-C5 the band is visible in the first two dilutions ion the saline-series 35 and in the first three dilutions in the OVA-series, indicating that the gene from which this EST is derived is 2-fold (2^1 , in table 5, this is scored as a 1) higher expressed after OVA-challenge compared to saline-challenge.

5 In a similar manner in Figure 1B the results for Cyp2f2 (signature sequence R1-OS-B1-A1) and Gob5 (signature sequence R1-SO-R1-C11) show that Cyp2f2 is highly, but not differentially expressed (scored as a 0 in table 5), whereas Gob5 is expressed after OVA-challenge at least 4096-fold stronger than after Saline-challenge (2 to the power 12, scored as a 12 in table 5).

10

Example 8: Expression of genes in prototypic cell-lines:

Allergic asthma is a complex chronic inflammatory disease that involves the activation of many inflammatory and structural cells, all of which participate in the typical pathophysiological changes of asthma [Barnes, 1998 #6873]. Many inflammatory cells are recruited to asthmatic airways or are activated in situ. These include mast-cells, macrophages, eosinophils, T lymphocytes, B lymphocytes, dendritic cells, basophils, neutrophils and platelets. It is now increasingly recognized that structural cells may also be important sources of mediators in asthma. Airway epithelial cells, smooth muscle cells, endothelial cells and fibroblasts are all capable of synthesizing and releasing inflammatory mediators. Moreover, these cells may become major sources of inflammatory mediators in the airway and this may explain how asthmatic inflammation persists even in the absence of activating stimuli. We have analyzed the expression of many of the identified genes in relevant murine cell-types (table 6). A cell-line expressing the relevant gene and the encoding protein can be used for functional studies into the role of the gene/protein and can be used for the screening of a compound (agonist or antagonist) that modulates at least one of the functions of the gene/protein. Cell-lines were cultured according to guidelines from the "American Type Culture Collection" (www.atcc.org) or as described in literature. The primary dendritic cells were generated from bone-marrow cells cultured in the presence of interleukin-4 and granulocyte-macrophage colony-stimulating factor as described in literature [Masurier, 1999 #6874]. After culture, cells were harvested and total RNA was extracted using Trizol according to the manufacturer's instructions. 1 µg of total RNA was transcribed into cDNA in a volume of 20 µl. cDNA was used in PCR reactions using gene specific primer pairs (see table 4) with a denaturation step of 20' at 95 degrees Celsius, followed by 35 cycli at 94 degrees Celsius for 20"; 55 degrees Celsius for 30", and 72 degrees Celsius for 30" and then by a final 2' at 72 degrees Celsius. In some

35

5 experiments, the cells were activated by a well-known stimulus for that cell-type (see table 6).

In table 6 , the expression (+) or absence (-) of expression of a particular gene in the respective cell-line is shown.

10 The mouse calcium-activated chloride channels gob-5 and the murine homologue (EST AA726662) of human CLCA2 are expressed in a prototypic B-lymphocyte cell-line (A20). This cell-line and other B-lymphocyte cell-lines or primary B-cell cultures can be used to determine one or more functions of these ion channels in these cells. Chloride channels are important for cell activation and adhesion.

15 Blockade of one or both of the chloride channels can be used in B-lymphocyte mediated diseases such as auto-immunity, allograft transplant rejection, allergy and asthma (type I hypersensitivity) and type III hypersensitivity (Arthus reaction, Farmer's lung) in which the disease is at least partially dependent on antibody production such as auto-antibodies, antibodies to graft tissue or
20 antibodies to allergens.

On the other hand, activation of one or both of these chloride channels can be used in infectious diseases or in combination with vaccines (to protect against infections (viruses, bacteria, fungi, or protozoa) to boost the protective B-lymphocyte mediated antibody response.

25

The mouse calcium-activated chloride channels gob-5 (human CLCA1 homologue) and the murine homologue (EST AA726662) of human CLCA2 and the murine homologue (EST W41083) of human CLCA4 are expressed in prototypic monocyte/macrophage cell-lines (J774A.1 and RAW264.7) either under
30 baseline conditions (EST W41083) or upon activation. These cell-lines and other macrophage/monocyte cell-lines or primary macrophage/monocyte cell cultures can be used to determine one or more functions of these ion channels in these cells. Chloride channels are involved in cell activation and adhesion.

Macrophages/monocytes are important effector cells in both the innate and
35 adaptive immune response. Macrophages/monocytes can take up antigens and present these after processing to T-lymphocytes. Macrophages/monocytes can also deliver co-stimulatory signals (B7 family members, CD40, cytokines) to lead to optimal T-cell activation. In particular the production of interleukin-12 by macrophages is important to direct T-lymphocyte responses into the type 1

5 direction. Type 1 T-lymphocytes are characterized by a particular set of
cytokines including interferon- γ . Modulation of one or more of these chloride
channels can be used to inhibit or stimulate particular monocyte/macrophage
functions such as expression of co-stimulatory molecules (CD40, B7 members) or
to inhibit or stimulate the production of cytokines such as interleukin-12 and
10 18. In this way, inhibition of macrophage function is beneficial in the treatment
of Th1 mediated diseases such as auto-immunity and Crohn's disease. Vice
versa, stimulation of macrophage function by modulation of these chloride
channels is beneficial in the treatment of Th2 mediated diseases such as allergy,
asthma, certain types of auto-immunity and ulcerative colitis or in the
15 potentiation of vaccination strategies. Macrophages/monocytes are also an
important source of inflammatory mediators such as oxygen radicals, nitric oxide
and tumor-necrosis factor- α that play a role in immune responses. Modulation of
chloride channels is effective in the limitation of the production and release of
these mediators.

20

The selective expression of the gene with signature sequence SvO2-1-D10 in the
prototypic mast-cell line (P815), the prototypic B-lymphocyte cell-line (A20) and
the prototypic macrophage/monocyte cell-lines (J774A.1 and RAW264.7)
demonstrates a potential role of this gene and the encoding protein in the
25 cellular function of these cell types. Modulation of the expression or activity of
this gene/protein is useful in diseases mediated by mast-cells (allergy, asthma,
multiple sclerosis etc.), mediated by B-lymphocytes (auto-immunity, allergy,
asthma etc) or modulated by macrophages/monocytes. These cell-lines or other
cell-lines representing the same cell-type or primary cell-cultures can be used to
30 determine gene/protein function and screening of a compound (agonist or
antagonist) that modulates at least one of the functions of the gene/protein.

The selective expression of the gene with signature sequence OtS2-G2 in the
mast cell-line CFTL12 and the primary dendritic cells as well as in the activated
35 mast-cell line P815 and in the activated T-cell line EL4 demonstrates a potential
role of this gene and the encoding protein in the cellular function of these cell-
types. Modulation of the expression or activity of this gene/protein is useful in
diseases mediated by mast-cells, T-lymphocytes or initiated by dendritic cells.
These cell-lines or other cell-lines representing the same cell-type or primary

5 cell-cultures can be used to determine gene/protein function and screening of a compound (agonist or antagonist) that modulates at least one of the functions of the gene/protein.

10 The selective expression of the gene with signature sequence R1-OS-B1-A3 in the prototypic mast cell-line P815 and in the activated prototypic B-lymphocyte cell-line A20 demonstrates a potential role of this gene and the encoding protein in the cellular function of these cell-types. Modulation of the expression or activity of this gene/protein is useful in diseases mediated by mast-cells or B-lymphocytes. These cell-lines or other cell-lines representing the same cell-type
15 or primary cell-cultures can be used to determine gene/protein function and screening of a compound (agonist or antagonist) that modulates at least one of the functions of the gene/protein.

20 The selective expression of the gene with signature sequence R1-OS-B1-A5 in the prototypic mast cell-line P815, the T-cell line EL4 and the prototypic macrophage/monocyte cell-line RAW264.7 demonstrates a potential role of this gene and the encoding protein in the cellular function of these cell-types. Modulation of the expression or activity of this gene/protein is useful in diseases mediated by mast-cells, T-lymphocytes or macrophages/monocytes. These cell-
25 lines or other cell-lines representing the same cell-type or primary cell-cultures can be used to determine gene/protein function and screening of a compound (agonist or antagonist) that modulates at least one of the functions of the gene/protein.

30 The selective expression of the gene with signature sequence OtS2-B9 in the in the T-cell line EL4, in the prototypic macrophage/monocyte cell-line J774A.1 and in primary dendritic cells demonstrates a potential role of this gene and the encoding protein in the cellular function of these cell-types. Modulation of the expression or activity of this gene/protein is useful in diseases mediated by T-
35 lymphocytes or by macrophages/monocytes or initiated by dendritic cells. These cell-lines or other cell-lines representing the same cell-type or primary cell-cultures can be used to determine gene/protein function and screening of a compound (agonist or antagonist) that modulates at least one of the functions of the gene/protein.

5

The selective expression of the murine homologue (mCaCC, GenBank Acc. AF052746) of human CLCA3 in the prototypic lung type-II epithelial cell-line C10 demonstrates a potential role of this gene and the encoding protein in the cellular function of this cell-type. This cell-line or other cell-lines representing type-II epithelial cells such as the human A549 cell-line or primary cell cultures of this cell-type can be used to determine the gene/protein function and screening of a compound (agonist or antagonist) that modulates at least one of the functions of the gene/protein. Type II lung alveolar cells produce surfactant. A deficiency in alveolar surfactant causes respiratory distress syndrome (RDS). Modulation of the expression or activity of this gene/protein is useful in diseases mediated by type-II alveolar cells such as RDS.

The selective expression of murine DC-SIGN (signature sequence OtS1-B7) in the primary cultures of bone-marrow derived dendritic cells demonstrates a potential role of this gene and the encoding protein in the cellular function of dendritic cells. Bone-marrow derived dendritic cells or cell-lines representing dendritic cells such as XS52 cell-line or other primary cell cultures of this cell-type can be used to determine the gene/protein function and screening of a compound (agonist or antagonist) that modulates at least one of the functions of the gene/protein. Dendritic cells are so-called professional antigen-presenting cells (APC) and thus play a crucial role in the initiation and progression of immune- and inflammatory responses mediated by T-lymphocytes. Blockade of mDC-SIGN is beneficial in the treatment of T-lymphocyte mediated diseases such as allergy, asthma, COPD, auto-immune diseases, inflammatory bowel diseases, allograft rejection and infectious diseases.

Example 9: Identification of full-length sequence of OtS1-B7:

Steps in the identification of the OtS1-B7 as the murine homologue of human DC-SIGN

1. The identified cDNA fragment with signature sequence OtS1-B7 was used for BLAST analysis leading to two hits with mouse genomic sequences: GenBank acc. AC73804 and AC3706.

- 5 2. Geneprediction using GenScan
 (<http://bioweb.pasteur.fr/seqanal/interfaces/genscan.html>), BLAST
 (<http://www.ncbi.nlm.nih.gov/BLAST/>) and ClustalW
 (<http://www2.ebi.ac.uk/clustalw/>) led to the construction of a 19619 bp long
 uninterrupted mouse genomic sequence, designated Contig1A. Contig1A
 10 consists of the following overlapping contigs present in AC073804 and
 AC73706:
 nt 1-11054 = nt 294022-305082 from AC073804
 nt 11009-19619 = nt 237022-228395 from AC073804 (reverse complement)
 nt 1805-7790 = nt 39946-34025 from AC073706 (reverse complement)
 15 nt 6918-15759 = nt 32026-23233 from AC073706 (reverse complement)
1. From contig1A, a gene comprising OtS1-B7, was derived. The
 characterization of this gene was based on in-silico bioinformatics analysis in
 combination with "wet" work in the laboratory as described below:
 2. Gene-prediction combined with extensive BLAST-searches and multiple
 20 alignment analyses yielded a putative gene consisting of 10 exons and
 encoding an mRNA with a length of approximately 1200 bp (table 7 and
 Figure 6).
 3. Subsequently, primers were developed (Table 8) and used for PCR analysis
 of the OtS1-B7 gene from cDNA of thoracic lymph nodes obtained from OVA-
 25 challenged mice. All primerpairs used yielded fragments after PCR with the
 lengths predicted by the OtS1-B7-sequence. Sequencing of a set of these
 overlapping fragments, confirmed that the OtS1-B7 gene-sequence was
 predicted correctly: no differences with respect to the deduced sequence were
 found.
 - 30 4. The OtS1-B7 gene comprises the OtS1-B7 fragment:
 nt 8426-8463 identical to nt 1-38 of OtS1-B7 (3'-part of exon 7)
 nt 8955-9106 identical to nt 39-190 of OtS1-B7 (exon 8)
 nt 10386-10495 identical to nt 191-300 of OtS1-B7 (exon 9)
 nt 11618-11732 identical to nt 301-415 of OtS1-B7 (5'-part of exon 10)
 - 35 5. In order to obtain the 5'- and the 3'-end of the OtS1-B7 cDNA, a variant of
 the RACE (rapid amplification of cDNA-ends) was used. At the 5'-end the
 sequence was shown to have a 5'-UTR of 22 bp. Determination of the 3'-end
 revealed that apart from the predominant 1.2 kb transcript, an

- 5 approximately 800 bp longer transcript was present. Both transcripts encode the same 325 bp ORF.
6. Based on (i) the strong homology (approximately 50%, see multiple sequence alignment, Figure 10) of OtS1-B7-ORF with human DC-SIGN, and (ii) the selective expression of OtS1-B7 in the primary dendritic cells (see example 8)
- 10 and (iii) the staining of spleen dendritic cells with antibodies to peptides derived from OtS1-B7-ORF (see example 70), we conclude that we have identified the murine homologue of human DC-SIGN, a Dendritic Cell specific ICAM-3 Grabbing Non-integrin.
7. The Genetic localization of OtS1-B7 was done by ePCR of the 196219 bp long
- 15 Contig1A-sequence (<http://www.ncbi.nlm.nih.gov/genome/sts/epcr.cgi>), which resulted in the identification of marker 440942 (GenBank acc. AI480608). This marker has been mapped to mouse chr 8 (WI-RH Map 13431.25 cR3000), in a chromosomal region syntenic with human 19p13.3, the chromosomal region where DC-SIGN has been located.
- 20 8. In the 16916 bp Contig1A contig one other gene was predicted by GenScan:
- | | |
|-------------|--|
| 14290-14329 | promotor |
| 17688-17690 | ATG-startcodon |
| 17688-18494 | 809 bp single exon, BLAST-searches with this exon show that it encodes a retrotransposon with approximately 3000 |
| 25 | active copies in the mouse genome |
| 18618-18623 | poly-Adenylation-site |
9. Southern-hybridization of a number of restrictiondigests (see Figure 7) of BALB/c genomic DNA was performed using a 1101 bp long Contig1A cDNA fragment comprising the whole coding region of OtS1-B7 plus 123 bp of the
- 30 3'-UTR. This probe was generated by PCR with primers 47 (nt 3655-3684 in Contig1A) and 51 (nt 11861-11891 in Contig1A) and 25 ng of it was radiolabeled with 50 uCi of 32P-labeled alpha-dATP using a Amersham multiprime labelingkit (RPN1600Z, AP Biotech) and then hybridized to alkaliblotted BALB/c-restrictiondigests in Church hybridizationbuffer at 65
- 35 degrees Celsius for about 18 hrs, washed 2 times with 2x SSC/0.1% SDS at RT for a few minutes each, and 2 times in 2xSSC/0.1% SDS for 10 and 90' respectively and autoradiographed at -70 degrees Celsius using intensifying screens for 2 and 5 days respectively.

- 5 10. Results and the interpretation of the Southern-hybridization are shown in Figure 7 and 4. Figure 7 shows the predicted restriction enzyme map for the OtS1-B7-gene. Figure 8 shows the EtBr-staining of the restriction-digests used (panel A), the autoradiograph after 2 and 5 days exposure time (panels B and C) and the interpretation (panels D and E). Panel D shows a graphical representation of all the hybridizing bands, the thickness of the bands indicates their relative strengths as judged by eye using both exposures. Panel E shows the expected hybridization pattern based on the predicted restriction enzyme map (shown in Figure 7). The thickness of the bands is drawn proportional to the length of the hybridizing region present in each restriction fragment.
- 10 11. We conclude that all bands derived from OtS1-B7 which are expected to hybridize with the probe used are indeed present, confirming the correctness of the structure of the predicted gene.
12. Also, for all 6 restriction enzymes used additional hybridizing bands can be observed. In all cases, these additional bands hybridize much more weakly. Therefore, we conclude that in addition to OtS1-B7 a second gene is present in the genome of BALB/c which shares homology to OtS1-B7. Because the lengths of the hybridizing bands for this second gene are different for all six enzymes used and because these bands hybridize much more weakly when compared to the hybridizing OtS1-B7-bands, we conclude that this second gene is distantly related or that it might be a pseudogene.
13. For OtS1-B7 itself we conclude that it is present as a single copy per haploid genome in the mouse.

30 Example 10: Polyclonal antibodies and immunohistochemistry:

Polyclonal antibodies were prepared to mDC-SIGN (signature sequence OtS1-B7) by immunizing rabbits with immunogenic peptides selected from the mDC-SIGN protein sequence. The peptides used for the immunizations were selected on the basis of extracellular localization and immunogenicity (Eurogentec, Belgium). KLH conjugated peptides used for antibody production:

AA 77-92 + C: H₂N - KTP NTE RQK EQE KIL QC - CONH₂ (17 AA) and
 AA 275-289 + C: H₂N - SRF QKY WNR GEP NNI C - CONH₂ (16 AA)

5 Peptides were synthesized and polyclonal antibodies were generated by Eurogentec according to their standard procedures. In short, peptides were synthesized by Fmoc chemistry and coupled to Keyhole Limpet Hemocyanin (KLH). Both KLH coupled peptides were mixed and used to immunize (200 µg in Freund's adjuvant) two rabbits on day 0, 14, 28 and 56. Serum was obtained
10 prior to immunization (pre-serum, day 0) and at 35, 66 and 87 days after immunization (immune serum).

Both rabbits generated antibodies to either of the peptides as demonstrated by an ELISA using the peptide as coat. The polyclonal antibodies were used for immunohistochemistry. Cryostat sections (5 µm) of trachea, thoracic lymph
15 nodes, spleen and dorsal root ganglia were used for immunohistochemistry. After blocking by incubation with 10% normal goat serum, tissues were washed and incubated with different dilutions (1:1000 to 1:5000) of either pre-immune- or immune-serum (day 87). Thereafter, tissues were incubated with anti-rabbit immunoglobulin antibody (DAKO) and after washing tissues were incubated
20 with substrate DAB (Sigma) according to the manufacturer's instructions. After fixation and counterstaining with hematoxyline, tissues were analyzed by light microscopy.

In the spleen from naive mice, there is a strong and localized staining of
25 marginal zone dendritic cells for mDC-SIGN in the tissues incubated with immune serum compared to pre-immune serum (Figure 8). Thus, there is expression of mDC-SIGN protein in spleen marginal zone dendritic cells. This strongly confirms that we have identified the murine homologue of human DC-SIGN.

30 In dorsal root ganglia from saline-challenged control mice, there is a very weak staining for mDC-SIGN in the tissues incubated with immune serum versus pre-immune serum (Figure 9). In the dorsal root ganglia from OVA-challenged mice (as described in example 7), there is a very strong staining for mDC-SIGN in the tissues incubated with immune serum compared to pre-immune serum. Thus,
35 there is a weak expression of mDC-SIGN protein in DRG from control mice and a very strong expression of mDC-SIGN protein in DRG from OVA-challenged mice. In the trachea from saline-challenged control mice, there is staining of epithelial cells for mDC-SIGN in the tissues incubated with immune serum versus pre-immune serum. In the trachea from OVA-challenged mice (as described in

- 5 example 7), there is a strong staining of epithelial cells for mDC-SIGN in the tissues incubated with immune serum compared to pre-immune serum (Figure 10). Thus, there is expression of mDC-SIGN protein in tracheal epithelial cells from control mice and a stronger expression of mDC-SIGN protein in DRG from OVA-challenged mice.
- 10 In the thoracic lymph nodes (TLN) from saline-challenged control mice, there is staining of dendritic cells for mDC-SIGN in the tissues incubated with immune serum versus pre-immune serum (Figure 11). In the TLN from OVA-challenged mice (as described in example 7), there is a strong staining of dendritic cells for mDC-SIGN in the tissues incubated with immune serum compared to pre-
- 15 immune serum. Thus, there is expression of mDC-SIGN protein in TLN from control mice and a stronger expression of mDC-SIGN protein in TLN from OVA-challenged mice
- Antibodies (mono- or polyclonal or fragments thereof) to DC-SIGN can be used for the isolation, staining (immunohistochemistry, flow cytometry) and
- 20 functional studies using murine dendritic cells.

5 **Example 11: Generation of mDC-SIGN "kn ck-out" mouse:**

In order to study the role of mDC-SIGN (signature sequence OtS1-B7), a targeting construct was designed to knock-out this gene in mice.

10 The targeting-construct contains a left arm encompassing part of intron 4, exon 5, intron 5 and part of intron 6, followed by a PGK-hyg cassette and a left arm encompassing part of intron 8, exon 9, intron 9, exon 10 and several kb of the region downstream of OtS1-B7 (see Figure 12).

After electroporation of the construct into 129/OLA E14 ES-cells, hygromycin resistant clones will be screened by Southern analysis or LD-PCR to obtain
15 clones which correctly targeted and which do not contain random insertions of the targeting construct (diagnostic restriction fragments and the hybridization probe to be used are indicated in the figure).

Some of these clones will be used for blastocyst-injections after which they will be transferred to 129 mice to generate mDC-SIGN knock-out mice.

20

Further examples of use.

DC-SIGN can be blocked by mono- and polyclonal antibodies or fragments
25 thereof directed against DC-SIGN (protein or peptide fragments); by the soluble protein ligands ICAM-2 en -3 or fragments thereof; by HIV gp120 or fragments thereof; by mannose carbohydrates such as mannan and D-mannose; fucose carbohydrates such as L-fucose; plant lectins such as concanavalin A; antibiotics such as pradimicin; sugars such as N-acetyl-D-glucosamine and galactose; and
30 the Man₉GlcNAc₂ oligosaccharide of soybean agglutinin. Calcium-activated chloride channels (CLCA1-4) can be blocked by mono- and polyclonal antibodies or fragments thereof directed against the ion channel (protein or peptide fragments); known non-specific chloride channel antagonists such as 4,4'-diisothiocyanatostilbene-2,2'-disulphonic acid (DIDS), 4-acetamido-4'-
35 isothiocyanostilbene-2,2'-disulfonic acid (SITS), 5-nitro-2-(3-phenylpropylamino)benzoic acid (NPPD), niflumic acid, and the anti-allergic drug cromolyn; Ion-channel toxins such as FTX-3.3 or synthetic analogues such as sFTX-3.3 and argiotoxin. Antibodies (mono- or polyclonal or fragments thereof) to murine DC-SIGN can be used for (i) staining of dendritic cells by

- 5 immunohistochemistry, flow cytometry etc.; (ii) for isolating and/or purifying dendritic cells from a biological sample or a culture medium; (iii) functional studies into the role of DC-SIGN.

A number of genes are strongly increased in expression in DRG's obtained from "asthmatic", OVA challenged, mice compared to control, saline challenged, mice
 10 such as genes with signature sequence: SvO2-1-A11; SvO2-1-C8, R1-OS-B1-C3; OtS2-B9, R1-OS-B1-D6, SvO2-1-B7 (with KPI domain) and OtS1-B7. Blockade of one or more of these genes or the encoding proteins by selective antagonists inhibits the excitability of sensory neurons and thereby prevents or decreases (1) the neurogenic component of inflammatory diseases, (2) hyperalgesia during
 15 inflammatory responses and (3) cough due to airway inflammation.

The calcium-activated chloride channels Gob-5 and the murine homologue (EST AA726662) of human CLCA2 as well as the gene OtS2-C3 (signature sequence ID) are upregulated in trachea derived from "asthmatic" mice compared to
 20 "healthy" control mice. Blockade of one or more of these genes or the encoding proteins is beneficial in the treatment of allergic airway diseases.

The murine homologue (EST AA726662) of human CLCA2 (also called CaCC3) is strongly upregulated in DRG's obtained from "asthmatic" mice compared to "healthy" control mice. This corroborates the data presented here in example 5. Dorsal root ganglia contain sensory nerve bodies that are involved in neurogenic
 25 inflammation which contributes to allergic inflammation and pain (inflammatory hyperalgesia). Interference with human calcium-activated chloride channel CLCA2 may limit neurogenic inflammation in asthma and other diseases with a neurogenic inflammatory component. Furthermore, cough, which is a prominent symptom of asthma, is believed to be a result of sensory nerve activation.

30 Blockade of hCLCA2 (or the murine homolog) by selective antagonists inhibits the excitability of sensory neurons and thereby prevents or decreases (1) the neurogenic component of inflammatory responses, (2) hyperalgesia during inflammatory responses and (3) cough due to airway inflammation.

35

Role of DC-SIGN:

Immature dendritic cells (DCs) migrate from the blood into peripheral tissues where they capture and process antigens and subsequently migrate to lymphoid

5 organs to either activate or tolerize T-lymphocytes in an antigen-specific way. DCs play an important role in allergic sensitization as well as in the induction of antigen-induced airway manifestations of asthma. In agreement herewith, we recently showed that passive transfer of ovalbumin (OVA) primed spleen derived DCs strongly potentiates the development of allergic airway inflammation,
10 airway hyperreactivity and Th2-associated cytokine production upon subsequent antigen inhalation. These data clearly demonstrate that DCs are key regulatory cells in the initiation and progression of Th2-dominated allergic airway responses. Recently, a DC-specific receptor called DC-SIGN (DC-Specific ICAM-3 Grabbing Non-integrin) was identified. DC-SIGN is a mannose binding cell-
15 surface receptor, member of the C-type lectin family and appears to be expressed exclusively by DCs. DC-SIGN mediates the interaction between DCs and resting T-cells via ICAM-3 and has recently been shown to be important in DC-induced proliferation of human resting T-cells in vitro. Moreover, DC-SIGN has also been shown to be involved in trans-endothelial migration of DCs via interaction with
20 ICAM-2 on human vascular endothelial cells. These data suggest an important role for DC-SIGN in the trafficking of DCs. We have discovered the murine homologue of DC-SIGN by differential gene expression using lung-draining lymph nodes obtained from control and OVA-challenged mice. The full-length sequence of murine DC-SIGN shows strong (50%) homology to human DC-SIGN.
25 Rabbit polyclonal antibodies to murine DC-SIGN derived peptides were generated and used for immunohistochemistry. The staining of spleen and lymphoid tissues from mice using this antibody demonstrate that murine DC-SIGN is expressed on DCs.

30 Another important function of DC-SIGN in the initial dissemination of HIV-1 shortly after infection. DC-SIGN is highly expressed on DC present in mucosal tissues and binds to the HIV-1 envelope glycoprotein gp120. DC-SIGN does not enable viral entry into DC, but protects the virus until DC migrate to T cell-rich lymph nodes. Here, DC-SIGN promotes efficient infection in trans of CD4+ T
35 cells. Transmission of HIV-1 by DC to T cells is inhibited by the blocking antibodies against DC-SIGN.

5 Interestingly, we demonstrate the expression of DC-SIGN at the protein level using polyclonal antibodies in mouse airway epithelial cells and in sensory neurons present in dorsal root ganglia.

Epithelial cells in the respiratory system are not passive bystanders during assault of the epithelial barrier but participate actively in the inflammatory
10 response to defend the airway. Because epithelial cells are located at sites of contact with the external environment, they are often the first cells to interact with potential microbial pathogens. Indeed, bacterial adherence to epithelial cells may be a prerequisite for colonization and infection and through this interaction epithelial cells may have the opportunity to detect and respond to
15 pathogens independent of signals from other cell types in the respiratory system. The capacity for epithelial cells to directly detect microbial pathogens and immediately initiate expression of genes directed toward defense may allow for more efficient activation of the inflammatory response. Although several molecules that participate in airway defense have been identified, the activation
20 and coordination of factors that result in a rapid and effective inflammatory response at the epithelial surface are only beginning to be elucidated.

One mechanism for epithelial cells to participate in airway defense is through coordination of leukocyte influx and activation by expression of adhesive surface proteins and secretion of chemotactic molecules (interleukin-8, eotaxin, rantes).
25 DC-SIGN can play an important role in both the adhesion of leukocytes expressing ICAM molecules (in particular ICAM-2 and ICAM-3) and in the adhesion of pathogens (bacteria, fungi, parasites and viruses). Antibodies to DC-SIGN or compound that block the interaction between either ICAM molecules and DC-SIGN or the interaction between sugar moieties or other surface
30 molecules of pathogens and DC-SIGN can be used to prevent or treat infections with these pathogens.

Blockade of DC-SIGN is useful as a treatment for allergic asthma, COPD or other inflammatory diseases of the airways.

35 Dorsal root ganglia contain sensory nerve bodies that are involved in neurogenic inflammation which contributes to allergic inflammation and pain (inflammatory hyperalgesia). Furthermore, there is strong and convincing evidence for interactions between the immune and peripheral nervous systems. Many regulatory molecules are candidate mediators for communication between

5 inflammatory cells and nerves. There is substantial evidence that various
immune (lymphocytes) and inflammatory cells (mast-cells, eosinophils etc.) are
in close contact with nerves. Lymphoid tissues, mucosal sites (gut, airway) and
skin are densely innervated and contacts between nerves and inflammatory cells
have been demonstrated. Mast cells are closely apposed to nerves in mucosa and
10 skin and nerve stimulation has been reported to cause mast cell activation. Such
data suggest a dynamic interplay between the immune and nervous systems
during immune and inflammatory responses. In agreement herewith, receptors
for various neurotransmitters, in particular neuropeptides (substance P, CGRP
etc.) are present on all immune- and inflammatory cells. A close contact between
15 these immune- and inflammatory cells and the neurons is required for these
neuronal mediators to be effective. DC-SIGN is an important adhesion molecule
on sensory nerves that can bind to ICAM molecules (ICAM-2 and -3) on immune
and inflammatory cells thereby establishing the close contact required for this
neuro-immune interaction. Blockade of DC-SIGN inhibits the neuronal
20 component of immune- and inflammatory responses and is beneficial in
inflammatory diseases such as auto-immunity, allergy, asthma, inflammatory
bowel disease etc.

Neurotropic viruses such as herpes simplex virus (HSV) and human
immunodeficiency virus (HIV) can infect peripheral neurons.

25 Cell-surface expression of DC-SIGN in neurons may be a an important step in
the infection of neurons with neurotropic viruses such as HSV and HIV mediated
by glycosylated viral envelope proteins. Compounds that inhibit the interaction
between DC-SIGN and the viral glycoproteins are useful in prevention and
treatment of these neurotropic viral infections.

30 The selective expression of CLCA2 in the prototypic human epithelial cell-line
demonstrates a role of this gene and the encoding protein in the cellular function
of these cell-types. Chloride channels play a role in production and secretion of
mucus and chemotactic molecules (interleukin-8, eotaxin, rantes) by epithelial
35 cells. CLCA2 also can play a role in cellular adhesion. This cell-line and other
epithelial cell-lines can be used to study the role of human CLCA2 gene or the
encoding protein in lung epithelial cell function such as mucus production and
secretion and can be used for the screening of compounds (agonist or antagonist)
that modulates at least one of the functions of the gene/protein.

5 Blockade of this ion channel will inhibit mucus production and is therefore beneficial in the treatment of airway diseases associated with increased mucus production such as asthma and COPD.

Compounds that upregulate the expression of CLCA2 in human epithelial cells are useful in the treatment of patients with cystic fibrosis which have a defect in
10 cAMP-mediated chloride secretion.

A number of genes are strongly increased in expression in DRG's obtained from "asthmatic", OVA challenged, mice compared to control, saline challenged, mice such as genes with signature sequence: SvO2-1-A11; SvO2-1-C8, R1-OS-B1-C3;
15 OtS2-B9, R1-OS-B1-D6, SvO2-1-B7 (with KPI domain) and OtS1-B7. Blockade of one or more of these genes or the encoding proteins by selective antagonists inhibits the excitability of sensory neurons and thereby prevents or decreases (1) the neurogenic component of inflammatory diseases, (2) hyperalgesia during inflammatory responses and (3) cough due to airway inflammation.

20

The calcium-activated chloride channels Gob-5 and the murine homologue (EST AA726662) of human CLCA2 as well as the gene OtS2-C3 (signature sequence ID) are upregulated in trachea derived from "asthmatic" mice compared to "healthy" control mice. Blockade of one or more of these genes or the encoding
25 proteins is beneficial in the treatment of allergic airway diseases.

The murine homologue (EST AA726662) of human CLCA2 (also called CaCC3) is strongly upregulated in DRG's obtained from "asthmatic" mice compared to "healthy" control mice. Dorsal root ganglia contain sensory nerve bodies that are
30 involved in neurogenic inflammation which contributes to allergic inflammation and pain (inflammatory hyperalgesia). Interference with human calcium-activated chloride channel CLCA2 may limit neurogenic inflammation in asthma and other diseases with a neurogenic inflammatory component. Furthermore, cough, which is a prominent symptom of asthma, is believed to be a result of
35 sensory nerve activation. Blockade of hCLCA2 (or the murine homolog) by selective antagonists inhibits the excitability of sensory neurons and thereby prevents or decreases (1) the neurogenic component of inflammatory responses, (2) hyperalgesia during inflammatory responses and (3) cough due to airway inflammation. It is demonstrated herein that the human lung epithelial cell-line

5 expresses the CLCA2 gene constitutively (Figure 13). The selective expression of CLCA2 in the prototypic human epithelial cell-line demonstrates a role of this gene and the encoding protein in the cellular function of these cell-types. Chloride channels play a role in production and secretion of mucus and chemotactic molecules (interleukin-8, eotaxin, rantes) by epithelial cells. CLCA2
10 also can play a role in cellular adhesion. This cell-line and other epithelial cell-lines can be used to study the role of human CLCA2 gene or the encoding protein in lung epithelial cell function such as mucus production and secretion and can be used for the screening of compounds (agonist or antagonist) that modulates at least one of the functions of the gene/protein. Blockade of this ion channel will
15 inhibit mucus production and is therefore beneficial in the treatment of airway diseases associated with increased mucus production such as asthma and COPD. Compounds that upregulate the expression of CLCA2 in human epithelial cells are useful in the treatment of patients with cystic fibrosis which have a defect in cAMP-mediated chloride secretion.

20

5 **Tabl s**

Table 1 : Identification of differentially expressed genes in "asthmatic" mice compared with "healthy" control animals. **Array ¹**: Expression ratio (asthma:healthy) obtained by hybridization of a cDNA micro-array with
10 fluorescently labeled amplicons (Cy5 versus Cy3) derived from "asthma" and "healthy" mice.

Blot ²: Expression ratio (asthma:healthy) obtained by virtual northern blotting of amplicons and hybridization with fluorescently labeled specific, individual gene fragments.

15

a) Known genes up-regulated in "asthma" versus "healthy" mice.

Signature Sequence	Sequence/gene	Human homolog	Array¹	Blot²
R1-SO-R1-A11	Ig γ	IgG γ	2.09	10
StO1-A10	Ig ϵ	Ig ϵ	2.08	
SvO2-1-C11	Ig μ	Ig μ		
StO1-A12	IgG1 H chain	IgG1 H chain	2.20	
R1-SO-R1-B7	Ig κ	Ig κ	2.36	4
R1-SO-R1-A7	SLPI (secretory leukocyte protease inhibitor)	SLPI	3.19	10
R1-SO-R1-E7	Tdt (terminal deoxynucleotidyl transferase)	Tdt	3.65	
StO1-B3	CsA-19	CsA-19	1.57	
StO1-B5	MHC-II (I ^{A-d})	MHC-II	3.11	
R1-SO-R1-C11	Gob-5 (ca ²⁺ activated Cl ⁻ channel)	CaCC1/CLCA1	1.88	2
R1-SO-R1-E11	Pendulin	Rch1/Srp1 α / Importin- α	0.84	2
R1-SO-R1-A12	EST AA277412; AW910210; AI591665;	CDC42-GAP (GTPase-activating	1.02	2

	AA980800	protein)		
StO1-C1	Aspartyl aminopeptidase	Aspartyl aminopeptidase	1.41	
StO1-D3	RA70 (mouse retinoic acid responsive gene)	SKAP-HOM (SKAP55 homolog)	0.77	
SvO2-1-B7	APLP2 (amyloid β precursor-like protein)	APLP2		
SvO2-1-D8	GDP-dissociation inhibitor (ly-GDI)	Ly-GDI		
SvO2-1-C4	Plastin-2 (PLS2)	L-Plastin		
SvO2-1-C12	Ubiquitin/60s			
SvO2-1-A4	H2-Oa (MHC-II)	HLA-DNA		
SvO2-1-G3	EST AI327412; AA140026	RNA Polymerase-II subunit (POLR2G)		
SvO2-1-A8	EST AW546508	Phospholipase- C γ 2 (PLC γ 2)		
SvO2-1-D4	EST AW044803; AA823969; AA869959	Clathrin (CLTCL2)		
SvO2-1-D5	EST BB000142	Glutamyl-propyl-tRNA synthetase (EPRS)		

b) Expressed sequence tags (EST's) up-regulated in "asthma" versus "healthy" mice

Signature sequence	Sequence/gen	Human homolog
SvO2-1-D10	EST AI153476; AA537538	
SvO2-1-A11	EST AI451488	AW173082
SvO2-1-C8	EST AA023597; AW476575	
SvO2-1-E6	EST AI587693; AA499481; AU080538	
SvO2-1-F1	EST C77954	

c) Known genes down-regulated in "asthma" versus "healthy" mice.

Signature sequence	Sequence/gene	Human homolog	Array 1	Blot 2
R1-OS-B1-B1	PIN (protein inhibitor of NnoS)	Dynein light chain	1.44	0.7
R1-OS-B1-A1	CYP2F2 (cytochrome P450 naphthalene hydroxylase)	CYP2F1	0.35	0.1
R1-OS-B1-B6	IDH- α (NAD ⁺ dependent isocitrate dehydrogenase)	NAD ⁺ dependent isocitrate dehydrogenase	0.71	0.5
R1-OS-B1-G3	Stat-1	Stat-1	0.65	0.3
R1-OS-B1-H1	SEPP1 Selenoprotein P	SEPP1	0.52	0.5
R1-OS-B1-C5	Decorin	Decorin	0.40	0.3
OtS2-F2	Cathepsin B	Cathepsin B	0.56	
OtS2-E6	Gluthation-S- transferase mu 2 (Gstm2)	Gluthation-S- transferase	0.40	
OtS2-H2	Breast heat shock 73 protein (Hsc73)	HSP 70	0.60	
OtS2-B12	Sulphated glycoprotein-2 isoform APOJ/Clu	Clusterin	0.46	
R1-OS-B1-D3	LR8/CLAST1	LR8	0.54	0.5
R1-OS-B1-C1	EST AW211263; AI194829; AI098607; W08910	Mitochondrial trifunctional protein	0.55	0.7
R1-OS-B1-A2	UBP43 (ubiquitin specific protein)	ISG43	0.80	0.5
R1-OS-B1-D5	Ferritine	Ferritine	0.45	1.0
OtS2-B4	Unidentified mitochondrial gene		0.50	

OtS2-A1	Mitochondrial cyt-C oxidase subunit I		0.43	
OtS2-C10	Mitochondrial enoyl-CoA hydratase (rat)	Mitochondrial enoyl-CoA hydratase	0.34	
OtS2-A6	AOP2 (antioxidant protein 2)	AOP2	0.45	
OtS2-D9	IL-2R- γ	IL-2R- γ	0.51	
OtS2-A7	EST AA475628	TIS11d (early response gene) /tristetraprolin	1.12	
OtS2-C6	HSP (84 kd heat shock protein)	HSP 90	0.75	
OtS2-A10	IFN γ R (interferon- γ receptor)	IFN γ R	0.32	
OtS2-C11	Ornithine decarboxylase (Odc)	Ornithine decarboxylase	0.55	
OtS1-C11	Stearoyl-CoA desaturase 1 (SCD1)	Stearoyl-CoA desaturase	0.38	
OtS2-B10	MUSLYSM4 (mouse lysozyme gene)		0.54	
OtS2-D8	Calnexin	Calnexin	0.61	
R1-OS-B1-D6	Plunc	Plunc	0.39	

d) Expressed sequence tags (EST's) down-regulated in "asthma" versus "healthy" mice.

Signature sequence	Sequence/gene	Human homolog	Array 1	Blot 2
OtS2-D3	EST AI451901; AW826053; AA712022, partially similar to mouse CR2		0.74	
OtS2-D2	EST AA423205, similar to		0.87	

	X57528 mouse retinoic acid receptor-alpha			
OtS2-D10	Similar but not identical to mouse CD59 (complement inhibitory protein)		0.53	
OtS1-B7	EST AA543877; AA914211 (similar but not identical to macrophage lectin-2)	Similar but not identical to membrane C-type lectin 2	0.43	
R1-OS-B1-C3	EST AA691014; AW321759		0.84	0.5
OtS2-G2	Mouse JHL1 (AF165227)		0.58	
R1-OS-B1-H6	EST AI450028, AW548213; AA672579	MUM2 (AF129332)	0.83	0.25
R1-OS-B1-A3	EST AA512682; AI314236		0.65	0.7
R1-OS-B1-C4	EST AA396183 (similar to rat ROD1)	ROD1	0.66	0.5
R1-OS-B1-A5	EST AW490156 (similarity to dynein beta subunit)	EST AI358291; AI623698	1.02	0.3
R1-OS-B1-B2	EST AI835555			0.7
OtS2-C1	EST AA939676; AA125221; AA798681; AA869527		0.77	
OtS2-D7	EST AU078971; AA178650; AA231343		1.60	
OtS2-B9	EST AA792488; AA177706		0.37	
OtS2-A9	EST AA273304; AA270364; AA671609	AF143676 (multi-spanning nuclear envelope membrane protein)	0.56	
R1-OS-B1-C6	EST AI874718; AA498063; AA615985		0.81	

OtS2-C3	EST AI788596; AI892968; AA939676		0.66	
OtS2-B6	EST AI528153; AA982059; AW488424		0.67	
OtS2-A12	EST AA940560 (Rho-GAP domain)	AF217507	0.65	
OtS2-B3	EST AL022972	AW958031	1.43	
OtS2-A5	EST AA433598; AL118320; AI507121		1.08	
OtS2-C4	EST AW913417; AI647667		0.68	

e) Genes down-regulated in "asthma" versus "healthy" mice.

Signature sequence	Sequence/gene	Human homolog	Array 1	Blot 2
R1-OS-B1-E5	See figure 4 for sequence		0.97	0.7
OtS2-C5	See figure 4 for sequence		0.35	

Table 2: members of the calcium-activated chloride channel family.

Human g n /protein	Murine homolog	Signature sequence
CaCC1 / CLCA1	Gob-5	R1-SO-R1-C11
CaCC2	EST W41083	
CaCC3 / CaCL2	EST AA726662	
CLCA3	CaCC / CLCA1	

Table 3: An example of some of the differentially expressed genes involved in the regulation/activation of T-lymphocytes from table 1.

Up-regulated genes/proteins	Signature sequence	Down-regulated genes/proteins	Signatur sequence
CsA-19	St-O1-B3	IL2-R-gamma	OTS2-D9
Pendulin	R1-SO-R1-E11	IFN- γ -R	OTS2-A10
RA70	StO1-D3	Stat-1	R1-OS-B1-G3
Ly-GDI	SV02-1-D8		
Plastin-2	SVO2-1-C4		
EST: RNA Polymerase-II subunit	SVO2-1-G3		
EST: Clathrin	SVO2-1-O4		
EST: Cdc42-GAP	R1-SO-R1-A12		

Table 4: Primer pairs used for semi-quantitative PCR analysis of indicated (signature sequence) genes and their respective product length.

Signature sequence	sens primer "forward"	anti-sense primer "reverse"	product length (base pairs)
OtS1-B7	ATGAGTGA CTCCACAGAA GCCAAGATGCAG	AAGAACAGGAAGGAGAGC AGCTGCAGGAC	415
SvO2-1-B7	1: ATACACAGGCTGTTCCCG TT 2: AAGTGGTGGAAAGACCGTG AC	1: ATGATGAAGCCTCCCGTG 2: AAATGCTGGATGAGGGTC TG	568 504 with KPI 336 without KPI
SvO2-1-D8	TGGACCTTACTGGGGATC TC ???	ACTCTTCTGGTGGGTGAG GA	401
OtS2-A6	ATGCCCCGAGGTTTGCTT CT	TGCCTGTCAGCTGGAGAG AG	514
R1-OS-B1-D3	AGTCAAAGTGGCCTCCAC AC	CAAGAGCACAGCTCACAA GC	197
R1-OS-B1-A1	CAGCCATCTTGCTTCTCCT C	ACAGAGCGGCTCAGGATA AA	508
R1-SO-R1-C11	GCCTTCGGACAGCATTTA CA	TGCGTTGTCCAGGTGATAA G	412
EST AA7266 62	GGTTGAGGAGCGAATGGA AGAGC	ATTGCCACGGCGCTATCC A	362
EST W41083	AGCTAGTCCTTCTGGACA ACGGTGC	TGTTGGATGGTCCCGAACT CAAA	654
mCaCC	ATTAGTCACATTTGACAGC GCTGCC	TGGGAGACGCTGCCACTT GTAGAT	414
SvO2-1-D10	TTTGAACCTCGCCCACTGT G	GCACCCATACTGATAGCTC TCA	806
SvO2-1-A11	TCTTCCTTTGCTCAGACAC ACAGG	TTCCCCCTCTTTACTCCT GG	418

SvO2-1-C8	GAAGACGCCACTGTTCCG AA	TGAGAGTGGAGGCTGCCG TC	635
SvO2-1-E6	TCGACCCGAATCTGTTTG CA	TTTCCCGCTTCCTGTCTC AG	633
OtS2-D3	TCAGAAGAAGCTTTGAAC TTTGG	ATCCTGGGGCAGCAAAAA	264
OtS2-D10	GAAGGTGTCTGTGAAGCC TGTGG	TGCATTCCGGCTACAGCAT AGA	307
mCD59	CAGTCACTGGCGATCTGA AAAG	TGCATTCCGGCTACAGCAT AGA	250 370 (5' UTR variant)
R1-OS-B1-C3	ACAAGGCTTTAAGACTGC GACAGC	GAGAGCCGGGAGAGTTTG CTAT	665
OtS2-G2	AGTGCACTTGCATGGAGC TCA	ACAAGGGGGAGAAGCAGC TG	428
R1-OS-B1-H6	GAGCTGACCAACATGGGT GC	GCGGGCACAGAGGATTCT TC	227
R1-OS-B1-A3	GATCAACGCAAGCTCTTG GC	CTTTGCCCAAATAGAGCC A	210
R1-OS-B1-C4	ACACTGTTGGGGAAAACG AG	GACTGAAGCAGCTCAAGA CC	121
R1-OS-B1-A5	ACCGAGACCAAGCTGCAG TG	GGCGAGGCTCCCACTTAC TC	413
R1-OS-B1-B2	CTGAGGGGAGCCTGCTGG AA	CCCAGTGGATGCCTGAAA CA	271
OtS2-C1	CCTAAGCGCTGGGATTTT AC	TGATCCTCATTGCAGAAGT TTAGCT	379
OtS2-D7	TTTTTCATGGCTTCCTGCG G	CACCCCTCTGCGACAAGA CA	403
OtS2-B9	GACCTGGACGAGACCCTG GT	AGAAAATTCAGCCACTGCC A	150
OtS2-A9	TCAGGAACTGAGTTCTCC AG	CTGGCTCTTCTCTTTACCC T	280
R1-OS-B1-C6	CATCAGAGCCAGCTATGC	GGAAGCATACTTCTTGGCC	433

	CG	TCA	
OtS2-C3	GCGCTGGGATTTTACGTG TG	CCTTCCTGAAAACATGCCT AGG	442
OtS2-B6	TTTAAAAGGGAGGGGTGG CA	TGGTGAAGGGTCTCTAGG GCA	347
OtS2-A12	GCATCTGTCGCTTGGAAG GA	GCAAAACGTCTCCCTCCAC C	353
OtS2-B3	AATGGGACTTCATGGCCT CC	GGCCGATTCCTTTGCAGAA A	375
OtS2-A5	AGCCCTGGACTGCAAAGC TC	GCCTGGGCTGGGTAACAA GA	298
OtS2-C4	TGTTTACAGACTTTGCAAC C	CATCAAGTCTGGTCTCTGA G	307
R1-OS-B1-E5	TTCTTTGTTACCTCAGGG GC	TTGCTGGCTTCTGTGACAT G	250
OtS2-C5	GTGTTTAGCATCTGAGCC TG	AGATAACACCCCTGTGTGA G	237
SvO2-1-F1	AGTGGGGGACATGAGGGT TGGC	GGCTGGCTCTGGCTCTGC TTTT	855
R1-OS-B1-D6	GCAAGCTGATTTTCAGGC TGCC	GGCTGCTGGGCATTTTGG AAAA	383
R1-SO-R1-A12	ATTCAGTGCTTGCCGGAT	TGGTTGGGTGCACGATGT	233
R1-OS-B1-B1	GGTGATCAAAAATGCAGA CATG	GAACAGAAGAATGGCCAC CT	241
HPRT	GTTGGATACAGGCCAGAC TTTGTTG or AGTCCCAGCGTCGTGATT AGCGATGA	GATTCAACTTGCGCTCATC TTAGGC or TGGCCTGTATCCAACACTT CGAGAGGT	158 or 516

1: primers used for PCR reactions of cDNA obtained from cell-lines (see table 6).

2: primers used for cDNA obtained from mouse tissues (see table 5) designed to detect APLP2 gene without or with the Kunitz protease inhibitor (KPI) domain.

- 5 Table 5. Difference in expression of the indicated gene in lung tissue, trachea, thoracic lymph nodes (TLN) and dorsal-root ganglia (DRG) of OVA sensitized mice challenged with OVA versus saline. The value indicated in the table represents the difference in the number of two-fold dilution steps. A value of "3" means that the expression in OVA challenged mice is at least $2^3 (=8)$ times
- 10 higher than in saline challenged mice. A value of "-3" means that the expression in OVA challenged mice is at least 8 times lower than in saline challenged mice. See example 1 for a detailed explanation.

Signature sequence	Trachea	Lung	DRG	TLN
OtS1-B7	0	0	13	0
SvO2-1-B7				
+KPI	0	-2	3	3
- KPI	0	-2	-2	3
SvO2-1-D8	0	0	0	2
OtS2-A6	ND	ND	0	-1
R1-OS-B1-D3	0	0	-1	0
R1-OS-B1-A1	2	0	2	0
R1-SO-R1-C11	12	12	ND	0
EST AA726662	4	0	5	-2
EST W41083	ND	ND	ND	ND
SvO2-1-D10	0	0	0	0
SvO2-1-A11	0	2	3	3
SvO2-1-C8	1	0	4	1
SvO2-1-E6	0	1	1	1
OtS2-D3	-1	3	0	0
OtS2-D10	-1	2	1	-2
R1-OS-B1-C3	0	-1	10	0
OtS2-G2	ND	ND	0	-1
R1-OS-B1-H6	0	1	-2	2
R1-OS-B1-A3	-1	1	-1	-3
R1-OS-B1-C4	0	0	2	0
R1-OS-B1-A5	0	2	-3	-3

R1-OS-B1-B2	0	0	-2	1
OtS2-C1	0	0	-2	2
OtS2-D7	0	2	0	2
OtS2-B9	ND	ND	3	0
OtS2-A9	1	3	-1	1
R1-OS-B1-C6	0	1	1	1
OtS2-C3	3	1	-1	-1
OtS2-B6	0	1	0	0
OtS2-A12	0	3	0	0
OtS2-B3	-1	-1	1	0
OtS2-A5	2	-1	-1	-1
OtS2-C4	0	-1	-1	-2
R1-OS-B1-E5	-1	0	-2	2
OtS2-C5	0	-2	1	0
SvO2-1-F1	1	-1	0	1
R1-OS-B1-D6				
383 bp	0	0	4	0
310 bp	absent	absent	-5	1

ND: Not determined

Table 6 : Expression of the specified gene in the indicated murine cell-line. "+" indicates that the gene is expressed in the cell-line; "-" indicates absence of expression of the specified gene in the cell-line.

Signature sequ nc	P815	CFTL1	EL4	3D054.	DO11.	A20	J774A.	RAW	C10	3T3	DC
OtS1-B7	-	+	-	-	-	-	1	-	-	-	+
SvO2-1-B7	+	+	+	+	+	+	+	+	+	+	+
SvO2-1-D8	+	+	+	+	+	+	+	+	+	+	+
OtS2-A6	+	+	+	+	+	+	+	+	+	+	+
R1-OS-B1-D3	+	+	+	+	+	+	+	+	+	+	+
R1-OS-B1-A1	-	-	-	-	-	-	-	-	-	-	-
R1-SO-R1-C11	-	-	-	-	-	+	+ ³	+ ³	-	-	-
EST	-	-	-	-	-	+	+ ³	-	-	+	-
AA726662											
EST W41083	-	+	-	-	-	-	+	+	-	+ ¹	-
mCaCC	ND	ND	ND	-	-	-	-	-	+	-	ND
SvO2-1-D10	+ ¹	-	-	-	-	+	+	+	-	-	-
SvO2-1-A11	+	+	+	+	+	+	+	+	+	+	+
SvO2-1-C8	+	+	+	+	+	+	+	+	+	+	+
SvO2-1-E6	+	+	+	+	+	+	+	+	+	+	+

[illegible]

OtS2-A5	+ ¹	+	+	+	+	+	+	+	+	+	+	+	+	+	+	-
OtS2-C4	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
R1-OS-B1-E5	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
OtS2-C5	+	+	+	+	+	+	+	+	+	+	+	+	+	+	-	-
SvO2-1-F1	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
R1-OS-B1-D6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
R1-SO-R1-A12	ND	ND	ND	+	+	+	+	+	+	+	+	+	+	+	-	ND
R1-OS-B1-B1	ND	ND	ND	+	+	+	+	+	+	+	+	+	+	+	+	ND

ND: Not determined.

1: only after in vitro activation with PMA (10 ng/ml) for three hours.

2: only after in vitro activation with an activating anti-CD40 monoclonal antibody (clone 3/23; 1 µg/ml) for three hours.

3: only after in vitro activation with lipopolysaccharide (1µg/ml) and interferon-γ (50 U/ml) for three hours.

Murine cell-lines used:

5 P815: Mast cell

CFTL12: Mast cell

EL4: T-lymphocyte

3DO54.8: T-helper lymphocyte

DO11.10: T-helper lymphocyte

10 A20: B-lymphocyte

8 J774A.1: Macrophage, Monocyte

15 RAW264.7: Macrophage, Monocyte

C10: Lung type II epithelial cell

3T3: Fibroblast

DC: Primary bone-marrow derived dendritic cell

20 Table 7 : Annotation of Contig1A (19619 bp) of the gene comprising the OtS1-B7 fragment. Numbers refer to the nucleotide position in Contig 1A.

3633	3654	5'-UTR
3655	3657	ATG-startcodon
3655	3700	46 bp exon 1
3701	3808	108 bp intron 1

5	3809	3895	87 bp exon 2	
	3896	4420		525 bp intron 2
	4421	4510	90 bp exon 3	
	4511	5011		501 bp intron 3
10	5012	5092	81 bp exon 4	
	5093	6149		1057 bp intron 4
	6150	6236	87 bp exon 5	
	6237	7064		828 bp intron 5
15	7065	7151	87 bp exon 6	
	7152	8376		1225 bp intron 6
	8377	8463	87 bp exon 7	
	8464	8954		491 bp intron 7
20	8955	9106	152 bp exon 8	
	9107	10385		1279 bp intron 8
	10386	10495	110 bp exon 9	
	10496	11617		1122 bp intron 9
25	11618	11966	349 bp exon 10	
	11618	12784	1167 bp exon 10A	
	11766	11768	TAG-stopcodon	
	11769	11966	3'-UTR	
25	11946	11950	poly adenylationsite	
	11769	12784	3'-UTR	

12769 12773 poly adenylation site
differential splicing yields 2 mRNA's of ca 1198 and 2016 bp,
respectively, both encoding the same 325 bp ORF

Table 8 : Primers used for the characterization of the gene comprising OtS1-B7. "F" in the primer name refers to forward or sense primer; "R" in the primer name refers to reverse or anti-sense primer.

Position in contig1A	primer name	sequence
3642-3659	0055-FOTS1-B7F	GACAGCGCAACCATGAG
3647-3673	0054-FOTS1-B7F	CGGCAACCATGAGTGACTCCACAGAAG
3655-3684	0047-OTS1-B7F	AAGAACAGGAAGGAGAGCAGCTGCAG GAC
4450-4478	0048-OtS1-B7-R	AGCTGGGTCAGTTCCTGGAGGATCTTC TCT
5049-5078	0049-OtS1-B7-R	AGCTGGGTCAGTTCCTGGAGGATCTTC TCT
5078-5092 + 6150-6163	0050-OtS1-B7-R	GGGGATCCTGGACGTAAGCTCATCTGT CA
4506-4510 + 5012-5038	0017-F-OtS1-B7	CCAAGTCTCCAAAACCCCAAATACCGA GAGGC
5012-5041	0032-OTS1-B7F	TCTCCAAAACCCCAAATACCGAGAGGC

			AGA
10393-10422	0033-OTS1-B7F		TGCAGCAGGCTTCTAAGGCTAAAGGAC CAA
11636-11665	0034-OTS1-B7R		TCCTCACCGATGTTGTTAGGCTCCCT CTA
11666-11695	0010-R-OtS1-B7		CAGCCATCCCCAGCAAATTCGACACAG TCT
11682-11711	0052-OtS1-B7-F		GCTGGGATGGCTGGAATGACTCTAAA TGT
11735-11763	0053-OtS1-B7-F		CAAGAAGTCTGCAACCCCATGCACTGA AG
11769-11796	0056-OtS1-B7-R		ATGGCATGAAGGTAGGAGCGGAGATG AG
11781-11828	0057-OtS1-B7-R		CGAAAGTGAGGCACATCCAT
11861-11891	0051-OtS1-B7-R		AAGAAGAAATCCAGAGCCTTTTTCACG ATCC
11862-11881	0124-OtS1-B7-F		GATCGTGAAAAAGGCTCTGG
12183-12202	0126-OtS1-B7-F		TGGCTAGATGTTCCCACTC
12832-12851	0125-OtS1-B7-R		TTCCCTGCAGGGATGAGCTAC
12558-12577	0127-OtS1-B7-R		TCAGATCACCAAGCCTTGCTA
12753-12779	0140-OtS1-B7-R		CAGGACTTTATTACAGCAACAGTAAAC

Table 7. Primer pairs used for PCR analysis of human calcium-activated chloride channel family members and HPRT in human H292 lung epithelial cells.

Gene	sense primer	anti-sense primer	product length (base pairs)
CLCA1	TGCAGACAGTTGAGC TGGGGTCCT	CCCCAAAAGCATCAA TGAGGCC	417
CLCA2	AAATTCATACCTTCGT GGGCATTGC	CTGGCCTGCCACGTA ACTAGAAACA	568
CLCA4	GCAAAACATTTCTG CTGCAGACTG	TGAGGCCATTGTTCT GAGCCTTCATC	421
HPRT	TGCTGAGGATTTGGA AAGGGTGTTT	TGACCAAGGAAAGCA AAGTCTGCAT	368

Table 8 : members of the calcium-activated chloride channel family.

Human gene/protein	Murine homologue
CLCA1 / CaCC1	Gob-5
CLCA2 / CaCC3 / CaCL2	EST AA726662
CLCA3	CaCC / CLCA1
CLCA4 / CaCC2	EST W41083

5 Figure legends

Figure 1: Effects of Ly-GDI and Cdc42-GAP on small GTP-binding proteins Rac and Cdc42

10

Figure 2: PCR products using cDNA obtained from dorsal root ganglia (DRG) isolated from "healthy" or "asthmatic" mice. PCR was carried out using conditions well known in the art using the gene-specific primer pairs for:

- a) EST AA726662 (Top)(sense primer: GGTTGAGGAGCGGAATGGAAGAGC;
15 antisense primer: ATTGCCCACGGCGCTATCCA, product length 362 base pairs);
- b) m_CaCC (Middle)(sense primer: ATTAGTCACATTTGACAGCGCTGCC; antisense
primer: TGGGAGACGCTGCCACTTG TAGAT, product length 414 base-pairs);
and for
- c) gob 5 (Bottom)(sense primer: GCCTTCGGACAGCATTTACA; anti-sense primer
20 TGCGTTGTCCAGGTGATAAG; product length 435 base-pairs).

Lane 1 refers to 100 bp DNA ladder; lane 2, 4 and 6 refers to cDNA obtained from DRG of "healthy" mice and prediluted respectively 1/4, 1/16 and 1/32; lane 3, 5 and 7 refers to cDNA obtained from DRG of "asthmatic" mice and prediluted respectively
25 1/4, 1/16 and 1/32.

Figure 3. Homology between LR8 and the beta chain of the high affinity IgE receptor.

30

Figure 4. Genes down-regulated in "asthma" versus "healthy" mice.

Figure legends

35

Figure 5A: PCR analysis of gene-fragments with signature sequences R1-OS-B1-C3 and OtS2-C5 using cDNA from dorsal root ganglia obtained from saline- (SAL) or

5 ovalbumin (OVA) challenged mice as described in example 1. HPRT house-keeping control gene is used to control for the relative amount of cDNA. Two-fold dilution series from left to right. The black bars indicate the dilutions that gave a PCR product.

10

Figure 5B: PCR analysis of genes Cyp2f2 and Gob-5 using cDNA from lung tissue obtained from saline- (SAL) or ovalbumin (OVA) challenged mice as described in example 1. HPRT house-keeping control gene is used to control for the relative amount of cDNA. Two-fold dilution series from left to right. The black bars indicate the dilutions that gave a PCR product.

Figure 6: Gene comprising OtS1-B7 fragment.

20

Figure 7: Restrictionmap of Contig 1A, the gene comprising OtS1-B7 fragment.

Figure 8: EtBr-staining of the restriction-digests used (panel A), the autoradiograph after 2 and 5 days exposure time (panels B and C) and the interpretation (panels D and E). Panel D shows a graphical representation of all the hybridizing bands, the thickness of the bands indicates their relative strengths as judged by eye using both exposures. Panel E shows the expected hybridization pattern based on the predicted restriction enzyme map (shown in Figure 3). The thickness of the bands is drawn proportional to the length of the hybridizing region present in each restriction fragment.

Figure 9: Complete sequence of Contig 1A, the gene comprising OtS1-B7 fragment. Contig1A consists of the following overlapping contigs present in Genbank acc. AC073804 and AC73706:

nt 1-11054 = nt 294022-305082 from AC073804

nt 11009-19619 = nt 237022-228395 from AC073804 (reverse complement)

nt 1805-7790 = nt 39946-34025 from AC073706 (reverse complement)

nt 6918-15759 = nt 32026-23233 from AC073706 (reverse complement)

- 10 Figure 10: The protein (325 AA) encoded by the predicted gene encompassing Contig 1A comprising the OtS1-B7 fragment.

Figure 11:

- 15 CLUSTAL W (1.81) multiple sequence alignment of the polypeptide derived from the gene comprising OtS1-B7 (OtS1-B7-ORF) and DC-SIGN (GenBank acc.nr. AAF77072, also designated CD209.

5

Figure 12: Outline for the generation of a genetically engineered null-mice for murine DC-SIGN (signature sequence OtS1-B7, indicated as OtB7 in the figure), the mouse homologue of human DC-SIGN.

10

Figure 13: Lanes 1-8 represent pcr products obtained using non-stimulated human lung epithelial cell-line H292. Lanes 10-17 represent pcr products obtained using PMA (10 ng/ml for 3 hours) stimulated H292 cells. Lanes 19-26 represent pcr products obtained using IL-9 (U/ml for 3 hours) stimulated H292 cells.

15

Pcr products in lanes 1,2,10,11,19,20 represent housekeeping enzyme HPRT. Pcr products in lanes 3,4,12,13,21,22 represent Calcium activated Chloride Channel 1 (CLCA1).

Pcr products in lanes 5,6,14,15,23,24 represent CLCA4

Pcr products in lanes 7,8,16,17,25,26 represent CLCA2

20

Lanes 9,18,27 represent a 100 bp ladder.

Figure 14: ClustalW analysis of calcium-activated chloride channels. Indicated are conserved cysteines, the von Willebrand factor type A domain and the MIDAS motif.

25

CLUSTAL W (1.81) multiple sequence alignment

Figure 15: ClustalW analysis of CD59, signature sequence OtS2-D10 and EST (GenBank acc. BE655906. Indicated are the forward and reverse primers as described in Table 1 (example 1).

30

CLUSTAL W (1.81) multiple sequence alignment

Figure 16: Top: Schematic representation of APLP2 mRNA and protein with the KPI domain (exon 7) and the selected primer pair to identify splice variants with or without the KPI-domain. Bottom: PCR analysis of cDNA from dorsal root ganglia obtained from saline (SAL)- or ovalbumin (OVA) challenged mice as described in

35

- 5 example 1). HPRT house-keeping control gene is used to control for the relative amount of DNA. The black bars indicate the dilutions that gave a PCR product.

Figure 17: PCR analysis of murine Plunc (signature sequence R1-OS-B1-D6) of cDNA
10 from dorsal root ganglia obtained from saline (SAL)- or ovalbumin (OVA) challenged mice as described in example (1). HPRT house-keeping control gene is used to control for the relative amount of DNA. Two-fold dilution series from left to right. The black bars indicate the dilutions that gave a PCR product.

5 Claims

1. A nucleic acid library comprising genes or fragments thereof said genes essentially capable of modulating an immune response observed with airway hyperresponsiveness and/or bronchoalveolar manifestations of asthma.
2. A library according to claim 1 wherein said immune response is up-regulated.
3. A library according to claim 1 wherein said immune response is down-regulated.
4. A library according to any one of claims 1-3 wherein said library comprises nucleic acid essentially equivalent to a signature sequence as shown in table 1, 2 or 3.
5. A library according to anyone of claims 1-4 wherein at least one of said genes encodes a regulatory molecule and/or co-stimulatory molecule and/or adhesion molecule and/or receptor molecule such as a calcium activated chloride channel or a DC-SIGN molecule involved in modulating an immune response.
6. A method for modulating an immune response of an individual comprising modulating a gene comprising a nucleic acid at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in table 1, 2 or 3.
7. A method according to claim 6 wherein said gene modulates a signal transduction cascade pertaining to an immune response.
8. A method according to claim 7 wherein said signal transduction cascade modulates the production of cytokines and/or chemokines and/or growth factors.
9. A method according to anyone of claims 6-8 wherein said gene modulates sensory nerve activation.
10. A method according to anyone of claims 6 -9 wherein said gene modulates a Th1 and/or Th2 mediated immune response.
11. A method according to anyone of claims 6-10 wherein said gene modulates the generation of anti-oxidants or free radicals.
12. A method according to anyone of claims 6-11 wherein said gene modulates a CD8⁺ T-lymphocyte response.
13. A method according to claims 6-12 wherein said gene encodes a gene product capable of modulating an immune response.

- 5 14. A method according to anyone of claims 6-13 wherein said immune response comprises airway hyperresponsiveness and/or bronchoalveolar manifestations of asthma.
15. A method according to anyone of claims 6-14 wherein said gene is modulated by transducing a cell of said individual.
- 10 16. A substance capable of modulating a gene comprising a nucleic acid at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in table 1, or 2 or 3.
17. A medicament comprising a substance according to claim 16.
18. Use of a substance according to claim 16 for the production of a medicament for
15 the treatment of an immune response observed with airway hyperresponsiveness and/or bronchoalveolar manifestations of asthma.
19. Use of a proteinaceous substance derived from a nucleic acid at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in table 1, 2 or 3 for the production of an antagonist against said substance.
- 20 20. Use according to claim 19 wherein said antagonist is an antibody or functional equivalent thereof.
21. An antagonist directed against a proteinaceous substance derived from a nucleic acid at least functionally equivalent to a nucleic acid identifiable by a signature sequence as shown in table 1, 2 or 3.
- 25 22. An antagonist according to claim 21 comprising an antibody or functional equivalent thereof.
23. A medicament comprising an antagonist according to claim 22.
24. Use of an antagonist according to claim 21 or 22 for the production of a medicament for the treatment of an immune response observed with airway
30 hyperresponsiveness and/or bronchoalveolar manifestations of asthma.





Figure 1.

Figure 2:



CLUSTAL W (1.81) multiple sequence alignment

3/24

Figure 4: Genes down-regulated in "asthma" versus "healthy" mice.

Sequence R1-OS-B1-E5:

Gatcaaatgtattctttgttacctcaggggcttcaggggctaggtgacaactccccagggctagaaaggtaagccca
tctaagtgttacaggagtgatTTTTGcctgtgactttgagatgcccaattagaaccagcctctggcccacctntcctg
gggaagcgacaatgagattgcctttatacttcacctgggtgcctaggcttgctcttaggcatccattttcctggtgagac
tttcttcatgtcacagaagccagcaaataagggtggagtcacatgaaggntcatgatc

Sequence OtS2-C5:

AgattgtttgagggataatgatttcaagtgttagcatctgagcctgcctgtaggttgatttcatctatTTTTtagtaa
acaagcattctttgttagtcaacatatcacatcaaataatgcggagcattttaaaaagctacttcatcctttggcattca
catcatctagtcaaacaggggttcaagtgcagacggncacttgccatgtagcgtggcacatcanataccgggtgtgt
gatgtgaanctcacacaggggtgttatctgaagcataatgggtggcttgggtaatatacatataagctcaanggnac
cncgaatttccttggaagaacatnaacctgggaancttttgngncccttacctgcctgnctaanaaacttgacc
cccaaagattcctantaaccgncgccantgtgctnacnttctncagatattcctacacttngggcgntnnann
ncctctnnangggccca

Figure 5A




Figure 5B




Figure 6




Figure 7





Figure 8



Filter 180101A 2p127 Hybridisation 24/01/01 2p137 Probe: Ots1-B7-cDNA 47-51 = 1101 bp cDNA (+1: ATG; +978: TAG)
 A: EtBr; B, C: 2 and 5 day exposures; D: interpretation (predicted bands red); E: idem, only predicted bands

Figure 9

BASE COUNT 6308 a 4234 c 4316 g 4761 t
ORIGIN

```

1 agtggaaaac agacagcatt ttcaacaatg gtgctggcaa actggtgggtt atcatgtaga
61 agaatgccaa ttgatccatt cctatctcct tgtactaaag tcaaactctaa gtggatcaag
121 gaactccaca taaaaccaga gacactgaaa cttatagagg agaaagtggg gaaaagcctc
181 aaagatatgg gcacagggga aaaattcctg aatagaacag catggccttg gccgtaagat
241 tgagaattgt caaatgggac ctcaataaaa ttgaaaaggt tctgtaaggc aaattacacc
301 gtcaataaga caaaaaaaag ccaccaacag attgggaaaag gatctttacc tatcctaaat
361 cagataaggg actaatatcc aatatataaa aagaactcaa gaaggtggac tctagaaaat
421 caaataaccc cattaaaaat ggggctcaga gctaaacaaa gatttctcac ctgaggaaaa
481 ccgaatggct gagaagcatt tgaaaaaatg ttcagcatcc ttaatcatca gggaaatgca
541 aatcaaaaaca accctgagat tccacctcac accagtccaga atggctaaga tcaaatattc
601 aggtgacagc agattctgga gaggatgtgg agaaagagga acactcctcc attgttgttg
661 gaattgcaag cttgtacaac cactctggaa atgagtctgg cagttcctca gaaaattgga
721 catagtacta ccgaaggatc ccgcaatacc tctcctgggc atatatccaa aagatgttcc
781 aaccagtaag aaggacacat cctccactat gttcatagca gccttatttg taatagccag
841 aagctggaaa gaaccagat gtccctcaac agaggaatgg atacagaaat tgtggtatat
901 ttacacaatg gaatactact cagctattac aaagaatgaa tttatgaaat tcataggcta
961 attgatggac ctggagggca tcatccttag taaggtaacc caatcacaaa agaactcaca
1021 caatatgtac tcaactgataa gtggatatta gctcataaac ttagaatacc caagatacaa
1081 gatacaattt gcaaaactta tgaaactcaa gaagaacgaa gaccaaagtg tggacacttt
1141 gcccttctt cgaattggga acaaaacctc catggaagga gttacagaga caaagtttgg
1201 agctgagacg aaaggatgga ccatctagag actgccatac ccaggatcca tcccataatc
1261 agcccccaaa cgctaaccac attgcacaca ctagcaagat gttgctgaaa ggacctgat
1321 ataactgtcc tgcgatgcta ttccagggcc tagcaaactc ataagtggat gctcacagtt
1381 agctattgga tggatcacag ggccccaat ggaggagcta gagaaagtac ccaatgagct
1441 aaagggatct gcaaccctat aggtggaaca acaatatgaa ctaaccagta tccccggag
1501 atcgtgtctc tagctgcata tgtatcagaa gatgacctag tgaaaagaga ggccatcagt
1561 gaaaagagag gccatttggt cttgcaaact ttatatgcct cagtacaggg gagcgttatg
1621 gccagaagt ggtagtggg gggatgggat tggggggatg ttgggggact tatggggtag
1681 cattggaaat gtaaatgaag aaaatatcta attaataaaa aaaagaaaga aaatgaatat
1741 gtggcttgat atcttatata aacagcagcc tctagcatct caggaagtat ctgtccttag
1801 ggaaggtag aggagaaact tttcattttc tccttggaac tatctgatta tctttggttt
1861 acaacataga agcagattac ccacattcaa ttctcagctt cactgtgaac cagctgtctg
1921 attattatta gacagtggcc tattctgact ttgcagtttc ccagtattac agtatttgta
1981 gttttttgta ttacagatct cttaggcata tcttctttta attaaaacgt aaaaacataa
2041 ctttggctct tacatacgtt gctgtcttat cctgattcca ttttgtatct gcctactttc
2101 cagccttcta cctgcaacag ccatgcctac tttggttaaca catttgggat tcccataacc
2161 ctaattatgg tttaacaacat agaagcagaa tagaatatgc attagccaaa gcaattaatg
2221 ttatacaaaa ctaaacatga actaaaataa catttcccca ctccaggtta cactttgaac
2281 attttaaaaa gagacaggag actataggtc tgcacttaga ccaataggag atatacaaaa
2341 caaagcaaaa aatattttaa gaatatcaat gttatttttc aagcagtcac tttctgggat
2401 tatcttgctc ccctagcaga attatgtttg tgtcaagaag aaagtgaggg gcttctctggc
2461 aggtcaggac ttaacactgg ttgtcacctt gtgcttcatt cttgtgatgc catagaggca
2521 ttgtcataga agatgggcct aatggctatt gtagatctct gttgtctcct ttgtcctggg
2581 aatggagtca aatagccatt atatccaggt aaataaaatc tttatatacct ataatcatga
2641 atttagctta tttccaacag gcctgggtat caggtcactc atcttatgtt ttgagaaagg
2701 gtctctcaat gaacctggaa ctatcgattt gactaggtta gtagatcaat gaactcctgt
2761 gaccatcctg tccactcttt acaacactgg agttacaggt gagtgtgcc acgtctggct
2821 ttttacctgg gtgctgggat ctgaactcat gcttgtgcag taagcacttt acccaatgaa
2881 ccaccttgcc aacttggtt gttttcccaa aattctacaa ttctgatata gctagggaac
2941 ttttcathtt ctcttgga ctatctgatt atctttgggt tacaacatag acgcagatta
3001 cccacattca attctcagct tcaactgtgaa ccagctgtct gaatattatt agacagttgc
3061 ctaatctgac tttgcagttt cccagctacc acagtgcaat gaggtttgag gaatgtttcc
3121 acccatcagt cagaaatcct gaccacaggt tctcaataga gaggtgcatg agaacagcaa

```

Figure 9, Contd.

```

3181 agtcagcaga aataccact gttcaggaca tagcaaagaa agatagcctg gagtcagaag
3241 ggcagaggaa ctgggaagat gggatattgc tctcctacat tcagcatagg tgaaaatatt
3301 gctctcctac attcagcata ggtgaaaagg gcataacaaa gtagatttat tgtattggct
3361 ttgaaatggc acccataaatt tggtcacact atgaacacac cagttcttcc tgctacaaaa
3421 ttccaaaatt caataccctt ccttaaaaaa caaacaacaa aacaaacaaa aaactaagtc
3481 ttgatatatc tggcaaaaaga taggctgtgt caaagggtgca gcccctcccc taggctcttc
3541 cgcaatacat gggcttcctt ttccctcttc cggagtgaag ggacatttag agaacttcag
3601 gggataaaag ctgtagtctc cagcattccc atgcaccagg ggacagcggc aacctagagt
3661 gactccacag aagccaagat gcagcctctt agctccatgg gtgaggctgg gctgggttct
3721 gggagcatgg tgagggaagt cagagggttc tgctcagagg tgagcccgcc cagctgactg
3781 gtgcttgact ggtgctctct tccctcagac gatgatgagt tgatggtcag cggcagcagg
3841 tattctatta aaagctccag actacgacca aattctggaa tcaagtgttt ggcaggtaca
3901 acatgggtgg gggctgagaa aaaaatgggt ctttctctca aagtgggttt tggggagttg
3961 aaggctagga ctctgaactt cctctctctg ggaagataga ggcgggacaa ggaatggagc
4021 gctacgggaa ggctggggta gatggctagg ggagacatca caggttgtgg aaggaggagg
4081 ctagggaagg aaatcatggg ccatgggaaa ggggatggta ggacacgaaa acttgggcta
4141 tgatactgtg gaagttggga cagggaaatg agggctctgg aaaatggagg gtgatgcaag
4201 gaattaagag tcttggggaa gtagaagctg gggtagggaa ctgagggtgt gggtagatgg
4261 aggatggagc agaaaatcag aagctttgag aagattgagg ccagggacaa aaacctggc
4321 ccatggggag gtagaatctg agtctagatt cacatgccag gtgggagggg gacgctgttc
4381 tggaaccagg ctactaaaaa gtccaatttt tccctggaag gatgctcggg acacagccaa
4441 gtccctctgg tctgcagct gctctcttcc ctgttcttgg ctgggctcct gctgatcatt
4501 cttttccaag gtcaggcaca atgaagggtc tagctcttgc aggaccttca cctagggcca
4561 ttttaggtct gggaggggaaa tggacagtgc aggtggatgg catatcttta aaggacgtcc
4621 ctgactctgg tataggacag aatgagaaaa agaagcatgg gtggatcctg gattcatttc
4681 tccttatggc tcagcatctt ctgagtggca ggttttctaa tcttcaaaca gaattaagga
4741 agatattaat gagcaactgc ctcagactct ggagtactgc catgtgccta tagtccagc
4801 tactggggaa gctgaggcac aatgataatt tgtgccaaag aatatgagag aagccttgac
4861 aacataatga gacctatctt taaaaaaaaa aagaagaaa gaaagaaaga aagaagaaa
4921 gaaagaaaga aaagttgaca gtgtatctga gtgcaggact tgacacacag gaagtattta
4981 ataataaat tatttttccc ctctctcaca gtctccaaaa ccccaaatac cgagaggcag
5041 aaggaacaag agaagatcct ccaggaactg acccagctga cagatgagct tagtgagtga
5101 ccaatactcg gaagtatcat ggactcagga aggtcttagg gaaaggggtc aattttccta
5161 aattgtcaga tctcttagag cctcaatttt ctcaagtctg tgaattcata ccacaagatt
5221 aacaacaaca aaaaatggta cttgggtatca atatgagttg ttacacagta ggttctgagt
5281 gtcttcaggg gctatgttca tagtaagtac tcaatatcca caaggatcat atacacagta
5341 gacattcaat gttcccagaa gacatgcaca tacttggcac acaacatgta ctgtgcatgc
5401 agcagatact acatattcat tggggccata aacacatgta atattcacag gcctcacata
5461 cacagtcagt actcaattga atagtctctc tgggttttgt tctgattgct aggcatacaa
5521 ttctcccagt caagaggata atactgggga ctccagcagg ttcaggttgt ggggtggagg
5581 tgttgggaag tgaataaggg aatgttccc taggatgctg tgtcactctg gagggcctga
5641 ggttaagtag acaacaacaa taatcatgta aggttgggtt tatcctgacc tgcctctcct
5701 gggattagat gctcttctca gtgttctgtt tcccagctct caaaggagat aaacaaaca
5761 tcaatcagaa actgtcctag atgtcggaa ggcagcacc acctgtagtc tgagctactg
5821 gggagggtaa gggagggata accacttatg tgcaggagt ttagagaagc atagatgcca
5881 actgaaattt atctaaaaag taaaataaca catgagccgg tgagatagct tagcagacaa
5941 aagtgtctgc ttccaagcct aatgacctga attcaatccc ttgaactcac ctggcaggag
6001 gagaactcct acaagtcttc ctctgacctc cattcacaca aacatgtatg cccctgggtc
6061 ccacatacaa taaataaatg cttttttttt tggagaccag tgatacatgg tagatattta
6121 ataataggcac tttgtttttc ttgacacagc gtccaggatc cccatctccc aagggaagaa
6181 tgagtccatg caggcgaaga tcaactgagca actgatgcag ctgaaaactg aactctgtga
6241 gtgagaaagc agcagctcaa gctgtgggt ctgtaggggc cagttttgag ccatacagac
6301 tctttgagcc ttgggttctc catctgtaaa ttgaaaacac aaagtaacag caaggatgat
6361 atttgctcct tacagggact gtacatgcaa aagaactcac atcccagggt gtgttcaca
6421 gtgtaggcac tcagtgtctc aaaggacct gcatacatat cttcaacgtc taatgtcac
6481 agtggtcata tgtacagagt aaactcaatg ttcacagtgc tgtacacaga gtatgatattc
6541 aattcaatgt cttgactcct attctgaact ctctctctat ttcacctatc agaggagtgg

```


Figure 9, Contd.

```

6601 acaggaactc ctgggctttc ctgggggttga ggagggattt aggaggcaga gtagggagta
6661 gtctctccagt gtgttggtgc aaggaggagac cttcactctg gagggcctga agatttgaag
6721 agaaaaggaa cataggtatt cattcaagtg tgggctcatt ctaacccccca accccagctc
6781 caggattaga tcccttctga atgttgactc tcccagtctc caggaaagta aacatggcat
6841 caatcagaaa ccatcccata aactggggtg gcaacctctg cctgcagtcc tagccactgg
6901 ggaactggaa aggggatggt tatttgtgcc tgaatttgta acaagctgtg tcatagtgtg
6961 gttcaaaaaa tatgacatga gatctcccag ggataggcaa tggcacacag tagctattta
7021 ataattggcag ttctttactt ttttctccat ttttcttggc acagtgtcca ggattcccat
7081 ctccagggg cagaatgagt ccatacaaga gaagatctct gagcaactga tgcagctgaa
7141 ggctgaactt cgtgagtgat aaaaaaccag aggttctgag gcctccagac actatagggg
7201 tcaattttct tgagtcattt gacttattta tgcctcagtt tcttcatctg tgaattgagg
7261 ccacaagtgg cagcaaggac aacacttgat gttt acagag gcaccagta ggcattcagt
7321 gttgatagg accatacaca cattaatac ttggtgttta taagcaccat gcatacatta
7381 ggtactcagt attcacaggg ccatgcacac agtaggtact atgtgttcat aggggtccata
7441 tatacactag gcactcaaca tttaaaaagc ctgtattggg taggttctct gagagaacaa
7501 attctataga atgaatattt atcaaaaggc tctactagat tagtttacac aatatggtct
7561 aacaagtcca cagtagctgt ctacatgctg cagaggatga gaacatagta gatgccaggt
7621 ccttgagtct ggatgccaca gagtcctgat ctggggcctg gaggatctct ggaaagcaca
7681 gatcatcagg ccacaa tgaa aatctgaagg tgtaaggatc aacatcagca gagaatagat
7741 gcaccagaga cagcaatagg gtagatggga agatggacag acaacagcag ccctgccatc
7801 actggcaggt gttccttacc ctgttaatct ttccatagaa taccctcata gccctgccct
7861 aagggtgtgc tcttgggtgt cattctagat acaatcatat taacatcaat tgtgtgtgta
7921 acacagtagg gactcaattt tcaactgaatt tgtaacata gtaggcagtc agtgatcaca
7981 gggattgtgc acagagtcac cacacagtgt tcttgaagtt atgcacagag taggaactca
8041 atattcagag gtaacatgca catgtttggc tctcagttaa gtcagtcctac tggcctctgt
8101 tctcaccaca caggagagga agtggaggca agatctctgg gtgttaggtc tctgaatctt
8161 tataggaaaa aactgtccct gatcctgggt tgtggtactt gcctgaaatc caagctctc
8221 aggaggccaa gggatgttgt atccttttgc ctaggagttt gagatgttcc gacaacaggg
8281 tgagctccat ctcaaaagag aatgacatg tcccgggga tgtagttaa gtcaagtgtac
8341 tcagctgcag ttccccatct ttttttcttg gtccagtttc caagatctcc agcttcccgg
8401 taaaggatga ttctaagcag gagaagatct accaacagct ggtacagatg aagactgaac
8461 tctgtgagtg aacagaaacc agaggcctca ggagcctcag gcagccatta ctttgggtca
8521 aattctttga gttttcagac atctttgatc ttcagttccc tctctaaatt gggcctataa
8581 tgtagcagca aggatagcaa ttggtattta taggagttct gcaaacagca ggcactcaat
8641 attaacaggg gctgtgcaca atgaacactg agtgtgcata gttgtgcaca cttcaggaac
8701 tcagtggtca caaacacat aagctcatct tctatcctct gttctgaact ttaaccctta
8761 ctcttccaa actaaagaaa gaagagctag gactcaggag tcttcttgag ttccctaga
8821 gtttcaaagg gatgtagaaa gcagaaaaga aatgggtccc caggatgctg tgtcaaggga
8881 gggccctgac tcaggagagt ttgaaggcta atcaggcaca agatcacagg catcctaacc
8941 cacttcccca acagtcgcc tgtgtcgact ctgcccctgg gactggacat tctcctagg
9001 aaattgttac ttcttctcca agtcccagcg gaactggaat gacgccgtca cagcttgcaa
9061 agaagtgaag gctcaactag tcatcatcaa tagtgatgaa gagcaggtac atttagtggg
9121 actccatcct tgtctggtct gtgcacctgg ctctgatca cataagctta agataatttg
9181 ccagagtat gtgaggaaaa gaagagacgg gggctctgag ccctttagat agaactttg
9241 tgagtgttt ggggacacct aaaatgcagt agatatcat tttgtactgg tcaactatta
9301 gccatctcct cttggagaga taaaagtctt ggtgtgcctg ctaattaaat agcacagcag
9361 acaaagtgt tgcctctaag cctcacacc tgagttcaat tcctaggacc ccctggtaa
9421 taggagagaa tcaactctt aagatgccct ctgacagaca tacctgcact gtggcatatg
9481 cccatccaga catagaagta gacataatta taagaaaaaa tgaagtcctg acatgggtct
9541 gcttcacaag cttgaagacc ttgagttcaa atccaaagat aaagaggaat ggggtgagat
9601 ggctcagtag atgaaggcgc ttgctgccaa gcctgacaat ttatcctctg aacctacatg
9661 gttcagagaa ccaacccta taaattgtcc tttgacctct atgtacaggc atattaatat
9721 ccataagaca tatacataga taagcatgca tacacgcata acctgatatg atatgtaatt
9781 ctctggtgt aaatatctc accatgacag cttcaagttt ataattggat gccactgaag
9841 aactgaaaag aaagggtatg tttcttaggt aacctgaat tagcatcatt tgcttctatc
9901 acattaaagc cagccatgag gaaattctat agactcattc tatagactca gaattcttaa
9961 gagccatcca gcaacattag cagaattggg gagggatgaa cagctgtgta attcgtgtgt

```


Figure 9, Contd.

```

10021 gtgcgtgtgt gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt
10081 ttcagacagg gtctcactct agttctatct ggcctggaac tcacagaaat cctgtgggtt
10141 tctgagatta aaggcatgta ccgtcatgtc catgcagcta ggtaccaccc tatgccaaagt
10201 gaatgtactg ccataggcta cagatgtaaa aatagctgac accatctaag cacacatgag
10261 tactcatggc ctgatatagc ataaggggaa aagataatgt tgtaagtaga agtttctgcc
10321 tgagggtggg gagacaagct gaaagtagga aactctcccc tgactgtcct cctctttacc
10381 tccagacctt cctgcagcag acttctaagg cttaaaggacc aacctggatg ggctgtcag
10441 acctgaagaa ggaggccacg tggctctggg tagatgggtc tactctgtca tccaggtaga
10501 tccagtgaac aaccagtagt gtagtccaga caggctctctg atgttctgat agctacctgt
10561 gagtctcatc ctcttcttcc tcacctctta gaaataagag ccaccatat tagctgatgg
10621 aaggaagttt tcctacccat gcacagatag aatatcagca aatcccacca tcaaagcaac
10681 aagaaaaact tccccctgag ggggtgttaat tttaatgtag gctattagta gaaaatacaa
10741 aataaagtaa ggccacaggg taaggggact attaacattg aaagatatat tattgggttg
10801 gggatataaa tatgttcatt aagtagcata aggtttgatc ccccatgtc atagtctgat
10861 atgggtgggtc atgctataaa caccagcagt tggaaggtag agggagaaga atcagttcaa
10921 tgttatcttc agctacaaaa tgggttctga gacagcctga gctacacagg aaggaagggg
10981 gagagagaaa gagaaaagca ggtaggggag gaaatgtaaa gaaggggag aggacaacag
11041 tagcttaaag ggagtttata tggatgttca ccgatccac agcacaacac agagaacatg
11101 gggaagaacc acaacaatc agaataaaaa ggaaggacac actgtgggaa agaacctta
11161 ctttgttgtc catgcataag aacaggagag actggcttgg catctattag ttaccattt
11221 taactttctg atccctaatt gtcttacaca tgcttggcat gtggcagatg tattgtggac
11281 cagaatgcaa gaaccagta aggaaggcaa aatccagatt gatgggttta caccacaaaa
11341 ataaaataaa ataaaataaa ataaaataaa ataaaataaa ataaaataaa ataaaataaa
11401 atagaaaaac ccacaccact ccttcaatgt aggatataac aagagtcatt ttccaaagcc
11461 agcagacca ggcatgcccc catctccaga ggaaggccca tctacaatat gcattctgga
11521 aggaggtaaa gacattgagt ttcagaaagc taaaaatatg gcatgggttca cagcatgcca
11581 ctggagcaga ctaacgtttt tctggctgac ttccagatt ccagaaatat tggaatagag
11641 gggagcctaa caacatcggt gaggaagact gtgtcgaatt tgctggggat ggctggaatg
11701 actctaaatg tgaactcaaa aagttctgga tctgcaagaa gtctgcaacc ccatgcactg
11761 aaggctagct catctcgcct cctaccttca tgccattctg ccaggcacat ggatgtgcct
11821 cactttcgtg ccagetcctt cttcctgcct gttggcctca ggatcgtgaa aaaggctctg
11881 ggattcttct ttttatcaga tttttcatcc tctgcattta tcatagtttc atttctgttg
11941 atgtgataaa actctctaac caaaaacaac taaggcagaa aggggtttat ttaccttac
12001 attccagatg agagcagggg ggtcaggatg gcaggaactt aagacaattg gtcacatcac
12061 atcaacagcc aggaggagac agaagtatgt gcaagctaac gcacacattt gcttattctc
12121 agttccattt tcctattcct atagttagg acccctgcct aggaaatggg gccattcata
12181 gtgggtaga tgttccacc tctgttaact tcaataagac aagccccac agacatgctc
12241 actggccaac ccaatgcagg caatacacca ttgagcctct tcccaggtga ctatacgtg
12301 tgtcaggctg actatcacia agggactcac tattgtcctt ttgctttcag gtttctctgg
12361 gcttagggct cactgtgtc cccccacttc agtgcagtta cctgatgtag gatgctttca
12421 gaatctgggt gttttccatt aacctactcc atcttccttg ctgagacaca tacactcaa
12481 ggtcagaaga agacattggt gttctctttg atagctcttt actcccttga gacaggagtt
12541 ggagttcatt attttttag caaggctggg gatctgaaag atccaacatt tttctgtctc
12601 cactcacctc ctaaataag ttacagtcac atgtggccat gtctggcctc taacaattac
12661 tagggcttca aggtcaggcc ctctttcttg cacatcagca ctcttatcca ctatagcatc
12721 cccagccat ttgtctattg tcaggtagtc tagtttactg ttgctgtaat aaagtcctga
12781 caaaatgcaa gttggaagag aaatggatta tttagcttac aattctagat tgtagctcat
12841 ccctgcagga atatcaagga aggaacttga atcagctcat gatattacat ccaaaagcag
12901 agagaataag ttgcatgcat gcctaatttt tctactgcaa tacagtgcgc caactccaga
12961 gaatgggtgct gccataatag gatgggtttc tgttcaattg acttaagaca atgaccccc
13021 ccatggatat ttctgcaacc tcgcccaaaa tagaccttat tgaggatat tcttctaggt
13081 tgtgtcaaac tggcaactaa agctaaccat cacatcaagt cctatctgcc tagtcccta
13141 agacttgatc ctatctctgt atacttctat tctatctgtt cacttacatc aacctgcctg
13201 aaaacttttg gctaggaacc ttccctggcc tctgtagctc atcatgcaa ctaaagcatg
13261 aagatcattc ttcttctcca tctatgactt ccaggcatca tcacacaaat atttcagctc
13321 aggtgctgga gaaacggctc agcagtttag aatgcactca ttgctctcct agaggagcat
13381 agctctcagc aatcgtacct gatgaaactc cagctccagg gaatctatca ccttttatg

```

Figure 9, Contd.

```

13441 gcttctgtgt gcatttgaac ttatgtgggg tataaacaca catcacaca cattgtacat
13501 gttatatata tatattatat atacatatat acatacacac atatgtatat gtataatcag
13561 ctggttccta tcttgagat atcatggtgg atactgagag ctccaagatt tctcctcaga
13621 agagaatgtc ttttccttct attagacagt attctattct attccaattg atctgtgggg
13681 tgtgtgtgtgt gtgtgtgtgt gtttgtgtgt gtgcacgcgc gcgtgcatgc gcatgcacat
13741 acacaggtag cacgatttat tttttattac tatggctggg gcagaagtca ctgagaccct
13801 tctttaagat ccctatttagc aaactccata attttcccag aaactatcca taaagttggt
13861 tttccagcat ctgacacaat ctgttcaggg ctttggctgt gactgtttgt ggctttggtt
13921 gtggctgtgg ccgtggctgc attcactgaa atatctatga ccagtccctt aagattgttg
13981 aaagccatat ttagaatgta gcttgtcaat atgaccattt atgaaaacag cagtactaag
14041 tttcctccag gtgtatggcc tcaccagctg tggatttttg gtcaaatttt gtaccagtca
14101 tgaattcctt cctaaagaga aggcattcaat acagtaagaa atagttggac actcccataa
14161 cagtcatgca tcagtggaaa catatttaat aaagaaaata caacacacaa ccacttttcc
14221 aaacaacttt tgctttattt gtttttttaa aaagaaagcc aatatttact tttcatcttt
14281 agtcttaata taaattttta aaagatgtgt gtgaatacct ttttgcatat tcttttcta
14341 atgcctttta tctcagctga acatctcaac ttcttgctgt tgcttcttca tcttaacatc
14401 tgtatttcca ctctcctctg gacttaatat ctggtccac aactccacct aaaaattctg
14461 tctctactgg aggccacatt ggtactagga actccaaaag tctcctgatc taccaaagac
14521 cacactggca ttaggaacaa aacaaacaaa caaacaaaca aacaaaacaa aacttcagtt
14581 acctggaacc tcagagggca tgccagttcc cagaacccca gaatttcaga ggtagttca
14641 catagggcac caaaccactg atggagacac actactagac ctgaagactt attggtcatc
14701 agaaccatag gttactcaaa ccagaagacc agaaaggaaa ccaaagcagt gggaaaaaac
14761 atccaacaaa gataaagtca gcaatgatca cctaaacata taataaccaa acccagatga
14821 ctagaggcca gcatatgaac acagtcaaca atatccaagg caatacatca ccaccagagc
14881 tatcctccta cagaaagcac tgaatttttt taacacagct gaagcacatg aaaattacct
14941 taaatccaat cttatgaaga taatagagac ctttaaagaa gaaatacaaa aaaaaaaac
15001 cttaaacaaa tcaggggtgag agtaagggag gcaaacagat aaaggaatgt gtttaagatg
15061 tgaaaataga aatagacgaa taaatgaaat acaaactgat ggaatactgg aaatggaaaa
15121 tctaggt aag ttaacagaa ctacagacag aagtatcact aacagaatac aagagatgga
15181 aaaggat atc aggcatagaa gataagatag aagaaactaa tatggcattt aaaaaatgtt
15241 atatctaaaa aggtcctgac acaaaatgtt caggaaatca aggaacctat aaagagacca
15301 aacctaagaa caataggaat agaagaggga gatttccagc tcagaattct taggaaaaaa
15361 tacctaacct aaagaagggtg atgcctataa aggtacaaga aacatacaga agaccacata
15421 tggtggacca gaaaagaaag tcttcccaag agataataat caaaacacta aatgtacaga
15481 gggaagaata ttaaaagcta aaagaggaaa aggcacaaaa aaaaccaaca acaacaacaa
15541 aaacatgtaa aggcaaacct agtagaatta tgccctactt ctcaacagaa aatctaaaaa
15601 gctagaaaag catggacaga tgtattacaa actctgagag accacagata tcagcccaga
15661 cgactgt aac aagcaaaact ttcaatcacc atagatggag aaaacaagat attctatgtc
15721 aaacccaat ctaaatacga tctttctatt aatccagccc tacagagggt acaagaagga
15781 aaacttcgtt ggtccgggac ccgcccgaact taggaaatta gtctgaacag gtgagagggt
15841 gcgccagaga acctgacagc ttctggaaca ggcagaagca cagaggcgct gaggcagcac
15901 cctgtgtggg ccggggacag ccggccacct tcgggaccgg aggacagggt cccaccggc
15961 aggggaggcg gcctaagcca cagcagcagc ggtcgccatc ttggtccggg acccgccgaa
16021 cttaggaat tagtctgaac aggtgagagg gtgcgccaga gaacctgaca gcttctggaa
16081 caggcagaag cacagaggcg ctgaggcagc accctgtgtg ggccggggac agccggccac
16141 ctccggacc ggaggacagg tgcccaccgg gcaggggagg cggcctaagc cacagcagca
16201 gcggtcgcca tcttggtccg ggaccggccg aacttaggaa attagtctga acaggtgaga
16261 gggtgcgcca gagaacctga cagcttctgg aacaggcgga agcacagagg cgctgaggca
16321 gcacctgtg tgggcccggg acagccggcc accttccgga ccagaggaca ggtgcccacc
16381 cggtgggga ggcggcctaa gccacagcag cagcggtcgc catcttggtc cgggaccggc
16441 cgaacttagg aaattagtct gaacaggtga gaggtgacac cagagaacct gacagcttct
16501 ggaacaggca gaagcacaga ggcgctgagg cagcaccctg tgtgggctgg ggacagccgg
16561 ccaccttcg gaccagagga cagggtgccg cccggctggg gaggcgacct aagccacagc
16621 agcagcggtc gccatcttgg tccgggaccc gccgaactta gggaattagt ctgaacaggt
16681 gagagggtgc gccagagaa ctgacagctt ctggaacagg cggaagcaca gaggcgctga
16741 ggcagcacc tttgtgggccc ggggacaccc agccaccgtc cggaccggag gacaggtgcc
16801 tgtccggctg gggaggcggc ctaagccaca gcagcagcgg tcgccatctt ggtccgagac

```

Figure 9, Contd.

```

16861 ccgccgaact taggaaatta gtctgaacag gtgagaggggt gcgccagaga acctgacagc
16921 ttctggaaca ggcagaagca cagaggcgct gaggcagcac cctgtgtggg ccggggacag
16981 ccggccacct tccggaccgg aggacagggtg cccacccggc aggggaggcg gcctaagcca
17041 cagcagcagc ggtcaccatc ttggtcccgg gactccaagg aacttaggaa tttagtctgc
17101 ttagggtgaga gtctgtacca cctgggaact gccaaagcaa cacagtgtct gagaaaggtc
17161 ctgttttggg ccttcttctt cggccaggag gaggtccaaa tacaagatat ctgcgcacct
17221 tccctgt aag agagctt gcc agcagagagt gctctgagca ctgaaactca gaggagagaa
17281 tctgtctccc aggtctgctg atagacggta acagaatcac cagaagaaca atctctaaac
17341 agagtcaact ataactacta actccagaga ttaccagatg gcgaaaggta aacggaggaa
17401 tcttactaac aggaaccaag accactcacc atcaccagaa cccagcacac ccacttcgcc
17461 cagtcagggt aacccaaca cacctgagaa cctagaccta gatttaaaag catatctcat
17521 gatgatggta gaggacatca agaaggactt taataaatca cttaaagaaa tacaggagaa
17581 cactgctaaa gagttacaag tccttaaaaga aaaacaggaa aacacaatca aacaggtaga
17641 agtccttaca gaaaaagagg aaaaaacata caaacagggtg atggaaaatg aacaaaacca
17701 tactagacct aaaaaggga gtagacacaa taaagaaaac tcaaagcgag gcacacgtag
17761 agatagaaac cctaggaaag aaatctggaa ccatagattt gagcatcagc aacagaatac
17821 aagagatgga agagagaatc tcagggtgcag aagattccat agagaacatc ggcacaacaa
17881 tcaaagaaaa tggaaaatgc aaaaagatcc taactcaaaa tatacaggaa atccaggaca
17941 caataagaag accaaacgta cggataatag gagtggatga gaatgaagat tttcaactca
18001 aagggtccagc aaacatcttc aacaaaatta ttgaagaaaa cttcccaaat ct aaagaatg
18061 agatgcatat gaacatacaa gaagcctaca gaactccaaa tagactggac cagaaaagaa
18121 attcctcccg acacataata atcagaacat caaatgcact aaataaagat agaatactaa
18181 aagcagtaag ggaaaaaggt caagtaacat ataaaggcaa gcctatcaga attacaccag
18241 atttttcacc agagactatg aaagccagaa gagcctggac agatgttata cagacactaa
18301 gagaacacaa actgcagccc aggctactat acccagccaa actctcaatt atcatagagg
18361 gagaaaccaa agtattccac gacaaaacca aattcacgca ttatctctcc acgaatccag
18421 cccttcaaag gataataaca gaaaaaaacc aatacaagaa cgggaacaac gccctagaaa
18481 aaacaagaag gtaatccctc aacaaaccta aaagaagaca gccacaagaa cagaatgccaa
18541 cctttaacaa ctaaaataac aggaagcaac aattactttt ccttaatatc tcttaacatc
18601 aatgggtctca actcgccaat aaaaagacat agactaacia ctggctacac aaacaagacc
18661 caacattttg ctgcttacag gaaactcatc tcagagaaaa agatagacac tacctcagaa
18721 tgaaaggctg gaaacaattt tccaagcaaa tggatgaag aaacaagcag gagtagccat
18781 cctaatactt gataagatga cttccaaccc aaagtcatca aaaaagacaa ggagggacac
18841 ttcattctca tcaaaggtaa aatcctccaa gaggaactct caattctgaa tatctatgct
18901 ccaaatacaa gagcagccac attcactaaa gaaactttag taaagctcaa agcacacatt
18961 gcgcctcaca caataatagt gggagacttc aacacaccac tttaccaat ggacagatca
19021 tggaacaga aactaaacag ggacacactg aaactaacag aagtgatgaa acaaatggat
19081 ctgacagata tctacagaac attttaccct aaaaacaaag gatatacctt ctctcagca
19141 cctcatggta ccttctccaa aattgaccac ataatagggtc acaaatcagg cctcaacaga
19201 ttcaaaaata ttgaaattgt cccatgtatc ctatcagatc accatgcact aaggctgatc
19261 ttcaataaca aaataaataa cagaaagcca acattcacat ggaaactgaa caacactctt
19321 ctcaatgata ccttgggtcaa ggaagggaata aagaagaaa ttaaagactt tttagagttt
19381 aatgaaaatg aagccacaac gtacccaaac ctttgggaca caatgaaagc atttctaaga
19441 gggaaactca tagctatgag tgccttcaag aaaaacggg agagagcaca tactagcagc
19501 ttgacacaca tctaaaagct ctagaaaaaa aggaagcaat tcacccagag gagtagacgg
19561 caggatataa tcaaactcgg ggtgaaatca accaagtga cagagactat tcagatacc

```

Figure 10

1	MSDSTEAKMQ	PLSSMDDDEL	MVSGSRYSIK	SSRLRPNSGI	KCLAGCSGHS	QVPLVLQLLS	60
61	FLFLAGLLI	ILFQVSKTPN	TERQKEQEKI	LQELTQLTDE	LTSRIPISQG	KNESMQAKIT	120
121	EQLMQLKTEL	LSRIPIFQGO	NESIQEKISE	QLMQLKAELL	SKI SSFPVKD	DSKQEKIYQQ	180
181	LVQMKTELEFR	LCRLCPWDWT	FLLGNCYFFS	KSQRNWDAV	TACKEVKAQL	VIINSDEEQT	240
241	FLQOTSKAKG	PTWMGLSDLK	KEATWLWVDG	STLSSRFQKY	WNRGEPNNIG	EEDCVEFAGD	300
301	GWNSKCELK	KFWICKKSAT	PCTEG				325

Figure 11

Sequence format is Pearson

Sequence 1: AAF77072 404 aa

Sequence 2: OtB7-ORF 325 aa

Sequences (1:2) Aligned. Score: 45

```

AAF77072      MSDSKEPRLQQLGLLEEEQLRGLG-----FRQTRGYKSLAGCLGHG--PLVLQLLS 49
OtB7-ORF      MSDSTEAKMQPLSSMDDDELMVSGSRYSIKSSRLRPNSGIKCLAGCSGHSQVPLVLQLLS 60
               ****.*.:.* *. :.:.* * : * . * .***** ** . *****

AAF77072      FTLLAG----LLVQVSKVPSSISQEQSRQDAIYQNLTLKAAVGELSEKSKLQEIYQELT 105
OtB7-ORF      FLFLAGLLLIILFQVSKTPN--TERQKEQEKILQELTQLT---DELTSR----- 104
               * :*** :*.*****.*. :.:*.:* * :*****. .**.:.

AAF77072      QLKAAVGELPEKSKLQEIYQELTRLKAAVGELPEKSKLQEIYQELTWLKAAVGELPEKSK 165
OtB7-ORF      ---IPISQGKNESMQAKITEQLMQLKTEL----- 130
               .:.. :.* :* :.* :*: :

AAF77072      MQEIYQELTRLKAAVGELPEKSKQOEIYQELTRLKAAVGELPEKSKQOEIYQELTRLKAA 225
OtB7-ORF      -----LSRIPIFQGN--ESIQEKISEQLMQLKAE--LSKISSFP----- 167
               *:.* :* :* :*: * :*: * :*: * :*.

AAF77072      VGELPEKSKQOEIYQELTQLKAAVERLCHPCPWEWTFQGNCFMSNSQRNWHDSITACK 285
OtB7-ORF      ---VKDDSKQEKIYQQLVQMKTELFRLCRLCPWDWTFLLGNCYFFSKSQRNWNDAVTACK 224
               : .*****:***:*.*: : : ***: ***:***: *****:*****:*****

AAF77072      EVGAQLVVIKSAEEQNFLQLQSSRSNRFTWMGLSDLNQEGTWQWVDGSPLLPSFKQYWNR 345
OtB7-ORF      EVKAQLVIINSDEEQTFLO-QTSKAKGPTWMGLSDLKKEATWLWVDGSTLSSRFQKYWNR 283
               ** *****:.* * **.* ** *:.: : *****:.* ** *****.* . *:*****

AAF77072      GEPNNVGEEEDCAEFSGNGWNDDKCNLAKFWICKKSAASC SRDEEQFLSPAPATPNPPPA 404
OtB7-ORF      GEPNNIGEEDCVEFAGDGWNDSKCELKKFWICKKSATPCTEG----- 325
               *****:*****.**:*:*****.*:* *****:.*:..

```


Figure 12




Figure 13




FIGURE 14

Gob-5 --MESLKS PVFLLILHLLEGVLSESL-----IQLNNGYEGIVIAIDHDVPEDRALIQH 52
HuCLCA1 --NGPFKSSVFILILHLLEGALSNSL-----IQLNNGYEGIVVAIDPNVPEDETLIQQ 52
HuCLCA4 --NGLFRGFVFLVLCLLH-QSNTSF-----IKLNNGFEDIVIVIDPSVPEDEKIEBQ 51
MuCaCC --MVPGLQVLLFLTLHLQ-NTBSSM-----VHLNSNGYEGVVIAINPSVPEDERLIPS 51
HuCLCA2 MTQRSIAGPICNLKPFVTLVALSSELPLFLGAGVQLQDNGYNGLLIAINPQVPENQNLISN 60
: * : * . : : : : : : : : : : : : : : : *

Gob-5 IKDMVTQASPYLFEATGKRFFYFKNVAILIPESWKAKPEYTRPKLETFTKNADVLVSTTSPL 112
HuCLCA1 IKDMVTQASLYLFEATGKRFFYFKNVAILIPETWTKADYVRPKLETYKNADVLVAESTPP 112
HuCLCA4 IEDMVTASTYLFEATEKRFFPKNVSIILPENWKENPQYKRPKHENKHADVIVAPPTLP 111
MuCaCC IKEMVTQASTYLFEASQGRVYFRNISILVPMTWKSKPEYLMKRESYDKADVIVADPHLQ 111
HuCLCA2 IKEMITEASPYLFNATKRRVFFRNKILIPATWKAN--NNSKIKQESYEKANVIVTDWYGA 119
*: : * * * * : : : : : * * : : * * : : * * : *

Gob-5 GNDEPYTEHIGACGEERGIHILTPDFLAGKKLTQ-YGPQDRTFVHEWAHFRWGVFNEYNN 171
HuCLCA1 GNDEPYTEQMGNCEERGERIHLTPDFIAGKKLAE-YGPQGKAFVHEWAHLRWGVFDEYNN 171
HuCLCA4 GRDEPYTKQFTECEGEYIHFPTDLLLGKKQNE-YGPPGKLFVHEWAHLRWGVFDEYNE 170
MuCaCC HGDDPYTLQYGCCEDRGQYIHFPTNFLLTDNLRI-YGPRGRVVFVHEWAHLRWGVFDEYNN 170
HuCLCA2 HGDDPYTLQYRGCEKEGYIHFPTNFLLNDNLTAGYGSRGVVFVHEWAHLRWGVFDEYNN 179
*: : * * : : * * : : : : : : : : : : * * : : * * : *

Gob-5 DEKFYLSKGG-PQAVECSAAITGKNQVRRCOGGSCITNGKCVIDRVTLGYKDNCFVFPDP 230
HuCLCA1 DEKFYLSNGR-IAVECSAGITGTNVVKCOGGSCYTK-RCFVNKVTGLYEKGCEFLQS 229
HuCLCA4 DQPFYRAKSKKIEATPCAGISGRNRVYKCOGGSCLSR-AGEIDSTTKLYGKDCQFFPDK 229
MuCaCC DQPFYMSRKNTIEATPCSTRITGTNVVHNCERGNCYTR-AGRDSKTRLYEPKCTFIPDK 229
HuCLCA2 DKPFYINGQNIKVTCSSDITG---IFVCEKGPCEOE-NCIIS---KLFKEGCTFIYNS 232
*: : * * : : * * : : * * : : * * : : * * : *

Gob-5 HQNEKASIMFNQININSVVEFCTEKNHNQEAAPNDQNCNLRSTWEVIOESEDFKQTTTPM- 289
HuCLCA1 RQTEKASIMFAQHVSIVEFCTEQNHNEAPNQNQKCNLRSTWEVIRDSDFKKTTPM- 288
HuCLCA4 VQTEKASIMFMQSIDSVVEFCNEKTHNQEAAPSLQNIKCNFRSTWEVISNEDFKNTIPM- 288
MuCaCC IQTAGASIMFMQNLNSVVEFCTEKNHNAEAPNLQNMCMNRSTWDVIKTSADFQNAAPMR 289
HuCLCA2 TQNATASIMFMQSLSSVVEFCNASTHNQEAAPNLQNMCSLRSAWDVITDSADPHHSFPMN 292
* . * * * * : : : * * * . * * . * * : : * * : *

Gob-5 -TAQPPAPTFSLLQIGQRIVCLVLDKSGSALNDRLNRMNQASRLFLQTVEQGSWVGMY 348
HuCLCA1 -TTQPPNPTFSLLQIGQRIVCLVLDKSGSATGNRLNRLNQAGQLFLQTVELGSWVGMY 347
HuCLCA4 -VTPPPPPVFSLLKIRQIRVCLVLDKSGSAGGKDRNLRNMQAAKHFLQTVENGSWVGMY 347
MuCaCC GTEAPPPPTFSLLKSRRRVCLVLDKSGSADKEDRLIRNMQAAELYLQIVEKESMVGLV 349
HuCLCA2 GTELPPPTFSLVQAGDKVCLVLDVSSKMAEADRLQLQAAEFYLMQIVEIHTFVGIA 352
. * * . * * : : : * * : : * * : : * * : : * * : *

Gob-5 TFDAAHYVQSELKQLNSGADRDLIKHLPTVSAGGT--SICSGLRATAFTVIRKKYP-TDG 405
HuCLCA1 TFDAAHYVQSELQINSQSDRDLAKRLPAAASGGT--SICSGLRSAFTVIRKKYP-TDG 404
HuCLCA4 HFDSTATIVNRLIQIRSSDERNTLMAGLPTYPLGGT--SICSGIKYAFQVIGELHSQLDG 405
MuCaCC TFDAAHIQNYLIKITSDDYQKITANLPQOASGGT--SICHGLQAGFQAITSSDQSTSG 407
HuCLCA2 SFDSEKGEIRAQLHQINSNDRKLLVSYLPTTVSAKTDISICSGLKGFEVVEKLNKAYG 412
* * : : * : : : : * * . * * * : : * : : *

Gob-5 SEIVLLTDGEDNTISSCFDLVKQSGAIHTVALGPAAAKELEQLSKMTGGLQTYSSDQVQ 465
HuCLCA1 SEIVLLTDGEDNTISGCFNEVKQSGAIHTVALGPSAAQEELELSKMTGGLQTYASDQVQ 464
HuCLCA4 SEVLLTDGEDNTASSCIDEVKQSGAIVHFIALGRAADEAVIEMSKITGGSHFYVSDAQ 465
MuCaCC SEIVLLTDGEDNGIRSCFEAVSRSGAIHTIALGPSAARELETLSDMTGGLRPFYANKDLN 467
HuCLCA2 SVMILVTSQDDKLLGNCLPTVLSSGSTIHSIALGSSAAPNLEELSRLTGGLKFFVPDISN 472
* : : * * : : : * : : * * : : * * : : * * : : *

Gob-5 NNGLVDAPAAALSSGNAAIAQHSIQLESRGVNLQNNQWMNGSVIVDSSVGKDTLFLITWTT 525
HuCLCA1 NNGLIDAFGALSSGNCAVSQRSIQLESKGLTLQNSQWMNGTVIVDSTVGKDTLFLITWTT 524
HuCLCA4 NNGLIDAFGALTSCNTDLSQKSLQLESKGLTLNSNAWMNDTVIIDSTVGKDTFFLITWNS 525
MuCaCC --SLIDAFSRISSTSGSVSQALQLESKAFDVRAGAWINGTVPLDSTVGNDTFFVITWMV 525
HuCLCA2 SNSMIDAFSRISSTGDIQQHIQLESTGENVKPHQLKNTVTVDNFTVGNDTFLVTVQA 532
: : * * . : : * : : * * : : : : : : : : * * : : * * : *

Gob-5 H-PPTIPIWDPSGV--EQNGFILDTT-TKVAYLQVPGTAKVGFWKYSIQASS---QTLTL 578
HuCLCA1 Q-PPQILLWDPSGQ--KQGGFVVDKN-TKMAYLQIPGIKVGTVKYSIQASS---QTLTL 577
HuCLCA4 L-PPSISLWDPSGT--INENFTVDAT-SKMAYLSIPGTAKVGTWAYNLQAKAN-PETLTI 580
MuCaCC K-KPRIILQDPKGGKYTTSDFDQDDKLNIRSARLQIPGTAEFTGTWYSITGTSK--QLITM 582
HuCLCA2 SGPPRIILFDPDGRKYTYNNFITNLT-FRTASLWIPGTAKPGHWTYTLNTHSLQALKV 591
* * : * * . * : : * * : : * * : : * * : : *

FIGURE 14, CONTD.

Gob-5	TVTSRAASATLPPITVTPVVKNTGKFSPVTVYASIRQGASPILRASVTALIESVNGKT	638
HuCLCA1	TVTSRASNATLPPITVTSKTNKDTSKFPSPLVVYANIRQGASPILRASVTALIESVNGKT	637
HuCLCA4	TVTSRAANSSVPPITVNAKMNKDVNSFPSMIVYAEILQGYVPVLGANVTAFIESQNGHT	640
MCaCC	TVTTRARSPTMEPLLATAHMSQSTAQYPSRMIVYARVSQGFLPVLGANVTALIEAEHGHO	642
HuCLCA2	TVTSRASNSAVPPATVEAFVERDSLHFPHPVMYANVKQGFYPILNATVTATVEPETGDP	651
	+:*+ ...: +: * : :+* : ** *:* *.*** :*. . *	
Gob-5	VTLELLDNGAGADATKNDGVYSRFFTAFDANGRYSVKIWALGGVTSRQRAAPPKNRAMY	698
HuCLCA1	VTLELLDNGAGADATKDDGVYSRYFTTYDTNGRYSVKVRALGGVNAARRRVI PQQSGALY	697
HuCLCA4	EVLELLDNGAGADSFKNMGVYSRYFTAYTENGRYSLKVRAGGANTARLKLRPPLNRAAY	700
MCaCC	VTLELWDNGAGADTVKNDGIYTRYFTDYHGNSRYSLKVRVQAQRNKTRLSLR-QKNKSLY	701
HuCLCA2	VTLRLLDDGAGADVIKNDGIYSRYFFSFAANGRYSLKVHVNHSPSISTPAHSIPGSHAMY	711
	.*. * :***** :+*:*+*+ : *.***:** : *	
Gob-5	IDGWIEDGEVRMNPFRPETS--YVQDKQLCFSTRSSGGSFVATNPAAPIPDLPFPPCQI	756
HuCLCA1	IPGWIENDEIQWNPPRPEINKDDVQHKQVCFSTRSSGGSFVASDVPN-APIPDLPFPPGQI	756
HuCLCA4	IPGWVNGEIEANPPRPEID-EDTQTLEDFSTRASGGAFFVVSQVPS-LPLPDQYPPSQI	758
MCaCC	IPGYVENGKIVLNPPRPDVQEEAIEATVEDFNRTSGGSFTVSGAPPDGDHARVFPPSKV	761
HuCLCA2	VPGYTANGNIQMNAPRKSVG-RNEEERKNGFSRVSSGGSFVSLGVPA-GPHPDVFPCKI	769
	: : : : : *.*. . . . : . . . :*****. . . . : ** :	
Gob-5	TDLKASIQGQNLVNLWTAPGDDYDHGRASNYIIRMSTSIVDLRDHFTSLQVNTTGLIP	816
HuCLCA1	TDLNAEIHGGSLINLTWTAPGDDYDHGTAHKYIIRISTSIDLRDKFNESLQVNTTALIP	816
HuCLCA4	TDLDATVHEDKII-LTWTAPGDNFVDGKVQRYIIRISASILDLRDSFDDALQVNTTDLSP	817
MCaCC	TDLEAEFIG-DYIHLTWTAPGKVLNDRAGRYIIRMSQHPLDLQEDFNNTLVNASSLIP	820
HuCLCA2	IDLEAVKVEEELT-LSWTAPGEDFDQGOATSYEIRMSKSLQNIQDDFNAILVNTSKRNP	828
 :*****. * * . * +*:*+ : : : : : * : : *	
Gob-5	KEASSEEIFEFELGGNTFG-----NGTDIFIAIQAVDKSNLKEISNIARVSVFI	866
HuCLCA1	KEANSEEVFLFKPENITFE-----NGTDLFIAIQAVDKVDLKEISNIARVSLFI	866
HuCLCA4	KEANSKESFAFKPENISEE-----NATHIFIAIKSIDKSNLTSKVSNIAQVTLFI	867
MCaCC	KEAGSKETFKFKPETFKIA-----NGIQLYIAIQADNEASLTSEVSNIAQAVKLT	870
HuCLCA2	QQAGIREIFTFSPQISTNGPEHQPNGETHESHRIYVAIRAMDRNSLQSAVSNIAQAPLFI	888
	:*.*. * * * : : : : : : : . * * :*****. : :	
Gob-5	PAQEP---PIPEDSTPPCPDISINS--TIPGIHVLKIMWKLGMQVTLGLH-----	913
HuCLCA1	PPQTPPETPSPDETSAPCPNIHINS--TIPGIHILKIMWKWIGELQLSIA-----	914
HuCLCA4	PQANP-DDIDPTPTPTPTPKSHNSGVNISTLVLSVIGSVVIVNFILSTTI-----	917
MCaCC	SLEDS-----ISALGDISAICMTIWGLTVIFNSILN-----	901
HuCLCA2	PPNSD----PVPARDYLILKGVLTAAGLIGIICLIIVVTHHTLSRKKRADKKENGTKLL	943
	. : . * : :	

Conserved cysteines

VLLTDGER von Willebrand factor type A domain

gnl|Smart|smart00327

VWA, von Willebrand factor (vWF) type A domain; VWA domains in extracellular eukaryotic proteins mediate adhesion via metal ion-dependent adhesion sites (MIDAS). Intracellular VWA domains and homologues in prokaryotes have recently been identified. The proposed VWA domains in integrin beta subunits have recently been substantiated using sequence-based methods (Ponting et al. Adv Prot Chem (2000) 54:185-244).

MIDAS motif

Affinity regulation: MIDAS Bonds in CD11's

The metal ion-dependent adhesion site (MIDAS) is believed to be the site on the alpha chain of LFA-1 (alpha-L, CD11a) which binds ligand (ICAM-1, ICAM-2, or ICAM-3). Although it is likely to be a critical portion of the ligand-binding site, other parts of LFA-1 may also make important contributions, notably the MIDAS site on CD18, and the 4th and 5th repeats of CD11a. The MIDAS motif consists of DxSxS...T...D, and is equally central to ligand binding for both CD11a/CD18 (LFA-1) and CD11b/CD18 (Complement receptor type 3, CR3).

Forward primer

----->

FIGURE 15

```
BE655906      AGTCACTGGGCGATCTGAAAAGTGTCTAGAGCAGGATCTAGCTGACTCTAAGATTGCAGGG 60
OtS2-D10      -----GATCTAGCTGACTCTAAGATTGCAGGG 27
CD59          AGTCACTGGGCGATCTGAAAAGTGTCTAGAGCAGGATCTAGCTGACTCTAAGATTGCAG-- 63
               .....*****

BE655906      TTGAAGGTGTCTGTGAAGCCTGTGGAAACTGCTGCTGTAAATCTTCAATCTGGCTGGG 120
OtS2-D10      TTGAAGGTGTCTGTGAAGCCTGTGGAAACTGCTGCTGTAAATCTTCAATCTGGCTGGG 87
CD59          -----

BE655906      GATGTGGCTCAAGATAGTGCTGCATGGTGGCCTGGCTTGCGTTCTTCATATATTAATAAT 180
OtS2-D10      GATGTGGCTCAAGATAGTGCTGCATGGTGGCCTGGCTTGCGTTCTTCATATATTAATAAT 147
CD59          -----AT 65
               **

BE655906      TTGGTAGCCCAGCACAAATGAGAGCTCAGAGGGGACTCATCTTACTCCTGCTGCTTCTGGC 240
OtS2-D10      TTGGTAGCCCAGCACAAATGAGAGCTCAGAGGGGACTCATCTTACTCCTGCTGCTTCTGGC 207
CD59          TTGGTAGCCCAGCACAAATGAGAGCTCAGAGGGGACTCATCTTACTCCTGCTGCTTCTGGC 125
               *****

BE655906      TGTGTTCTGTTCACAGCTGTAGCCTCACATGCTACCACGTGTTTCCAACCGGTGGTTTC 300
OtS2-D10      TGTGTTCTGTTCACAGCTGTAGCCTCACATGCTACCACGTGTTTCCAACCGGTGGTTTC 267
CD59          TGTGTTCTGTTCACAGCTGTAGCCTCACATGCTACCACGTGTTTCCAACCGGTGGTTTC 185
               *****

BE655906      TTCATGCAATATGAACAGCACTTGCTCTCCTGACCAGGATTCCTGTCTCTATGCTGTAGC 360
OtS2-D10      TTCATGCAATATGAACAGCACTTGCTCTCCTGACCAGGATTCCTGTCTCTATGCTGTAGC 327
CD59          TTCATGCAATATGAACAGCACTTGCTCTCCTGACCAGGATTCCTGTCTCTATGCTGTAGC 245
               *****

               <-----
               reverse

BE655906      CGGAATGCAAGTGATCAAAGGTGTTGGAAACAATCAGATTGTCATG----- 407
OtS2-D10      CGGAATGCAAGTGATCAAAGGTGTTGGAAACAATCAGATTGTCATGGTGATC----- 378
CD59          CGGAATGCAAGTGATCAAAGGTGTTGGAAACAATCAGATTGTCATGGTGAGATCATTAT 305
               *****
               -----
               primer
```

Figure 16




Figure 17

